var title_f12_5_12368="Waldeyers ring";
var content_f12_5_12368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Waldeyer's ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 347px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFbAYYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorE8ReIINIj2DEt0fuxg9Pc0pSUVdl06cqkuWCuzWubiG1haW4kSKMdWY4Fchq3jiONzHpkHnY/wCWkmQv4Dr/ACrk9Rv7vU5zLdys3PC/wr9BVYR+grknXk/hPcw+WU4a1dX+Bqz+LdZmyBcLEPSNAP51APEGr/8AP/N+YqksBJ6VZitc9qy5pvqdvs6EVpFfcWF17WD/AMv0v6Uj6/rJGPtsv4YqSK0J4AqRrLA6U/e7mf7lP4V9xntrerN1v7n8HIph1bVP+ghdf9/WqzLa89KrPbkdBUvm7msfZfyr7h8ev6zFjbfznH947v51p2XjfU4WH2pIrhO/y7T+YrDaM+lMKe1CnJbMJUKE1aUUeo6N4l0/VAqrJ5M5/wCWcnH5HvW3XiQQqcrwa6LQ/FN1p7CO6LT2/TBPK/Q10QxHSR5eIyu3vUX8j0uiqWmanaalFvs5lf1X+JfqKu10pp6o8eUXF2krMKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoormfFviIaaptbQg3jDk9ox/jUykoq7NKVKVaXJDcd4m8Sxaaj29qRJekY45Efuff2rz3MlxM0szl5GOSx6k03a0jl3JZmOST3q7bQ1xTm6j1PoqFCGGjaO/cakBboKnjthnFWY1C0xJgJsHFKyQ3NvYeluB2qzHGoqu9yo71EbwA9aq6Rm4ykasaqKdLt21lfbqQ3oPenzIj2MrluRVNVXQc1C16PWoXuwalyRtGnJBIFU80LAHNVZJtzjmrltKBipTuauLihz2e1Kz5oSCa2XuAVwTVKQiQ4HehpE05S6lGCSa0mWa2kaORehU4ruvD3i+O5KW+pARTHgS/wt9fSuSmgATpWfJEeopxlKm9Aq0KeJjae/c9sByOKK838M+KJrApb3xaW16A9WT6eo9q9EgmjniWWF1eNhkMp4NdkKimtD5/E4WeHlaW3ckooorQ5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKhvLiO0tpZ522xxruY0bDSbdkZfinWl0exymGuZcrGp7e5+leYlpJ5mlmYvI5yzHkk1b1fUJtZ1N7mQEJ92NP7q0iw4T3rhqT535H0eFw6w8LP4nuSWyKcVZZljHUVlGdomINQzXbPhVyWPAArPmsdPsnJ3L892F6Gs6a5O7cDVm00PU70B0h2oe7sB+nWtFfB98y/NNAPxJ/pRyTlshe3w9LRyRg/bWzyaX7UPWtp/BN918+2/Fj/hWfdeFNViJ2xxygd0kH9cUnCouhccThpOymimboetL9oz0NRSaPfx/ft5B9Bn+VLa6dcThvJUuFYo2COCOo+tTafY2c6KV+ZfeI9zg9aFlLdM1oW/hq9lYbkRAe7uBWzb+E2AHnXtuh9uf8KpUpvoYzxmHh9pHMgsPmqQXBUd811o8Jwkcaih/wCAj/Gql54W8lCwvIm9Bj/69X7Ga6GKzDDy3l+DOaN2c9TV+xlUncTTF0a6mtzNaxieIMy5jPOQSDx9RWczyW8hV1ZWHUEYIrJqUH7x1RdOsrQZ0EsqsAqnJNPe3GwcVg213+8BNa8V6HAFWpJmM6UobFS5hIzgVp+FfEUmj3QhuSzWTn5h12H1FRvtkFZ9zbdaNYvmiDjCrF06i0Z7LDKk0SSwuHjcZVgeCKfXm3gfXmsLhdPu2/0aQ/Ix/gb/AANek13U6imrnzeKw0sPPle3QKKKK0OYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4bx/qpaRNNhbgYaXHf0FdjqF1HY2U1zMcJGpY+/tXkTyyXd3JPKSXkYsT9a5687LlXU9PLaHPN1JbL8yzZwjGanuCqIaSNhGlamj2MUq/bL3Bi/gQ9/esIxctEelWqqmueRQ07RTer9ovC0Vr1GOrf/AFqwfiHcW+mafZppyCN/PDqepO3nJ/HFdL4m8RW9jbM87hEA/dxA/M59AK8e1S9uNXvnubgnnhEzwi+lbOMYKy3ObDuriZ889Iroeg6N48tHtE+0ztazD7y7SVJ9QQKuTePdOUHF/I59Ejb/AArzKCxLDkVdi08egpe1aNnl1Fu+p1d18Q4ySLe2upvd2CD+tZc/jfUpc/Z7OGMHu5Ln+lVYrBR2qytiv92pdVmkcFQj9kp3HiTXZ4mQzJEG4JjTB/OqWmX2q6aZPsdyyiQ7mDAMCfXnvW8un/7NSLp4H8NTzs2VKmlyqKsUE8Ra93njb6xCnHxLrq/xQH/tnWkLHA+7THscj7tPnl3J9hR/lRnf8JZra9Vtj/wA/wCNRTeLtbKkAwJnusfI/M1dksP9mqktgf7tHPIPq9H+VHR/DbxdHa2402+ZVkDExtIcb8knGfXJ/GvQbqPTdWj23cI3dmPBH49a8Qn04MpDLU2naxquiuPs8xmgH/LGYll/D0/CrjUTXLI5K+Bbn7Si7M9D1fwhLCDLpr+fF12E/MPoe9czmSCQq4ZWU4IIwRWppvxDsmQC5MtpJ3DKXX8CP8KW31a18VapJDbqdkSZNwVwxYnAAHp16/pWc6MXrA0oYuvT93ER0XX+tytDeFV5qeKVpzk/dqtqFhPp9x5dwhX+63Zh6ii2mKnFYXadmehaMo80Cxcw8ZHBr0LwVrJ1GyNvOf8ASbcAEn+JexrhlIkUZFJp94+larFcx5wpww9R3FawnySv0OPE0PrFNw6rY9foqOCVJ4UliYMjgMpHpUlegfMbaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFR3EyW8Ek0p2oilmPtQCV9EcX8QdTJaPTYunEkh/kP61zEShFGetNubl9Q1Ga6l5aRs/QdhSXGQvHavPnLmbkfUUKKpU1T+/1EmmUsA7hI15dyeFHc1Z17xHaabp6uZEchcQwxt97/AOt71pWWkRLoLy3a7pLleVb+4e1eJ3Vt5Wo3NunKxSMg+gJFaxTgr9zncYYuo430j+JNdXVxql89zdOXdj+CjsB7VftLcdxUVpb7QOK1raDJ6VDZ6CSSsh8UQwMCrsFuT2qxa2vTisyz0/xDqPiJprqX+zNGs5SIbeIq8l5j+N252p6KOfXHFJK5Ep8vQi1PxJoOj3S22oanbx3RIAgUmSTn/YUFv0qfU9bmsL+SztvDut6hIgH723hQQnIB++7Ad+3euqtdKtYLma4htYI7ibBllSMB3wMfMep6Dr6VdWICnoZvnfU5rWLjVrW3tZNI0I6g8oJkje6SAxcDAOcg9T09KfFNrJ0KS5l0WBNVBOyyF6GRhkf8tdnHGT92umVOaWaPAFAtb7nM+Hp9bvJZV1rRLfTY1UFHivhcFz6EbFxVKwvvEc2oxwX3haO1tWbDXKakkgVfXbtBJ9q7JRxS7aLhZ6a/l/kcRrmtXel6hJE3hnV7y0XG26shHKGyMn5N4YYOR07fStC6u9Otri0t7u6gtrm7UtDDM4R3xjIAPUjI4rp9g9Kzdc0HTNdsza6vY295Af4ZUDbfcHqD7ijQPeV7MzLiyGDxWReWPB4p3iLU7TwFpOmxiJptJicQ3Dvcl5reM/dfa2WcA8HnIHQGpZ/FPhljtTXNOmb+5DOsrfkuTRyspVorRvU5m9suTkYNa3w9vk03XWhn+VbgBVY9NwOR/Wob3WdNmB+zQancehh024Zf++tm39awby6uJCRDoWqsQeGYRR4/76cH9KqN07iqOFWDg3ufSFza2Ws6d5UpGcZB7qfUV5zq2nTaXeGGUhh1V16MK4bT/GXi6xQImmwSxjp9qutrfmgb+tM1Xxl4rv40SSDSLZVOekkx/PK06sYzV+pyYONbDz5d4/13PRtOkBSi/i3KTXHafDrk6RyHX4I0cZBtrAL/AOhu9bJ8PXVxGGuvEmtTf7KmCIf+ORg/mTWCSatc7pOUZXS/I9K+Hmo+fYSWUh/eQHK/7p/+v/OuskkSJC8rqiDqzHAFeD6J4Z0yDXIVvptVuIJDscS6ncbSDxyA4H6V6jH8PfB6OJG8NaTPKORJcWqzOP8AgTgmuyhK8bdjwswpOFXmtpLUtX/jTwvpx/0/xJotqfSa+iT+bexq5oevaZr0Usuj3sV5FEwVniyVzjPB6H8KnsNK0/TwBYWFpagcfuIVT+Qq26h0ZGGVYYP0rY4DwPwj8ZptT+MV1pt1qNlJ4bvJbq00+CLaZYngCYkYgbtsmJNoPXjFLF8W9Zn1fRdfvLJbLwxcaPqWpR2cE4mmuEh27TJ8gCNwcAMR83OMV6+vhDQF03SrBNKtls9KnW5sYgMC3kUkhl9+T+dVNN+H/hPTNQe9sPD+nwXLrIjOkQ5WT7646bT6dOT6mgDz23+M2rjSvtd14NnQzzWcdm5knghnFw23AklgTLJlc7QVOcg4q/bfFbVJm/spvD1tF4lbWn0ZYGvz9lDLF5vmGUR7sbe2zJP5Dr7L4c+ELEN9k8PWEIMsc3yR4wyNuTHoA3IA4q5feDPDl/Bew3uj2k8d5ci8nDpnfMAFEmeobAxkYoA82tPi9HcT2urXFlfwW8eiX99cWcdwjx+ZbTeWyj93lySDtcOoweV9NT4d+K/Eeu/EW9ttditrOzfQ7W/gsrafz0QyO3zFyindjAIGRxwea7mDwj4ft/s4g0eyjW3tHsYkWIBVgc5aPb02k9R3qPw34M8OeGLiWfQNItbCaWMRO8K4LIDkA/SgDoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW+IN75GlJbIcPO3P+6P8iuprzXx1dfatf8AIX7tugT8Tyf51jXlaB25fT9pXV9lqYduNq5qxZqtzqNvC/3C2W+g5NRMu1MGub1DxDJpd8UtUjeQryXydtccd0j6Cabi3Hc9H8T6xBaWMkrMBHGOB6nsBXjNnG887zS8vIxdvqTVi91O+1mVTeSAohyqKMKDV/T7cADit5zuc+Ew3sIu+7JYLbpxWvZWvI4p9nb7iOK2ra3CgcVkdLdjlfGen315b6NY2CXHlXGpQ/a5IcgpAmXY7h0yUVfxrtEjA7VleLF1ZPD11J4daMapEFkiSQArLtYEx89NwBXPbNP8O+ILXXNFtdRtlljSdcmKVSrxsDhlYHuCCPwquhgn777msFoxVc3se7HNSxzLJ900i2miWMfNTrheBToV+cZqxcJ8tUtjJu0igop2KSV1iUljVF78/wAKVNzVJvY0AKo6to2n6xHHHqdrHcxxtuVJMkZ+nf8AGmx6gc/OnFWY76NjzxQmEoO2qMyDwh4etkZbbQdKhVgQRHZxrkfgKr+FL211C3v7exsls7fTLyTT1jTAX93jkADAHPSrWueKtK0e7srO4lea/vJFjgtLdDJK2Ty20chQMkseMCrGi6VYaIJ7W0ciW7nmvXEj7ndnbLt6kAsB7cVXTUxTSlaJPJbBhyKyr/Sw4JAo0nxt4a1fUDYWGr2z3ucCB8xu3+6rAFuh6ZrfZMila25pGaeqZ57e6eUBytYN5b7cgjivTNRsw6niuP1S02swxxTRrGVzN8NXhilazkPyt80eex7iu602Xcm0mvNLhWgmWVDh0O4V22j3izRxzIflcZ+hrOas7mtuaNjTv48fMOo5Feq6Hdi+0i1uB1dBu+o4P6ivNJAJYs+1dT8Or3da3Ni5+aJt6/7p6/r/ADrWi7Tt3PLzGHPR5usTsKKKK7DwQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjuJlt7eSaQ4SNSxPsBmvH45nvL2a5l+/K5c/jXpHjS7S08O3e5sNKvlIPUn/62a85sE2xZPeuSu7ySPbyyFqcp99BmoHYnWvM7hzc380h53McfSu68T3Pk2MzA4O3A+p4riLGPLgmsobtnrLSKNKxh6ACuhsoenFULCLpxXQ2EHQ4pslsv2UAAHFVvEviOw8N20L3ouJJZ28uCC2haWSVsZwqqPT1xVfxFNqEmm3Fl4cubOPVzsBaZs+QjHBk2jqQAxAOASPwqx4f0k6VpcFpJd3V68eS09zIXkkYkkkn6np2HFGxi7t2RRutb1ebQre/07w/dTXMrfNYzzxwSxp83JJJXPA4z/F7Gqn2e48X6NFNaXOreHr6CYlkKoJEcAjbIhyHQ5yB0PBrsUCj2FYOhaZPpXiXxNfSPCbfU54ZYVjJJASFUO7gYJKk8ZpqxMua6S2f9XIrfT9etNCnjuLqw1DV1J8mR4mt4mHGN4G4g9entTvC//CRG6lTX7LS4YlXKS2Vy8m5s9NrIuBjvmte6v4YhulkUfU1VttVhmdvKkVsdQDyKV0WoSfUg0vXPEcurRW114Qngtmk2m6GoQOqJ/eK5DfgAaueJvEOqaZqD2tt4U1bUIVCkXNu8IRsjOBucHjp0rTsbgOQQcitO+l8yJT3Aq01Y5ZwkpJX/ACOF8S6nqkMVtJpmhT6i8oy8QuIoTDwD8xc89ccZ6UtpLrV1oEs/9jw2uqg4jtJ7sMjDI5MiA44z27Vo3VwI5iOpqk+uQq2xXLHp8oJH51nodnJLoyvoMHiVp5f+Eih0eOEqPLWxkkdg3+0WAGPpVCz8N65HqMdzqXie4uIo2LC2gtI4I29m+8xH41txaujnlsfWr8F3HJ948UByNJX1sZFpp1pp2q3Oo21nAl9c4864CDfIAAAC3XGAOKj0WwjPjfVdcvZY5rmaGG3tVx81tCASw/4E+T+ArfZY5AdpBrkrnQri18bDW7aSFLOazNveI7FSWVt0bjjBPzODkjjFCbRMoxdtOp12r6NpetxRJqtjb3axOJI/NQEowOQQeo6dqybfXL+28cTaJq1tGLW7jM+mXUKnDhQPMjk5OHBOQehB9av2t0yHa5rm/GNz4t0zwvrGrWmr6XmzgkuEhTTXB2qCSCzStk4HXaB7VcXfQyqxcPeO4mjDLXN6zaZBIFFppGqX9pDcP4s1MRzRiQC3traMEMM/xRMRx7596gu/CKyA/aNZ1yc89bwx/wDosLRYcZvojlNRt8buKPDd2IGmt5nVFHzqWOPrT9V8HaYhbfHdzf8AXe9ml/8AQnNc1/YGj2OoRTf2VYsob5t0Ctx07iiSTVjeMp9l9/8AwD0iLxToVtFi81rTIP8ArrdRr/M1L4a8d+H7LxFDLFqUdxDKNjfZkafOemAgOecdKi0S2s7Yg2ttbxdwY4wvb2rXuyY3inT7yMGBrOMktexFSnKV4O2p2R8d6dJ/x6ab4juuwKaJdID9GeNVI9wcUf8ACWahJ/x5+DfEc+ejN9lhH4+ZOpx+BPtXS2c63VrDOn3ZEDD8RU1ejufLNWdmeb/Ed9X1L4b+INRlGr+GbzS7S4vbb7LfIHlZIXYBymRtyBxn8a5fwt4um8H2Hw2Gua48+n+KLCS+1C/1q5LGCUW0LqkbkhUUs7cNnPbmvbpo0mieKZFkidSrIwyGB6gjuKhextHhhie1gaKAgxIYwVjI4G0dsdsUCPmJPin4huL2HxO2raRpty/hA332K5WQ21xKl5OojijMoIkcIq7ssfb06nXvjFrNp4x020tBYrbtc6fbXmn3MASWM3CozBXMwdmXceRFtGBknmvbf7F0vdC39m2WYQBEfIT93gkjbxxySeO5qSfTbGe5FxPZW0k4x+8eJS3ByOSM8HmgDgvg3d6hfeE/EDG7aW8XWtRigkui0qpiVggIyDtHHAI46YrzrwV8TPEZ8DeDY73xBoS3Oqy3a3GrX8ZdbLyVLLFMPMUGVz0OV+UfdJ5r6Jgt4bdWW3ijiVmLkIoUFj1Jx3PrVc6Xp7QSwmxtTDK/myIYV2u/94jHJ96APDJfiv4y1LS1udLtdG09ofCf/CSXCXdvLIzMssisiYcYVljBGQSN3U9RZl+Lmsf8JxodlKdNtdLvv7PURwxLdzM9xGjusgEyyRYD4U+W4PBPHFe3SWVrI7tJbQOzxeQxaMEtH/cPqvJ46U1dNsUuY7hbO2W4jUIkoiUMqgYABxkD2oA8M+EPiC91jxJ4DlkkkgguvDt7NJapcTSR71ugob967sxx3ZiefTivfarW9hZ2xiNvaW8RiUpGUjVdik5IGBwM84qzQAUUUUAFFFFABRRRQAUUUUAFFFFAHnnxJvDLqFrYqfkjXzG+p/8ArfzrBLiKAfSn6/ObzxJeyE5AkKD6Dgfyqvef6vFedOV5Nn1eHpKFKEPI5Hxfdb/JgB5Y7z/SqNinIqHWpPO1eQDomF/KtDTo8stVHRG8jf06LgcVtRMEXC9azrVdiDHWtG2jx8xqWyLdWYvg/Rf7PuNV1K4uY7y+1K6aVp05CxqdscY9lHH1zXUg7iFUZauT8OeH7rw//aNvp16J9PkLS2VnMm0WzsWZl3jkoWPHGRz1qvDqfiO1NxH4gXR4beSIog06WVpd5/22CgcZ6DOcc1Vr6mMdEopamrrms/u9S0/RryxfXLeHeIZZOI2bO0uBkjp0+nrWP4dtW0XQLbTYZnlMQLS3D9ZZGJZ2/FiTVDQdKstGsmS1iWCDJkldm3PI3dnY8sfc1j6xrct+zQWuY7XpkcF//rUN9EawpvSU9zZ1DW7G2chna4lH8Kcgfj0rKHiTN5DItsIkVhkhsnHesmK1z2p11b7YSR2qTU9g8Py7pSmcjPFdPqRVYBt9K4fwjNvS1f8AvRIfxxXX38pa3Oewq4vQ5q0b1Ezz3xVfta6fdSr/AKxyI1Ppn/62a4y31vUYsESIwHGCgrp/HAH9lR4/iuBn8jXKwwgqM1COk1bXxOpO2+tcf7cR/oa6O0mE0Cz2MweM+n8q4l7ZSOlNsru50q4820bg/fjP3WHvQO56Naap5ThZxsPr2q5rFhZ+ItGutNv1321ymxgDgjuCD2IOCD6isPTr601a23jjs6nqhqGSe40a4XYxltSfu9x9KaIlFPRkyanB4U0jTLPxfrNv9sfdEl3IpRZdp4LMeA20rnJGTnFSeI/F/wDY2hxT6T5N/fXrrDp8Snek8hPqv8IGSTnoK1be8ttTtgkixzQSDBV1yD7EGsXTfFfhS4vLfSdI1TTnnyVhgtmBHAJwu3jpnpT87GEk4rkbtfbv/wAE9Agk8yNSSC2OcetEq5FYen38YuZIFmjaSPAkjDAsmRkZHbg5rdVg6AjvQncUo8pgaxbbkJrhdatvlbAr069i3oRXF61bYJGKpFwZF4ZujJYxEn5k+Q/hXVsPNtSPauB8PSGG+ntyeD84rurF98OPasrWlY0nqkz0HwRP53h6BScmJmjP55/rW9XE/D+4KTXdqTwcSAfof6V21d1J3gj5nGw5K0l8/vCiiitDlCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZPIIYZJGOFRSx/AU+s3xHMINCvnP/PIqPqeP60pOyuVCPNJR7nlMJMtxJI3VmLH8TUeozCON2J4UE1ParhSaw/EU3l2dw2f4cfnxXmH2EdWchBmaZ5D1Zia6TSU6cVg6anyD3rpIpYLGykuruVIYIkLySOcBVHJJrV7C9TU+2WltcWsNzcRRTXLFIUdgDIwGSFHfgVnW+la7cayb7WNaMNrDKTb6fYDZGyA8GV2G5yR1UYAPTNGk6DAviK51+5ufttxKgjtCVG22ixyE55LHJLd84+uxdTc4zU3tsQoub945vxLoVrLdyazZ3t5perZX/SraU/vMDARoydrjA6EVFHJNqF/5so56Bf7oq1FKdSvvNAJtbc4T/aPdqytbujpwulh4klbahHYHkmndvQuNOMW2luUfEeofa7j7Javm2i4Yr0dv8BVO2g4BPSobKHOK041wQKNirjki44FQXafumBHataBBiqt4gJNIR0vgucfYbE56KUP4Eiu61AFLLeejDivJfDGoJZStaXLiNWffE7HAz3Brtpb6eaAIzgRgfeLcAUJ2JnDmaaOd8aAf2RAc8tccfka5uBeBV3xLqCX97Db2rB7e2zlx0Zj1x7cVVhGCKCy0Ifk6VTuYsGtRDmOqdwvJoEZcU0tjcrcQHDDqOzD0NdK92l7ZrNEcoeoPVT6GufuE61BaXTWMrd4ZOHX+oqrdRnVWiy2UEU8JLBxl07Ef411OiXdtJaLFGkcSD7mxQoB9CBWLp6rNaW465QYqO5ik0mfz1BMLf6xR6eo96lMcoposa74O0TVr37bNaG31NSCL20cwT5HTLrgngY5zU+seLbjw1fQy6jYM/h5kAlvoSXa1fJ5kTGfLxj5hnHOR0q9Z3H2gKVYMpXKt/eFW1/ToafN3MJUlZ8ujNssssSujBkYAgjoQa5rXoBtJAqlca5qel+MLSC7H2jQtTUQQvHH81pcAE4YjqrjPPYjHA5ra1dA8RqjOD1a7Hnch+zarBOOF3Yb6Gu40t/mxXFa1H94dxXS6FcebBBJn7yjP1qJ7pnStYtHaeF5hb+IISThZMxn8en64r0WvKYJDDdQTL1Rg35GvVVIZQR0IzXTQejR4GZxtOMu6FoopsjpFG0kjKiKCzMxwAB1JNdB5g6is/Stb0rVzJ/ZOp2N8Y8b/s1wku3PrtJxUupanZaYLY6hdQ2wuZ0toTKwXzJXOFQZ6sT0FAFuikdlRWZ2CqoySTgAVRGsaab20sxfWxubyNpreMSAtMi43MvqBkcj1oAv0UUUAFFRwXENwrNbyxyqrFCUYMAw6g47j0qSgAoorIt/EuiXF9HZwarZyXclxNaJEsoLNNEMyxgf3lHJHagDXooooAKKKKACiiigArnPHkhTQ9gOPMlVSPUcn+ldHXI/EZsWFp/11P8AKs6ztBnTg1evFeZxZOyI4rj/ABVMfsyoP43/AJV080uUxXGeJJN97FEP4Fyfqa8+Osj6mKsmJpcedoq54k0V9ds7Sx81Es/tMct2hHM0Snds/FgufbNQaZ8uPU0mkWN1/wAJnrOpXcZWIwQWto2RygBdz/322OfStXuRJXXK1udgZAiemK5/Wrtn2W0R/eTdSOy//Xq7dTgAhjhQMk+gqhoUZvbx7yQYBOEHoO1QjZKyN+2tIrPSVSMDJHNcZ42tikllKf4lYH6jH+NdzPCiIXD528lSa47x3cLJFaDoxdiB7YH/ANan1JT0MKwHFXh9+qNq21RV1TyDTYi/FwtVrjmrERBWoJyAaQFKaBZFw65FVxZIO5x6ZrQZgVqKgYyGFUG1Ripgu1hSRfep7nBFAi0h+WoZ6dGwxTJ2GKAKcgyKz7lcqa0HYYqnMM00wO08NMf7DsnIyyjH4A4ravlS6hweSev0rJ8HtG+jIG5ZNy/Tk1twSReUemakpnGW+tafpF49nc6nZxwkkxs86jY3cHnitO28a6Ay4XWLOY9P3Mglz/3zmjWPD9kbXda2VvE45/dxKv8AIUulXbz24Ln9/F8sg9fQ09CLTfVf18yZvF+neW/2Q38shU7DFplzKuexO1On41neGPG1xrPh+F7rRdUk1KItb3awW+1FmQ4YZcjHrg9M4611EEu5RVHSdWtz4i1XRorRYHgjiu2kXAExkLAkgDqCnJPXNUmuxjOMlJNy/A47WtRv5JGKeHtRQHvNLAufykJ/MU/w3qWuNAYbfSLTMb9Z74pjPP8ADG1dTr8OQWArn9Ek8nV2jPAkX9RRLWOxcIu/xP8AD/I6KOXxTLGpFvokH/beWX/2Rf8APpXo+mW3jW70+2k/t3QLeMoOE0iWR+B/eNwB/wCO1yNk+6ID0r0vwnL5miQj+4Sv65/rWtCV2eXmdO0U/MzP7B8Sy/6/xjPGf+nXToE/9DD8f55qe40a9tvDGs20urajrNxcW0qxm7WBWBKEBVEUcY5PqCfeukorqPFPnLwZ8NvEugeBZNf+zRv4ij8PtpltpNqjWchzJvLSyq+55B22lemBg81BovhrxlKYLe8s9al0628U6Rf2qXu7MUKgmdgHmlZVDYODI34EkV9KVwE3iLxDqeveMrXw5BaPHotuttbRyjBuL54xJlmJAEahkBHUknn1APMNM0HxzqPjG4F5Za5YWeoQ6nb30X2yVrfJU/ZysjTvkk4wypEBnABGan8J6H4v03w94esrC18S2S22hahBdQz3TFReeUgiKDeQF3A7MYxzgCu08T+NfFPg5tNOraQupjUtai023SzCKxi8nJf5nA8x3DlVOAFHJB66lv8AFDS5vESab/Z+pR2j6k2irqLrH5H25VLGHAff2I3bduQRnvQB51b+GfiFY2Trot7rrX9/4Pjad76+aUJqfmR7lUux2Ps8wDGAOue9dn8ENO1zTxrf9tSa0LaUwNBBqMLIsL7WEgjL3M7sD8pOSBk/LnJwmmfGnRr2Syd9G121sb2G8ltbqaCMrMbVXaVVCOzZARsccniq9j8X7PXbDTLvTIbiyiudXsbHcwtrzzFuCwCERXGYm+XndyuR8rcgAHF6N4S8S6Loeo6fBYeKPsyeJDPqCQ37br2wLSkG3bzQdxyhkwVZuMk4NaWneF/Gupnw9Za5deI7fTPs2pGRYtRdJUUuDapO6N8zhfUn0J6iuk0LxT448RaVe3Oi2mmyNa3eqWx3jaGeJglsnLdySzH0QgYJFdKdc1XSvH2jaJqsltcWWrWMjQyxRFGS6gCmQHkjYytuHcFSOaAPHL/SviPNZ+EpGtvEF9qEWnQQzW0tzJBCJRId0jTRToRIFxkyI4xjrnFdPouheKZviToOoavb6hNaWfiTXJVmuHLiG0kh2wYyeEJ4UDgele30UAFFFFABRRRQAUUUUAFcL8S5jusoe2Gf+Qruq8++JWf7QtM9PK4/M1jiPgZ35ar4iPzONlYAcnAHNcO8v2zUJpv4S3H07V03iGfydMmYHlhsH41zOmp0rjp9z6WXY07Ifv1A7VDoWo3LeJPEdjdyl1tnhlgBAGI3j6D1+ZXqfTTm4NV/F2rXGjWMV7BbrPaxyj7YACXSLu6gdcHBI9M1W7sZy0tJvRFjV5WeNYk+9M2D9BXQaZb+XbRRphSoyT71yllf2t3crexSLNb7R5TIchh6itr7dezr/o1swX1PFKxq3fY1JnkJIYggHnFch45kVtQto1PKREkemT/9ate6a+tLSa7vZ7e3t41LyPK2AoHc1zekadqXiqGXV3RbWCeQ/Z/OyGliAAV9uPlB7A9ue9CXUlySfL1KUMgC4zVpLgY61fPg7UR92e2P4n/CoZPC2rx9Fhf/AHZP8aegCRXWB1pGl3HrVSfTNUt+ZLOXHqo3fyqmbho22uGVh2IxQBq7hRkVli6PrQ1yfWiwGoHC96Y84zWdHLLM4SFHkc9Aoya07bw/qtyATGsCnvI2P060gsRfattRyXYPU1tweEGJ/wBJvc+0a/1NX4vCWnr98zP9X/wouh2OPacHvUbzD1rvV8L6WOsBP1dv8aefDOkkc2v5O3+NFwsc74PvCL17YyAJIu4D/aH/ANb+Vd5bC2XIcgEdSawk8L6bHIHhWaJwcgrIePzrB0rQPEGlaxLax3zXmkMrSQXM8mZYmyP3b5+8OSQ3tg9qFZkybVkd95aSSsQcIBnFczq0J0nVEuVGYJOHA9DTra81GONZkEd3A4yskLBgw9R60X2ow30TRXIKPjo4xTsCNK3ba2M5U8g+1VIV03/hLLieOQnV1so45U5wsO9yp9Mli3vxVTT9Qhg053vZ44Y7b70sjBVC+pJqbSNIa11jWtWmnWV78xCMKMCOKNMKvXrksfxpJWFN3asa2oKJbcmuKnP2bU4Jf7rjNdpbSLNbMM9K47X0CyZHUHNWhI7nTmyCK9G8DPnTpk/uyZ/Mf/Wry7R5t0MT/wB5Aa9G8ASllu07fKf50qDtJI4szjei36HX0UUV3nzgVzGk+HLjSfHGt6taXER0zWI4pLi2YEOlzGuzep6YZAoIPdc+tdPRQBheL/C2n+K7G1ttTNyn2S6S8t5raZopIZkBCurDvhmH41lwfDnw9B4iXWEhujMt0b8QNdSG3F0V2mfyydvmEfxfj15rsaKAOJt/hn4et7DRrOFLxItIF4LUrcsrr9qDiU7hg5/eNgggjjHSq1j8JvDNpMlxsvp7wX1tqDXVxdNJK8kBJiDE9VBJ4755rv6KAMjwz4esPDdnc22mLIsVxdS3j733HzJG3N+GT0rPuPDlxffEGz1++niNnptpJBYW6A7hJKV82Vz67VCgDsSe9dPRQAUUUUAFFFFABRRRQAUUUUAFef8AxHHmahaqDyI/616BXA/EJSNRtmPQp/WsMR8B35a7V18zzDxnbSx2UDDmMP8AN9SOKw9OIyK7/WrX7dps0PGWTj6jkV5xas0cvln74OMe9csNj6GMnLc14JFglZnOPSrEdlc6g/zfu4D3I6irOn6RllnvOSeQn+NbqrkADgUNmiRymoaBf2a2z+GLixiMIIa2u4C0co4x8y8pjHGAevStOSbXxoUbw2en/wBrnhomnYQryeQ23J4wcYrdSH2qdYaLtkOKTdmc1pGnanPY3MXiqexv/tBB+zxW+IYwP4fmJLc85NboUge1WxD7VDdTW1ps+1XEMO9gieY4XcTwAM9TS3BNRRFg0hzWZ4g8U6HoF5HaapeGO7kjEqwxwySuVJIBwik9QfyqSLWVutBl1Oy07Up1UkJbm3MU0nIHCvt456nHQ0+Vi9tC9r6l0g1HJBFLxLEjj0ZQap6Bf6pqM039oaBcaXAqgxvPcRu0hz02oTjj1qnp48XPfxNqFtocFhu+dYp5ZJcexKhc9P8A61HKw9qnayevkX5NE0uUfPYwf8BXb/Kol0PSlmAWyixjODk1U1fTfElzfytp+vWthZHHlxf2eJXHAzli4HXOOO9Sa5p2p3bWv9na3NppQESNHbxSeaTjGd4OMYPT1ot5j5nr7r/D/M1oreG3XbbwxxL6IoFBUmqaaTqf9gNZnXJzqBORqH2eLeBuz9zbs6fL09+tL4f0fVLGSb+09bl1RHA2CS2jiKHnPKAZzx19KVgVR3St+X+ZdRMdqkCH0rI0jR/FFvfwtf67YXtnn95GNOMLng8KwkIHOOoqbVrfxgNQmOjN4fNiceWt0swkHAzuKkg85xgDinykuvpdpmmEPpS+WfSq+vSa9apatoul2eoEg+ekt2YCp4xtOxs9+uOnvSDUr628PHUNS0O7S7U4axs3W5kxuxlSMA8c/T34o5WL2yvYsmM01kyCCMg1X8P6/Za6tyLeG9tpbbBmivLV4GTOcfeAB6HoT0rUVEljV4mV0YZVlOQR6g0NWKjUUldHJaV4TstG1Y3mkS3NlbvuMtjE/wDozsf4gh+6f93FQXUfiiXUnX7H4ek04y/KzyyiXys9xsI3Y98ZrsHiI7VCVxRd9QUI2tHQ4rXfAlrqmopdyTyvDEAUsXI8guD95h/EenByBV4XlxaAw3iFD0B7GumwahubeK5iMcyhlPrRzPqUopNtdTE026CxSA9zWLrrBiSDV3ULWXS24y9ux4b09jWNeuJB1q0Kx1nh6Tdp1s3+xj8jXpXw6bdLeeyrXmPheCQ6ZEB6kjPpXp/w/C2kF9JcOka5TLMcAde9TS/iI5Mxa+rv5fmdtRWNd+KvD1kSLzXtJt8Eg+beRpjHXqazf+Fi+Dm/1PibSbk+lrcrOc+nyE8+1egfMnV0VxPijxZe6V8SPAmgWkds9jrwvjcSOrGRfJhEibCCAMk85B46YrJ1j4lRaDr3imC6hvb9dPvtPsYraCGNSHuYgQFYuN2Sed23HTkc0AemUV5fa/FyK5ki06Pw5qY8RyanLpg0oyRbg8cYldzJu2bQhBznr7c1a8O/FjS9bisHh0++hN3p95qKrJs+VLaYxOpw3UkEjtigD0aivI9e+OGlaPpuk6lJpdzLY31jDqD7bmHzoY5GIGYt244wCT054JOcdR4D8RahrOr+NLe92SJpWqtaWyooU+WIkYAnucseaAO0oryHwt8XL/UPD9ncah4auP7U1DUpdPsLa3miC3DIZNx3Fzt2BPmJ6k/Lkc1eb4v2txZ6Q2keH9V1C91GC6lW0RoY2hNu22VXLOBwc4xnOOOtAHqFFeSr8b9ImvdDt7XTbrOqWsV0jXVxDbALI20KhkcCRgQchfwyeKbo3xA1HUPFvhawgn8yz1DVtWsbnzbdY2xbRsyBcMeAR16kdQKAPXKKKKACiiigAooooAK434jQ5trWYdVYrXZVheNYPO0GUgZMZD/0/rWVZXgzpwc+SvF+Z59Gd0YNcvc6bBaa1JNtyWO5AegrorUllxVLxDCfJjnUcxnB+hriifS/DIWDMnJq9ElZ+mvuVTmtiNOlFjRyFRKnSLNPiiJxVyGHpkVSRjKdjjtIk17VvFV5IVGn6BYStbLFJCTLfOF5k3H7sYJGMZzg89quR+AvDg1WbU30a0mv5pDK006+awYnOV3Z28+mK1/E2jatfwW8mgawdMvbdy6h4llhn4+5IvXHuCCOvPFL/a91onhZNR8XWqpcxttuF0uOS5RRuIDgBd23GCcjitVHscMqqTtLX1LJtfamG3x2qbw54h0TxNbST6DqNtfRxkCQRN80ZPQMp5U8HqB0rSeEelJwNI17mI0IHaoJIsCtiSMCqk0eKho3jO5jypiqDN++MZHWtmaPrxWNfAxXEcgHGcVDOmDualqu6Jc1aSMVHa4KjFXo1zVIylIYkee1TpBmpYkFW41FWkc852KYts0htfarN3e2llZ3F3d3EUNtbqWmldwFjAGSSe3FYvhvxnoXia+lttCupbzykLvMlvIIeCBgSFQpPPQE9/Sq5TF1rOxl32sfPPbL4f1q7UFo2xbKEccg4LsoIP6/SuEi+z+DdXt7mw0DW9KttQcWsemyXdt9nmncjayxrI5U+pXAx1FehWV34yv9YjNxpOlaTpEchEgmujcXEyc4KhAETPB5J/wsDwppcfiWfX3hefVHGxJZ5GkEC7QCsak4QHknHXJp2SJUnOzMN7vxLJ/qvD9in/XxqZX/ANAiaoinit+fs+hwcf8APeWX/wBkX/6/tXZunpUZTiszrV+5xjWHid87tV0eEekenSMfzM2P0qBtH1tj+98ROv8A1wso1/8AQt3FdpJGCKqyR1LNUk+/3s46fw1PcRmO88Q6xOh4KnyEB/74iFcTq3hZbO7aN7vUpYycq32yRc/98kV63cjYK5ydEudQjjYZBcUKTK5I9UO0jwVoq2UYuLWSchQD51zLIPfhmNd14H8B+FHhnuZfDWjSyBwqyS2UbsOOcEgnvWbt8uIdhXf+C026GjY++7N/T+laUW3M8vMFFUrpbst2ug6PaLi00rT4BjGIrZF49OBWlRRXYeIcv4y8DaL4vu9MutYW7F1pvm/ZZrW7kt3j8wKHwyEHkKB+frVb/hW/hsmZpLa4keaazuJHkupGZ5LVAkLEk5JAUZ/vdTmuxooA838Z/DC21RZLjQJILDVJdQOoyXUzXBYSNH5bFGimjZMqACAcH071Ho/wa8OW3hjQ9K1X7Rfz6VFPEt3HNJbPIszs8isEflSzH5ST+OTn0yigDz2/+D3g6+s47WWyvEt1s4rBo4b6aNZYYzmMSBWAfb2LZrrdF0DT9Gu9UudPiaOXU7k3dyS5bfJtC5GenCjgVq0UAcT/AMKw8MC1mt47e9ije8N/GYr+dGtpyWJeEh8xZ3tkLgHPParun+AfDmmyaU1hYeR/ZlvNa2wWVyFSYgyZyfmLEZLHJySc11NFAHBr8J/CYt7C2a1vXsbMRhLNr+c27+WcoXi37XIPqPrmtLT/AAF4f0/ULC+tbWRbixu7q9gYzMdstwCJTjPOQTweB2rqqKACiiigAooooAKKKKACq2pw+fp1zFjO+NgB+FWaKTV1YcXZ3R4zaNsmZT2NWLlUmjdGHysCDTdctzY65dQ4wA5I+h5FOt8OvPWvNWmh9Y2pJTXU5zTpGt7loJPvKcV1Nv8AMBXN+IYDb3Md0n3W+VvrW1o9wJY155qynqjbt/Q1diqlDVuM4qkc0y7EcVOGqojVMrVomcsokVzZWtxb3UMsCGO6UpMANpkBGDkjnocVz2geCNM8O3/2nSLjVYYQhT7G9/LLb899jsea6fOaUnincjlV7nE3OieKV1h7mDxYhsGn8z7HPpkbbY92fLV1KnpxuOT9aPEi+KjeofDz6H9j8sB1vkl8zfk5IKHGMY4xnOea66Tmqrjk1DZ0QirHLaoniL+xbX7B/ZP9rZX7R53meRjB3bMfN1xjPbNZPleIDpFz/ah0pdRy32c2wkMQ+XjeGwTz1x2rtpV61maimYTgVDOqmtb3MTwrF4nF0H1280h7QIQI7O3kRi3Ylmc+/GKs/wBj+KH1YzjxVDHYefvW1TTEz5e7OwuXJPHG4Aeta1lxGo9q0oulNMicFtr95ia/4duNZvUlTxFrOm26x7Db2EkcYY5J3FihbODjgjoMVev/AArpmr6JZ6XrP2q/t7YqyvLcusjsARl2QqWzk5B4PpWktWIzVJmE6aZQ0Dw3o3h/TnsNG063tLORi7xRrw7EAZOepwB19K1xwAAMAdMUwGpOMVRlZIaTxUElSsaryGkzSCImpmM0802pNkRulVZlxV1ulVJyACTUs0izH1RwkZrC0ePz9T8w9I6ua7cgAjNL4eh8uDzGHL81L0Nuhr3T/IFFemeHYTBodmjdfLDfnz/WvLWbzbhEHc4r2CFBHEiDoqgD8K2w6u2zx8zdoxiPooorrPHCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOA+JNkUnt71F4YbGPuOn6fyrmbN69R8S2H9paNcQAfPt3p/vD/OK8mtGKPtbqDXBXjyzv3Po8uq+1ocr3iW7+3F3bSROOGHB9DXP6NcPa3Bhl4ZDgiurjw6Vz3iGyKsLuEfMv3wO49ak64PodXaSh0BBq+h4rkfD+oCRQpNdbbOrrg9atGVRWJ0apQ1Vs4PFODVVzBxuWQaGbiolagsKdyeUGOTULU5mpmaktKxHKOKzrtdyEVpv3rNvjtTJ6ZqWbU3qMt+MVoRdKoxdiOlXIjQip6k4qVDUINOBqjJq5ZU1IGqsGpwencycR7tULnNDtUZNJlxjYD1pKCajZ6RaQOeKytSn2KQDzV2eUKpOa5vVbnIJzSZrBGRdBru8WMHqa6WKLy4QMYAFZ2g2ZYmeQctwPpWndNgHHSpZTfQs+GrY3eu20YBID72+g5r1euB+HEO69u5z/AAIFH4n/AOtXfV1YdWjfueFmc+aty9gooorc84KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8m8X2P9m67KEXEUv7xMdMH/6+a9ZrmvHeltqGk+bEMzW5Ljjkr3H9fwrDEQ5o6dDvy6v7Gsk9nocDbzELU0yeZH8wyCOazIXwcHqKvCY7AK4k7o+hnGzujAubd9MuPOjz5LH8q6LStTWVFy1RyKs8ZVlDKeCDWDc2sumymSHc0B5/3atMLcx6JYyI4wx696kmQK+FPWuM0zV+gZuK6O0vUkIO7NWmc8qbTui8Qy9abuq7E8UsfUZqOS1PVaq3YxVRXtIqZopzxsvUVGxx1qTRag7Vn34DQuKtM1U7xv3bUmaQWolof3K/SraGqFq2I1q7Gc0kVInUnFPDc01DgU7IqjMeGFLmo/wpdpPamSwZqaWxTvKz14qGYhAcmkCa2B5OKrSTBepqrc3arnBrHu74nJLYFSbRiW9Qvc5APFYyRteXIQZ2jlj6CkhSa9l4BWL+8a3rS3jt48KPqfWlc0fuokQrDGFUYAGBVW4kyKluGBNQwQPd3kNvEMvIwUCpfYUUl7zPQ/h/aGDRTMwwZ3LD6Dgf1rpqgsrdbS0ht0+7GgUe+Knr0YR5YpHytep7WpKfcKKKKoyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkIBBB5B7UtFAHlHjLSP7K1UtEp+zTfMnt6ismJ8kV69rWmQatYvb3A90fup9a8gu7aWwvJLedSrocHNefWp+zldbM+mwGKWIp8sviRpQqNmRTJFByDUNvPgYzVqLEjVO6NneL1MK+0ormSz+VuuzsfpVS31Ca2fbKrIw7GuukiULWdd2sc67ZEDL/Kne25cZqQ6x1oYGTW/Z60hADEVxM+lBR/o0rRn0bkVVK6hbdYy6juhz+nWmpdiZ0oz3PUlu4JR1FRzCIjgivN4dZliOGYqfQ1cTXnP8dXzGP1az0Z1s2wdDWXePkECssauW6sKGvlcdahu5vCHLuaEMmABV2KQAcmsAXiinHURjrSRUo3OlV1xyaeJIx1Nco2rY/iqJ9Wz0aquZezZ1z30MfeoZNXjA4rjzd3Ex/dxSP9BT1t76X+AIP9o0cweyXU3rjWsfdNZV3q5wSzVGmlM2POmJ9lFXINLgTBEW4+rc1PMWoxiZCz3F2f3MbEf3jwKt2+lsx33L7z2UdK3EtwF5GKNoHFGoOa6FVIdmMYAHapiw24PWlkOEJFU5HJNTsCvIbK3zGuk8AacbnVGu3H7u3HHux6VzKq0sqogLMxwAO5r1vQNNTTNNigUDzMbpD6sa0ow5pX7HJmFf2VLlW8jSooorvPnAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuf8XaCur2W6FVF5HyjdNw/uk10FFTKKkrM0pVZUpqcN0eHSJLbTPFMhSRDtZTwQasW05XvXoXi7w0uqobm1CpeKOfSQen1rzKVJLeVo5VKupwQRgg1504Ok7M+ow2Ihi4XW/VGuk288mpwgbpWNFNir0FzyOaFK4502tixLbjFQ+SO1TvcApzSQYbk1VkQm0tSpNaiQfMisPRhmqkmlwOPmt0H+6MfyrokiBFPNtkUcovb23OUOkQj+FwPY00aVD6y/8AfVdZ9kBHNRvaoo6CjlY1XRzqaTCRz5h/4FT10i3ByUJ+rmttYwTirAtlx2oSYOtYwF0+2TgW6H6jP86tRQIv3IkX6LitNoVB6U0hR0FHKL2tymY3bpmhYWHWr4xjimyEBc0+UXtGVxH7VNGABULSgUxrgYo2BpssStgGqLPyTSyXIIqpJLkGpbLhBjpZuCM1TMmWwKRmLGuo8FeH/t1z9quo/wDRIzwD/G3p9KmKc3ZGtScMPBzkbfgfQVhhTUbpczOP3akfdHr9a7GkAAGBwB0FLXpQgoKyPla9aVebnIKKKKoxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsLX/DVnq+ZGzFc44kXv9R3rdoqZRUlZl06k6UuaDszxrWtFvNImKXKfuyflkXlW/GqEchU17hPDHPE0U8ayRtwVYZBrkNc8EwTKZNKIhl6mNySp+npXHPDNaxPdw2awnaNZWffocGJ8kA1bgnwRzUGo6Vfac5F3bSRjsxGVP49KpK5Wue7i9T1OWNRXi7nQx3J4watJd8YNcytwwPWoptTlQt5cYdVIUkvjJOOBwfUVftLGE8Odc12uOtV5Ljd3rnJdSKTMnluVUAs2Rjk8fWpJr8QsQ4fbsLbgMjjtR7REKgkbcU3JqVbg5xWLDdZUHkZGcGnG6x3p85To3Nt5cjrVaST3rLN4fWmNdE96HMcaDRqrcYBGailus8ZrO87ioXlJ71LmWqOpeknqBpsVT3EmnqrO6qoLMeAAMk1PNc2VNImMhNNwScVv6P4U1G+cedEbWLu0owfwHWu50fw1YabhgnnTD/lpIOn0HatYUZTOGvmFGhotX5HL+GPCL3O251NWjh6rH0Zvr6CvQIYkgiWOJFSNRgKOgp9FdsKagtD5/EYmeIlef3BRRR3rQ5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBsiLIjJIqsjcFWGQa5vVPBum3mWgDWsnrH938v8MV01FTKEZbo1pVqlJ3g7HmN74F1GEk27xXC+x2n8jXN3vhzVbSRRNayLCJPMJ2k59sjjrzXuVFc8sJB7HfDNqy+NJnz/NYy+bIXjUMzBg7AhkwB/h+tNNvcPvWVg6N8ue+3PIxjqema+gWRW+8oP1FM8iL/AJ5R/wDfIqPqfmbf2uusPx/4B4ZyexpVjeRtqKzH0AzXuXkQ/wDPJP8AvkUqRRxn93Gi/QAU/qnmX/bX9z8f+AeKxaVfyfcs7lvpE3+FW08Oas6hhYT4PquP517FRVLCx6szec1OkUeRx+FdZc4Fk492ZR/Wr9v4F1OTHmvbxDvliT+gr02iqWGgZyzeu9kkcPZ+AYlIN5eOw/uxLj9TXT6Zoun6YP8ARLZFf++eW/M1o0VpGlCOyOOri61bSctAooorQ5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Waldeyer's ring is the ring of lymphoid tissue in the pharynx formed by the palatine tonsils, pharyngeal tonsils, tubal tonsils, and lingual tonsils.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12368=[""].join("\n");
var outline_f12_5_12368=null;
var title_f12_5_12369="Syringoma";
var content_f12_5_12369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar syringoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12369=[""].join("\n");
var outline_f12_5_12369=null;
var title_f12_5_12370="Comparison of WHO and CDC weight-for-age charts 0 to 24 months";
var content_f12_5_12370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comparison of WHO and CDC weight-for-age measurements for children younger than 24 months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 741px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CDC: Centers for Disease Control and Prevention; WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Grummer-Strawn, LM, Reinold, C, Krebs, NF. Use of World Health Organization and CDC growth charts for children aged 0 to 59 months in the United States. MMWR Recomm Rep 2010; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12370=[""].join("\n");
var outline_f12_5_12370=null;
var title_f12_5_12371="Tetanus toxoid (adsorbed): Patient drug information";
var content_f12_5_12371=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetanus toxoid (adsorbed): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3430?source=see_link\">",
"     see \"Tetanus toxoid (adsorbed): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/52/24389?source=see_link\">",
"     see \"Tetanus toxoid (adsorbed): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705824",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop tetanus.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetanus toxoid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696438",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All bad side effects to this vaccine must be reported to the U.S. Department of Health and Human Services Vaccine Adverse Event Reporting System. Ask your doctor to file the report. You may also call to file a report at 1-800-822-7967.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11918 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12371=[""].join("\n");
var outline_f12_5_12371=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028874\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028873\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028878\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028879\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028881\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028876\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028877\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028883\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3430?source=related_link\">",
"      Tetanus toxoid (adsorbed): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/52/24389?source=related_link\">",
"      Tetanus toxoid (adsorbed): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12372="What's new in psychiatry";
var content_f12_5_12372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   What's new in psychiatry",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12372/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12372/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12372/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/5/12372/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ANXIETY DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral couples therapy for PTSD",
"    </span>",
"   </p>",
"   <p>",
"    Cognitive and behavioral psychotherapies can reduce symptoms of patients with posttraumatic stress disorder (PTSD), but there has been little research on interventions for relationship problems associated with the disorder. A randomized trial compared a manual-based, cognitive-behavioral couples therapy to a waitlist control in 40 couples that included a person with PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/1\">",
"     1",
"    </a>",
"    ]. Couples with PTSD who received the 15-session intervention experienced more improvement in intimate-relationship satisfaction and greater reduction in PTSD symptoms in the partner with the disorder, compared to the control group. This intervention shows promise, but needs further testing in larger samples of couples that have relationship difficulties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H324030410#H324030410\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Couples therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIPOLAR DISORDER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adjunctive ziprasidone is not efficacious for manic or mixed episodes",
"    </span>",
"   </p>",
"   <p>",
"    Severe manic or mixed episodes are characterized by suicidal or homicidal ideation or behavior, aggressiveness, psychotic features (eg, delusions or hallucinations), and poor judgment that places the patient or others at risk. These episodes are generally treated with a medication combination such as lithium or divalproex plus an antipsychotic. However, in two randomized trials, the addition of ziprasidone to lithium or divalproex&nbsp;was not beneficial. In one trial,&nbsp;over 600&nbsp;patients with manic or mixed episodes who had not responded to either lithium or divalproex were randomized&nbsp;to adjunctive ziprasidone at two different doses or placebo for three weeks&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/2\">",
"     2",
"    </a>",
"    ]. Neither high dose nor low dose ziprasidone provided any benefit&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link&amp;anchor=H2269895045#H2269895045\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'First line medication combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHILD AND ADOLESCENT PSYCHIATRY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Suicidal risk in adolescents with psychiatric disorders",
"    </span>",
"   </p>",
"   <p>",
"    The risk of suicide in adolescents with psychiatric disorders depends upon the severity of the illness. As an example, suicidal behavior is increased in patients with psychotic features, such as command auditory hallucinations to commit self-harm. A community-based study found that among two adolescent populations (age 11 to 13 years, n = 78, and age 13 to 15 years, n = 72), suicidal ideation or behavior were more common in adolescents with psychiatric disorders (eg, depressive disorder, anxiety disorder, or attention deficit hyperactivity disorder) plus psychotic symptoms, compared to adolescents with psychiatric disorders but no psychotic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link&amp;anchor=H7#H7\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\", section on 'Psychiatric disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COGNITIVE DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Discontinuing antipsychotic agents in patients with dementia",
"    </span>",
"   </p>",
"   <p>",
"    Because antipsychotic agents are associated with an increased risk of mortality in patients with dementia, it has been recommended that discontinuation of these agents should be attempted at regular intervals. One trial showed that this is not always possible. Among 180 patients with Alzheimer disease and psychosis or agitation who had initially responded to treatment with a 16 week course of risperidone, those randomly assigned to immediate drug discontinuation had an increased risk of relapse of psychosis or agitation over 16 weeks of followup (60 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/4\">",
"     4",
"    </a>",
"    ]. Those who were assigned to drug discontinuation after an additional 16 weeks of treatment also had a higher rate of relapse over the ensuing 16 weeks compared to those who continued treatment throughout (48 versus 15 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Antipsychotic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DEPRESSIVE DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral therapy for perinatal depression",
"    </span>",
"   </p>",
"   <p>",
"    Cognitive-behavioral therapy (CBT) can be useful in pregnant and postpartum patients.&nbsp;This was demonstrated in&nbsp;a 16-week randomized trial in which&nbsp;CBT (12 individual sessions, each lasting 50 minutes) was compared with standard care (feedback about depression status, educational material about perinatal depression, and referrals for psychotherapy) in 55 low-income, perinatal outpatients with unipolar major depression who were attending obstetric clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/5\">",
"     5",
"    </a>",
"    ]. CBT&nbsp;included efforts to increase adherence, such as telephone calls, letters, and home visits by therapists. Improvement was greater with CBT than standard care, and treatment gains persisted at the three-month follow-up assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H13804399#H13804399\">",
"     \"Depression in pregnant women: Management\", section on 'Cognitive-behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Transcranial direct current stimulation for major depression",
"    </span>",
"   </p>",
"   <p>",
"    Transcranial direct current stimulation is an investigational approach for treating major depression&nbsp;that uses two scalp electrodes to deliver a constant, low intensity direct current to specific cortical regions. Based upon randomized trials, the treatment is beneficial and well tolerated. As an example,&nbsp;a six week trial&nbsp;compared active transcranial direct current stimulation with sham stimulation in 60 patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/6\">",
"     6",
"    </a>",
"    ]. Remission occurred in more patients who received active stimulation (40 versus 13 percent), and the procedure was generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=see_link&amp;anchor=H29061782#H29061782\">",
"     \"Unipolar depression in adults: Overview of neuromodulation procedures\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=see_link&amp;anchor=H258782016#H258782016\">",
"     \"Unipolar depression in adults: Overview of neuromodulation procedures\", section on 'Safety and side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Efficacy of antidepressants for dysthymic disorder",
"    </span>",
"   </p>",
"   <p>",
"    A new study has confirmed that antidepressants are efficacious for dysthymic disorder, which is characterized by dysphoria and other depressive symptoms that last for at least two years. A meta-analysis of 20 randomized trials (nearly 3000 patients,&nbsp;most of whom were diagnosed with dysthymia)&nbsp;compared selective serotonin reuptake inhibitors (SSRIs) with placebo, tricyclic antidepressants with placebo, and SSRIs with tricyclics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/7\">",
"     7",
"    </a>",
"    ]. Treatment duration ranged from 4 to 12 weeks. Remission was greater with SSRIs or tricyclics than with placebo and was comparable for SSRIs and tricyclics. Discontinuation of treatment as well as adverse effects occurred less often with SSRIs than tricyclics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H524936#H524936\">",
"     \"Initial treatment of depression in adults\", section on 'Dysthymic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy of electroconvulsive therapy compared with repetitive transcranial magnetic stimulation",
"    </span>",
"   </p>",
"   <p>",
"    For treatment of major depression, electroconvulsive therapy (ECT) is more efficacious than repetitive transcranial magnetic stimulation (TMS).&nbsp;This was confirmed in a&nbsp;meta-analysis of six randomized trials that included over 200 patients with major depression and compared ECT (bilateral or unilateral; average of&nbsp;eight treatments) with repetitive TMS (&ge;5 Hertz, applied over the left dorsolateral prefrontal cortex; average of 15 treatments). Remission occurred in more patients who received ECT than repetitive TMS (52 versus 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/8\">",
"     8",
"    </a>",
"    ]. Discontinuation rates were similar with both therapies. However, cognitive impairment may be greater with ECT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=see_link&amp;anchor=H21629511#H21629511\">",
"     \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\", section on 'Compared with transcranial magnetic stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CYP2D6 genotypes, SSRIs, and breast cancer treatment with tamoxifen",
"    </span>",
"   </p>",
"   <p>",
"    Tamoxifen is converted to its active metabolites by two rate-limiting enzymes, cytochrome P450 2D6 (CYP2D6) and UDP-glucuronyltransferase-2B7 (UGT2B7). An unplanned analysis of a large randomized trial in women with breast cancer showed&nbsp;that poor metabolizers (defined by the presence of specific CYP2D6 genotypes)&nbsp;had a significantly higher risk of a breast cancer event (recurrence, contralateral breast or second non-breast cancer, or death) compared to&nbsp;faster metabolizers during treatment with tamoxifen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the relationship between CYP2D6 metabolism and breast cancer outcomes for women on tamoxifen have not been consistently demonstrated, we prefer not to treat&nbsp;breast cancer&nbsp;patients with agents that are known to be potent or moderate CYP2D6&nbsp;inhibitors (eg, some selective serotonin reuptake inhibitors). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link&amp;anchor=H125175232#H125175232\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Altered tamoxifen metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Use of selective serotonin reuptake inhibitors (SSRIs) to treat pregnant patients does not appear to be associated with stillbirth or infant mortality. In an observational study of over one million pregnancies, registries from five countries were examined for information about prescriptions, maternal characteristics, pregnancy outcomes, and neonatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/10\">",
"     10",
"    </a>",
"    ]. More than 29,000 women had filled a prescription for an SSRI. After accounting for maternal age, smoking, diabetes, hypertension, and hospitalization for psychiatric illness, the risks of stillbirth and infant mortality were comparable for women who used or did not use SSRIs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H8#H8\">",
"     \"Depression in pregnant women: Management\", section on 'Pregnancy complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors and bleeding",
"    </span>",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRIs) are believed to alter platelet aggregation. A meta-analysis of 16 observational studies (n = 506,411) found that the risk of intracranial hemorrhage was elevated in patients who received SSRIs compared to controls who did not; heterogeneity across studies was small to moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/11\">",
"     11",
"    </a>",
"    ]. In a separate analysis, the risk of brain hemorrhage was elevated in patients taking the combination of SSRIs and anticoagulants, compared with anticoagulants alone. However, the clinical significance of these findings is not clear. Based upon the meta-analysis, it was estimated that SSRIs may lead to one additional intracerebral hemorrhage for every 10,000 patients treated for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H12543449#H12543449\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Maintenance treatment with electroconvulsive therapy",
"    </span>",
"   </p>",
"   <p>",
"    Although electroconvulsive therapy (ECT) is the most effective treatment for major depression, patients who remit with ECT often suffer recurrences.",
"    <span class=\"nowrap\">",
"     Continuation/maintenance",
"    </span>",
"    treatment with ECT plus pharmacotherapy may be more effective than pharmacotherapy alone. A one year, open label, randomized trial compared maintenance ECT (weekly for six weeks and then every two weeks) plus pharmacotherapy (varying combinations of antidepressants, lithium, and antipsychotics) with pharmacotherapy alone in 56 patients who responded to an acute course of ECT for unipolar or bipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/13\">",
"     13",
"    </a>",
"    ]. Depression recurred in fewer patients who received combination treatment than pharmacotherapy alone (32 versus 61 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Continuation and maintenance ECT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EATING DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     An investigational treatment for anorexia nervosa",
"    </span>",
"   </p>",
"   <p>",
"    Anorexia nervosa that is refractory to conventional treatment is often fatal.&nbsp;In a nine month, observational,&nbsp;phase&nbsp;one&nbsp;study of six female patients with&nbsp;intractable anorexia nervosa (mean duration of illness 18 years; history of general medical complications), electrodes were implanted bilaterally into the subcallosal cingulate gyrus and connected to a subcutaneous pulse generator&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/14\">",
"     14",
"    </a>",
"    ].&nbsp;Weight gain occurred in three patients, and improvement of mood and anxiety symptoms occurred in four patients. Adverse events include seizure, air embolus, intraoperative panic attack, and pain. This investigational&nbsp;procedure may eventually prove useful&nbsp;for otherwise intractable&nbsp;patients.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H92063582#H92063582\">",
"     \"Eating disorders: Treatment\", section on 'Investigational approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MEDICAL CONSEQUENCES OF PSYCHIATRIC TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants and fractures",
"    </span>",
"   </p>",
"   <p>",
"    Tricyclic antidepressants may increase the risk of fractures. In a meta-analysis of 12 observational studies (269,381 individuals) the risk of fractures in tricyclic users was 45 percent higher&nbsp;than in&nbsp;non-tricyclic users [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/15\">",
"     15",
"    </a>",
"    ]. The association was also observed in the subgroup of studies that adjusted for fracture risk factors such as age, sex, comorbidity, bone mineral density, and medications known to increase fracture risk. Although the underlying mechanism for the association between tricyclics and fractures is not clear, it may be due to an increased risk of falls in tricyclic users (perhaps secondary to orthostatic hypotension, gait disturbance, or delirium), rather than effects upon bone mineral density. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link&amp;anchor=H1822567#H1822567\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Metformin for antipsychotic-induced amenorrhea",
"    </span>",
"   </p>",
"   <p>",
"    First-generation antipsychotic drugs, and the second-generation drugs risperidone and paliperidone, can elevate plasma prolactin. This elevation can lead to menstrual disturbances in women. A randomized trial suggested that metformin can be an effective treatment for antipsychotic-induced amenorrhea in cases where a change in antipsychotic would be undesirable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/16\">",
"     16",
"    </a>",
"    ]. Metformin 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was compared to placebo in 84 women with first-episode schizophrenia and antipsychotic-induced amenorrhea and weight gain. After six months of treatment, significantly more patients in the metformin group resumed menstruation compared to the placebo group (66.7 versus 4.8 percent); the mean body mass index (BMI) decreased among patients receiving metformin, while BMI increased in patients on placebo. A longer trial demonstrating that metformin leads to the return of ovulatory cycles is needed before metformin should be a standard recommendation for antipsychotic-induced amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link&amp;anchor=H28219073#H28219073\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\", section on 'Prolactin elevation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SOMATOFORM AND FACTITIOUS DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Reassurance provided by diagnostic testing",
"    </span>",
"   </p>",
"   <p>",
"    Diagnostic tests are often ordered for patients with a low pretest probability of serious disease to provide reassurance, as well as to rule out illnesses. A meta-analysis of three open label randomized trials compared initial diagnostic testing (eg, cranial magnetic resonance imaging) with no testing in&nbsp;more than 700&nbsp;patients with a low probability of disease (eg, headache) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/17\">",
"     17",
"    </a>",
"    ].&nbsp;Illness worry (concern that symptoms may represent serious illness) was comparable for both groups in the short term (&le;3 months) and long term (&gt;3 months). Additional analyses found that testing did not reduce nonspecific anxiety or resolve symptoms, but did lead to a small decrease in the number of subsequent visits to primary care.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H15#H15\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER PSYCHIATRY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     ADHD pharmacotherapy and criminal conviction rates",
"    </span>",
"   </p>",
"   <p>",
"    Short-term clinical trials of medication in adult attention deficit hyperactivity disorder (ADHD) have shown a beneficial effect of treatment on conduct problems, but longer-term studies have been limited by high dropout rates. ADHD symptoms are typically chronic,&nbsp;and discontinuities in treatment&nbsp;are common. A study using national registry data collected&nbsp;during a four year period&nbsp;on&nbsp;over 25,000&nbsp;Swedish individuals diagnosed with ADHD compared subjects&rsquo; criminal conviction rates during periods when they were either&nbsp;medicated or unmedicated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/18\">",
"     18",
"    </a>",
"    ]. Conviction rates were 32 and 41 percent lower in men and women, respectively, during medicated periods compared&nbsp;with unmedicated periods. This association between criminal convictions and ADHD treatment requires further study, optimally through longer-term, randomized trials.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20599?source=see_link&amp;anchor=H102937254#H102937254\">",
"     \"Pharmacotherapy for adult ADHD\", section on 'Effects on high risk behaviors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Control of the agitated patient",
"    </span>",
"   </p>",
"   <p>",
"    The best medication for sedating acutely agitated patients remains a subject of debate, but combination therapy appears to be an effective approach. In a multicenter randomized trial, the combination of either droperidol (5 mg IV) and midazolam or olanzapine (5 mg IV) and midazolam provided more rapid sedation of acutely agitated emergency department patients (n = 336) than midazolam alone (2.5 to 5 mg IV used for all three groups) without an increase in adverse events and with less need for rescue medication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12372/abstract/19\">",
"     19",
"    </a>",
"    ]. The mean times to sedation were 21.3 minutes for the droperidol group, 14 minutes for the olanzapine group, and 67.8 minutes for the midazolam only (ie, control) group. Further study of intravenous olanzapine and other second-generation antipsychotics is needed before this approach can be widely recommended for the treatment of acute agitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link&amp;anchor=H21#H21\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/1\">",
"      Monson CM, Fredman SJ, Macdonald A, et al. Effect of cognitive-behavioral couple therapy for PTSD: a randomized controlled trial. JAMA 2012; 308:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/2\">",
"      Sachs GS, Vanderburg DG, Edman S, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2012; 73:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/3\">",
"      Kelleher I, Lynch F, Harley M, et al. Psychotic symptoms in adolescence index risk for suicidal behavior: findings from 2 population-based case-control clinical interview studies. Arch Gen Psychiatry 2012; 69:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/4\">",
"      Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/5\">",
"      O'Mahen H, Himle JA, Fedock G, et al. A PILOT RANDOMIZED CONTROLLED TRIAL OF COGNITIVE BEHAVIORAL THERAPY FOR PERINATAL DEPRESSION ADAPTED FOR WOMEN WITH LOW INCOMES. Depress Anxiety 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/6\">",
"      Brunoni AR, Valiengo L, Baccaro A, et al. The Sertraline vs Electrical Current Therapy for Treating Depression Clinical Study: Results From a Factorial, Randomized, Controlled Trial. JAMA Psychiatry 2013; 70:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/7\">",
"      von Wolff A, H&ouml;lzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013; 144:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/8\">",
"      Berlim MT, Van den Eynde F, Daskalakis ZJ. EFFICACY AND ACCEPTABILITY OF HIGH FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS) VERSUS ELECTROCONVULSIVE THERAPY (ECT) FOR MAJOR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. Depress Anxiety 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/9\">",
"      Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/10\">",
"      Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/11\">",
"      Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/12\">",
"      McGrath ER, O'Donnell MJ. Estimating treatment effects in observational studies. Neurology 2012; 79:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/13\">",
"      Nordenskj&ouml;ld A, von Knorring L, Ljung T, et al. Continuation Electroconvulsive Therapy With Pharmacotherapy Versus Pharmacotherapy Alone for Prevention of Relapse of Depression: A Randomized Controlled Trial. J ECT 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/14\">",
"      Lipsman N, Woodside DB, Giacobbe P, et al. Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/15\">",
"      Wu Q, Qu W, Crowell MD, et al. Tricyclic antidepressant use and risk of fractures: A meta-analysis of cohort and case-control studies. J Bone Miner Res 2013; 28:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/16\">",
"      Wu RR, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012; 169:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/17\">",
"      Rolfe A, Burton C. Reassurance After Diagnostic Testing With a Low Pretest Probability of Serious Disease: Systematic Review and Meta-analysis. JAMA Intern Med 2013; 173:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/18\">",
"      Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12372/abstract/19\">",
"      Chan EW, Taylor DM, Knott JC, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med 2013; 61:72.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83935 Version 2375.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-84DF8DAFCC-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12372=[""].join("\n");
var outline_f12_5_12372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ANXIETY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Cognitive-behavioral couples therapy for PTSD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIPOLAR DISORDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adjunctive ziprasidone is not efficacious for manic or mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHILD AND ADOLESCENT PSYCHIATRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Suicidal risk in adolescents with psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COGNITIVE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Discontinuing antipsychotic agents in patients with dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DEPRESSIVE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cognitive-behavioral therapy for perinatal depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Transcranial direct current stimulation for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Efficacy of antidepressants for dysthymic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy of electroconvulsive therapy compared with repetitive transcranial magnetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CYP2D6 genotypes, SSRIs, and breast cancer treatment with tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Selective serotonin reuptake inhibitors during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Selective serotonin reuptake inhibitors and bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Maintenance treatment with electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EATING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      An investigational treatment for anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MEDICAL CONSEQUENCES OF PSYCHIATRIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tricyclic antidepressants and fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Metformin for antipsychotic-induced amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SOMATOFORM AND FACTITIOUS DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Reassurance provided by diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER PSYCHIATRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADHD pharmacotherapy and criminal conviction rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Control of the agitated patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20599?source=related_link\">",
"      Pharmacotherapy for adult ADHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=related_link\">",
"      Unipolar depression in adults: Overview of neuromodulation procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12373="Ursodiol: Drug information";
var content_f12_5_12373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ursodiol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/34/25124?source=see_link\">",
"    see \"Ursodiol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"    see \"Ursodiol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actigall&reg;;",
"     </li>",
"     <li>",
"      Urso 250&reg;;",
"     </li>",
"     <li>",
"      Urso Forte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Ursodiol C;",
"     </li>",
"     <li>",
"      PHL-Ursodiol C;",
"     </li>",
"     <li>",
"      PMS-Ursodiol C;",
"     </li>",
"     <li>",
"      Urso&reg;;",
"     </li>",
"     <li>",
"      Urso&reg; DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gallstone Dissolution Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gallstone dissolution (Actigall&reg;):",
"     </b>",
"     Oral: 8-10 mg/kg/day in 2-3 divided doses; use beyond 24 months is not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gallstone prevention (Actigall&reg;):",
"     </b>",
"     Oral: 300 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary biliary cirrhosis (Urso&reg;, Urso Forte&reg;):",
"     </b>",
"     Oral: 13-15 mg/kg/day in 2-4 divided doses (with food)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actigall&reg;: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urso 250&reg;: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urso Forte&reg;: 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer with aluminum-based antacids. If aluminum-based antacids are needed, administer 2 hours after ursodiol. Urso Forte&reg; can be split into halves for appropriate dosage; do not chew. Urso&reg; and Urso Forte&reg; should be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Actigall&reg;: Gallbladder stone dissolution; prevention of gallstones in obese patients experiencing rapid weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urso&reg;, Urso Forte&reg;: Primary biliary cirrhosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10579627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ursodiol may be confused with ulipristal",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (up to 25%), dizziness (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (up to 27%), constipation (up to 26%), dyspepsia (17%), nausea (up to 17%), vomiting (up to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (up to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (up to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (5%), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (up to 8%), peptic ulcer (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (3%), thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholecystitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis (6%), myalgia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (up to 8%), bronchitis (7%), cough (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (9%), flu-like syndrome (7%), allergy (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, angioedema, anorexia, biliary pain, esophagitis, fever, malaise, metallic taste, peripheral edema, pruritus, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ursodiol or any component of the formulation; not to be used with cholesterol, radiopaque, bile pigment stones; patients with unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula; allergy to bile acids",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with chronic liver disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Gallbladder stone dissolution may take several months of therapy; complete dissolution may not occur and recurrence of stones within 5 years has been observed in up to 50% of patients. Patients should be cautiously selected for therapy, consider alternative treatments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nonvisualizing gallbladder: Use with caution in patients with a nonvisualizing gallbladder.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May decrease the serum concentration of Ursodiol. Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Ursodiol. Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrendipine: Ursodiol may decrease the absorption of Nitrendipine.  Management: Consider therapeutic alternatives.  If concomitant therapy cannot be avoided, avoid simultaneous administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13966873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Ursodiol (ursodeoxycholic acid) is the treatment of choice for intrahepatic cholestasis of pregnancy (Kremer, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F232644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F232627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urso&reg; and Urso Forte&reg; should be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F232626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Actigall Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $771.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ursodiol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $257.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Urso 250 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $354.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Urso Forte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $628.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ursodiol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $268.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $475.34",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F232616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Gallstone disease: ALT, AST, sonogram",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Hepatic disease: Monitor hepatic function tests frequently. Canadian labeling recommends obtaining liver function tests (including GGT, AST, ALT, bilirubin, and alkaline phosphatase) monthly for the first 3 months and every 6 months thereafter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F232628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actigall (NZ);",
"     </li>",
"     <li>",
"      Adursal (FI);",
"     </li>",
"     <li>",
"      Canlin (TW);",
"     </li>",
"     <li>",
"      Deursil (IT);",
"     </li>",
"     <li>",
"      Dexo (PY);",
"     </li>",
"     <li>",
"      Estazor (ID);",
"     </li>",
"     <li>",
"      Litanin (ES);",
"     </li>",
"     <li>",
"      Taurolite (CL);",
"     </li>",
"     <li>",
"      Udihep (TH);",
"     </li>",
"     <li>",
"      Urdafalk (ID);",
"     </li>",
"     <li>",
"      Urosan (JP);",
"     </li>",
"     <li>",
"      Ursa (KP);",
"     </li>",
"     <li>",
"      URSA (TH);",
"     </li>",
"     <li>",
"      Ursacol (BR, CO, IT);",
"     </li>",
"     <li>",
"      Urso (IN);",
"     </li>",
"     <li>",
"      Urso Vinas (ES);",
"     </li>",
"     <li>",
"      Ursobilane (ES);",
"     </li>",
"     <li>",
"      Ursochol (BE, CH, ES, ID, LU, NL);",
"     </li>",
"     <li>",
"      Ursodamor (IT);",
"     </li>",
"     <li>",
"      Ursofalk (AR, AT, AU, BG, CL, CN, CO, CR, CZ, DE, EC, EE, GR, GT, HK, HN, HU, IE, IL, LU, MX, MY, NI, PA, PE, PH, PK, PT, SE, SV, TH, TR, UY);",
"     </li>",
"     <li>",
"      Ursogal (GB);",
"     </li>",
"     <li>",
"      Ursolic (TW);",
"     </li>",
"     <li>",
"      Ursolin (TH);",
"     </li>",
"     <li>",
"      Ursolit (IL);",
"     </li>",
"     <li>",
"      Ursolite (ES);",
"     </li>",
"     <li>",
"      Ursolvan (FR);",
"     </li>",
"     <li>",
"      Ursopol (PL);",
"     </li>",
"     <li>",
"      Ursosan (JP, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases the cholesterol content of bile and bile stones by reducing the secretion of cholesterol from the liver and the fractional reabsorption of cholesterol by the intestines. Mechanism of action in primary biliary cirrhosis is not clearly defined.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes extensive enterohepatic recycling; following hepatic conjugation and biliary secretion, the drug is hydrolyzed to active ursodiol, where it is recycled or transformed to lithocholic acid by colonic microbial flora",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Johnson CE and Nesbitt J, &ldquo;Stability of Ursodiol in an Extemporaneously Compounded Oral Liquid,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(16):1798-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12373/abstract-text/8528836/pubmed\" id=\"8528836\" target=\"_blank\">",
"        8528836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondrackiene J, Beuers U, and Kupcinskas L, \"Efficacy and Safety of Ursodeoxycholic Acid Versus Cholestyramine in Intrahepatic Cholestasis of Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2005, 129(3):894-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12373/abstract-text/16143129/pubmed\" id=\"16143129\" target=\"_blank\">",
"        16143129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kremer AE, Oude Elferink RP, and Beuers U, \"Pathophysiology and Current Management of Pruritus in Liver Disease,\"",
"      <i>",
"       Clin Res Hepatol Gastroenterol",
"      </i>",
"      , 2011, 35(2):89-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12373/abstract-text/21809485/pubmed\" id=\"21809485\" target=\"_blank\">",
"        21809485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindor KD, Kowdley KV, Luketic VA, et al, \"High-Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 50(3):808-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12373/abstract-text/19585548/pubmed\" id=\"19585548\" target=\"_blank\">",
"        19585548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10033 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12373=[""].join("\n");
var outline_f12_5_12373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232635\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232636\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232676\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232639\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232640\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232618\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232603\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803233\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232620\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579627\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232674\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232624\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232607\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300198\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223602\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232614\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13966873\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232644\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232627\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232626\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232616\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232628\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232606\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232623\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/34/25124?source=related_link\">",
"      Ursodiol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=related_link\">",
"      Ursodiol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12374="Varicella virus vaccine: Pediatric drug information";
var content_f12_5_12374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Varicella virus vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"    see \"Varicella virus vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"    see \"Varicella virus vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Varivax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Varilrix&reg;;",
"     </li>",
"     <li>",
"      Varivax&reg; III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"      see \"Varicella virus vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 months: SubQ: 0.5 mL; a second dose may be administered &ge;3 months later.",
"     <b>",
"      Note:",
"     </b>",
"     The ACIP recommends the routine childhood vaccination be 2 doses, with the first dose administered at 12-15 months of age. School age children should receive the second dose at 4-6 years of age, but it may be administered earlier provided &ge;3 months have elapsed after the first dose. All children and adolescents who received only 1 dose of vaccine should receive a second dose (CDC, 2007). If the second dose was administered &ge;4 weeks after the first dose, it may be considered as valid [CDC, 61(5), 2012].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;13 years and Adults: SubQ: 0.5 mL followed by a second dose at least 4-8 weeks later.",
"     <b>",
"      Note:",
"     </b>",
"     The ACIP recommends that all adolescents and adults who received only 1 dose of vaccine receive a second dose (CDC, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postexposure prophylaxis (healthy, previously unvaccinated individuals):",
"     </b>",
"     Children (&ge;12 months), Adolescents, and Adults: SubQ: 0.5 mL administered ideally within 72 hours postexposure but may be used up to 120 hours (5 days) postexposure",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varivax&reg;: 1350 PFU [contains bovine serum, gelatin, neomycin (may have trace amounts), sucrose 25 mg/vial; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstitute vaccine with 0.7 mL of the provided diluent. Gently agitate to mix thoroughly. Total volume of reconstituted vaccine will be ~0.5 mL. Inject subcutaneously into the outer aspect of the upper arm or anterolateral aspect of the thigh;",
"     <b>",
"      not for I.V.  or I.M. administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccine: Store intact vials in freezer at -50&deg;C  to -15&deg;C (-58&deg;F  to 5&deg;F);  may be stored under refrigeration 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 72 hours; if not used within 72 hours, vaccine should be discarded; protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diluent: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) or in refrigerator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reconstituted vaccine: Discard after 30 minutes if not used; do not freeze reconstituted vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunization against varicella in individuals who do not have evidence of immunity (FDA approved in ages &ge;12 months and adults).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACIP recommends vaccination for all children, adolescents, and adults who do not have evidence of immunity. Vaccination is especially important for:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Healthcare personnel",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Persons with close contact to those at high risk for severe disease",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Persons living or working in environments where transmission is likely (teachers, childcare workers, residents, and staff of institutional settings)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Persons in environments where transmission has been reported",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Nonpregnant women of childbearing age",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Adolescents and adults in households with children",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; International travelers",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Postexposure prophylaxis: Vaccination within 3 days (possibly 5 days) after exposure to rash is effective in preventing illness or modifying severity of disease (CDC, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Varicella virus vaccine has been given in error (instead of the indicated varicella immune globulin) to pregnant women exposed to varicella.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Both varicella vaccine and zoster vaccine are live, attenuated strains of varicella-zoster virus. Their indications, dosing, and composition are distinct. Varicella is indicated in children to prevent chickenpox, while zoster vaccine is indicated in older individuals to prevent reactivation of the virus which causes shingles. Zoster vaccine is",
"       <b>",
"        not",
"       </b>",
"       a substitute for varicella vaccine and should not be used in children.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F233547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Chills, fatigue, fever, headache, irritability, malaise, nervousness, sleep disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Contact rash, dermatitis, diaper rash, dry skin, eczema, generalized varicella-like rash, heat rash, itching, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, cold/canker sore, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site reaction, varicella-like rash at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, stiff neck",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Otic: Otitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, lower/upper respiratory illness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, teething",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, anaphylactic shock, angioneurotic edema, aplastic anemia, aseptic meningitis, ataxia, Bell's palsy, cerebellar ataxia (acute), cerebrovascular accident, disseminated varicella infection, encephalitis, erythema multiforme, febrile seizure, Guillain-Barr&eacute; syndrome, hemiparesis (acute), Henoch-Sch&ouml;nlein purpura, hepatitis, herpes zoster, nonfebrile seizure, pneumonitis, Stevens-Johnson syndrome, thrombocytopenia (including idiopathic thrombocytopenia purpura), transverse myelitis, varicella (vaccine strain)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (severe allergy or anaphylactic) to any component of the vaccine, including gelatin; a history of anaphylactoid reaction to neomycin; immunosuppressed or immunodeficient individuals including individuals with leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; persons with AIDS or other clinical manifestations of HIV (per manufacturer labeling); those receiving immunosuppressive therapy (including immunosuppressive doses of corticosteroids); primary and acquired immunodeficiency states; active, untreated tuberculosis; current febrile illness (per manufacturer labeling); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9606989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer to patients with mild acute illness (with or without low grade fever) (CDC, 2007). Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011). Defer use in patients with a family history of congenital or hereditary immunodeficiency until immune competence in the vaccine recipient is demonstrated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactoid reaction should be available during vaccine use. Salicylates should be avoided for 6 weeks after vaccination; varicella vaccine and antibody-containing products (eg, immune globulin, blood products) should",
"     <b>",
"      not",
"     </b>",
"     be administered simultaneously; vaccinated individuals should not have close association with susceptible high-risk individuals (newborns, pregnant women, immunocompromised persons) for 6 weeks following vaccination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Children with HIV infection with age-specific CD4+ T-lymphocyte percentages &ge;15% may receive live attenuated varicella vaccine. Vaccination may be considered for adolescents and adults with CD4+ T-lymphocyte counts &ge;200 cells/&mu;L (CDC, 2007). Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Products may contain albumin, gelatin, and/or neomycin. Use is contraindicated in patients with history of anaphylactic/anaphylactoid reactions to neomycin; contact dermatitis due to neomycin is not a contraindication to the vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Smallpox Vaccine: May enhance the adverse/toxic effect of Varicella Virus Vaccine. It may be difficult to determine which vaccine caused skin lesions or other adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Varivax&reg; should not be administered to pregnant females and pregnancy should be avoided for 3 months (per manufacturer labeling; 1 month per ACIP) following vaccination.  Varicella disease during the 1st or 2nd trimesters may result in congenital varicella syndrome. The onset of maternal varicella infection from 5 days prior to 2 days after delivery may cause varicella infection in the newborn. All women should be assessed for immunity during a prenatal visit; those without evidence of immunity should be vaccinated upon completion or termination of pregnancy (CDC, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A pregnancy registry has been established for pregnant women exposed to varicella virus vaccine (800-986-8999).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rash, fever; observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to re-establish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a live, attenuated vaccine, varicella virus vaccine offers active immunity to disease caused by the varicella-zoster virus",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Seroconversion: ~4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Antibody titers detectable at 10 years postvaccination",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"      see \"Varicella virus vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid pregnancy for 3 months following vaccination; avoid salicylates for 6 weeks after vaccination; avoid close association with susceptible high risk individuals following vaccination",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10285525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR-4):1-40. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/17585291/pubmed\" id=\"17585291\" target=\"_blank\">",
"        17585291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-61. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommended Immunization Schedules for Persons Aged 0 Through 18 Years-United States, 2012,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep 2012",
"      </i>",
"      , 61(5). Available at",
"      <a href=\"file://www.cdc.gov/vaccines/recs/schedules/downloads/child/mmwr-child-schedule.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/vaccines/recs/schedules/downloads/child/mmwr-child-schedule.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Simultaneous Administration of Varicella Vaccine and Other Recommended Childhood Vaccines--United States, 1995-1999,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2001, 50(47):1058-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/11808928/pubmed\" id=\"11808928\" target=\"_blank\">",
"        11808928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chaves SS, Gargiullo P, Zhang JX, et al, \"Loss of Vaccine-Induced Immunity to Varicella Over Time,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(11):1121-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/17360990/pubmed\" id=\"17360990\" target=\"_blank\">",
"        17360990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuter BJ, Weibel RE, Guess HA, et al, &ldquo;Oka/Merck Varicella Vaccine in Healthy Children: Final Report of a 2-Year Efficacy Study and 7-Year Follow-Up Studies,&rdquo;",
"      <i>",
"       Vaccine",
"      </i>",
"      , 1991, 9(9):643-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/1659052/pubmed\" id=\"1659052\" target=\"_blank\">",
"        1659052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12374/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13006 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12374=[""].join("\n");
var outline_f12_5_12374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233527\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233528\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062852\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062844\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233498\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062856\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062847\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062855\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233548\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233547\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062859\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606989\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062843\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300208\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233505\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233519\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062851\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062842\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062858\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062849\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10285525\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13006\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13006|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=related_link\">",
"      Varicella virus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=related_link\">",
"      Varicella virus vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12375="Noninvasive positive pressure therapy of the obesity hypoventilation syndrome";
var content_f12_5_12375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12375/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12375/contributors\">",
"     Thomas J Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12375/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12375/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12375/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12375/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/5/12375/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 22, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity Hypoventilation Syndrome (OHS) occurs in obese (body mass index (BMI)",
"    <span class=\"nowrap\">",
"     &gt;30kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    patients when awake alveolar hypoventilation (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;45 mmHg) cannot be attributed to pulmonary parenchymal disease, skeletal restriction, neuromuscular weakness, or pleural pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients with OHS present with chronic hypoventilation, although some may develop acute cardiopulmonary compromise that can be fatal if untreated. Application of positive airway pressure is the mainstay of therapy, regardless of the presentation.",
"   </p>",
"   <p>",
"    In this topic review, positive pressure therapy for patients with OHS is discussed. The pathogenesis, clinical manifestations, diagnosis, and treatment of OHS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=see_link\">",
"     \"Treatment of the obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=see_link\">",
"     \"Pathogenesis of obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MODES OF NONINVASIVE POSITIVE PRESSURE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major categories of noninvasive positive pressure therapy that are used to treat patients with OHS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continuous positive airway pressure (CPAP)",
"     </li>",
"     <li>",
"      Noninvasive positive pressure ventilation (NPPV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the available modes of NPPV, there is bilevel positive airway pressure (BPAP) and volume cycled positive pressure ventilation (VCPPV).",
"   </p>",
"   <p>",
"    Noninvasive positive pressure therapy is typically administered during sleep via nasal mask, full face mask (covering the nose and mouth), nasal pillows, or hybrid mask (oral mask with nasal pillows). During an episode of acute decompensation, it may be necessary to apply NPPV during wakefulness. NPPV can also be administered via mouthpiece.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Continuous positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with coexisting OHS and obstructive sleep apnea (OSA, a disorder characterized by obstructive apneas and hypopneas), nocturnal CPAP may improve alveolar ventilation during sleep while also treating the OSA. Several case reports and prospective series initially reported reduction of awake arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) after the initiation of chronic nocturnal CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Since nocturnal CPAP does not directly augment ventilation other than by maintaining upper airway patency, the CPAP-related improvement of hypercapnia during both wakefulness and sleep may be due to relief of ventilatory muscle fatigue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    augmentation of central ventilatory drive [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/6\">",
"     6",
"    </a>",
"    ]. The latter may be facilitated by relief of nocturnal asphyxia or sleep fragmentation.",
"   </p>",
"   <p>",
"    Nocturnal CPAP therapy does not benefit all patients with OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Patients who benefit from nocturnal CPAP therapy tend to have a higher baseline apnea hypopnea index (AHI), less restrictive physiology on spirometry, and less severe oxyhemoglobin desaturation during baseline polysomnography than patients who do not improve with CPAP and require BPAP. However, these individual patient characteristics are not useful determinants of the type of positive pressure therapy that should be initially titrated during nocturnal polysomnography.",
"   </p>",
"   <p>",
"    The failure of CPAP to eliminate nocturnal oxyhemoglobin desaturation remains a frequent indication for NPPV. This was illustrated by a study that matched 23 patients with OSA alone to 23 patients with OHS plus OSA according to their BMI, AHI, and spirometry [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/8\">",
"     8",
"    </a>",
"    ]. Forty-three percent of the patients with OHS plus OSA continued to spend more than 20 percent of their total sleep time with an SpO2 &lt;90 percent even after their CPAP had been titrated to a level that significantly improved the AHI, rapid eye movement (REM) sleep duration, and sleep fragmentation.",
"   </p>",
"   <p>",
"    There are limited clinical data comparing CPAP to NPPV in patients with OHS. One trial randomly assigned 36 patients with coexisting OHS and OSA, as well as mild residual hypoventilation on CPAP, to either continue CPAP or begin BPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/9\">",
"     9",
"    </a>",
"    ]. The trial defined mild residual hypoventilation as nocturnal oxyhemoglobin desaturation to &lt;80 percent for fewer than ten minutes and nocturnal carbon dioxide retention of less than 10 mmHg. After three months, the patients had similar improvement in their awake PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , regardless of whether they received CPAP or BPAP (although subjective sleep quality and psychomotor vigilance testing improved in the BPAP group). Nine patients with OHS plus OSA had to be placed directly on BPAP because initial CPAP failed (significant oxyhemoglobin desaturation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carbon dioxide retention), emphasizing the importance of close observation during the initiation of CPAP in patients with OHS.",
"   </p>",
"   <p>",
"    The observations that nocturnal CPAP therapy does not benefit all patients with OHS suggest that some patients with coexisting OHS and OSA probably have abnormal control of breathing and persistent hypoventilation even when the upper airway is patent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/4\">",
"     4",
"    </a>",
"    ]. Moreover, the relative contributions of the underlying pathophysiologic mechanisms that lead to chronic hypoventilation probably differ among patients who benefit from CPAP compared to those who do not respond to CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, patients who use nocturnal CPAP should be monitored for evidence that nocturnal hypoventilation still exists despite compliance with therapy. Clinical symptoms and signs suggestive of persistent sleep-related hypercapnia include nocturnal dyspnea, a sensation of smothering at night, chronic morning headaches, or failure of awake arterial blood gases to improve. Any of these findings should prompt investigation of whether the CPAP has been appropriately titrated, applied, and adhered to. Polysomnographically titrated NPPV should be considered if nocturnal hypoventilation persists despite adequate CPAP therapy for two to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Noninvasive positive pressure ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPPV improves nocturnal alveolar ventilation and may also stabilize or improve daytime alveolar ventilation in patients with OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/5,10-14\">",
"     5,10-14",
"    </a>",
"    ]. BPAP and VCPPV are available modes of NPPV, with use of the former being more common (",
"    <a class=\"graphic graphic_table graphicRef76747 \" href=\"UTD.htm?26/53/27483\">",
"     table 1",
"    </a>",
"    ). Hybrid modes also exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bilevel positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;During BPAP therapy, an inspiratory positive airway pressure (IPAP) and an expiratory positive airway pressure (EPAP) are independently titrated and set. Tidal volume correlates with the difference between the IPAP and the EPAP. As an example, tidal volume is greater using an IPAP of 15 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and an EPAP of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O), than an IPAP of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and an EPAP of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O). Alveolar ventilation is enhanced by a larger tidal volume, assuming that the respiratory rate is constant.",
"   </p>",
"   <p>",
"    Nocturnal BPAP therapy usually decreases nocturnal PaCO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], daytime PaCO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/9,11,14\">",
"     9,11,14",
"    </a>",
"    ], and daytime sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] in patients with OHS. It may also improve long-term survival. This was illustrated by a series of 130 patients receiving BPAP for OHS, which found 1-, 2-, 3-, and 5-year survival rates of 98, 93, 88, and 77 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/14\">",
"     14",
"    </a>",
"    ]. These survival rates were better than the 18-month survival rate of 77 percent previously reported for a cohort of patients with OHS, most of whom were untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/17\">",
"     17",
"    </a>",
"    ]. Finally, there is evidence that BPAP maintains normocapnia chronically [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/11,14\">",
"     11,14",
"    </a>",
"    ] (probably by improving chemosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/18\">",
"     18",
"    </a>",
"    ]) and decreases restrictive physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BPAP probably offers several advantages compared to CPAP. These include active ventilation rather than pneumatic splinting, a lower mean airway pressure (which may lead to better tolerance of the therapy), better rest of the ventilatory muscles, more rapid improvement of respiratory acidosis, and a rapid return of normal ventilatory control or chemoreceptor function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/12\">",
"     12",
"    </a>",
"    ]. Well done clinical trials comparing BPAP to other NPPV modalities for the treatment of OHS have not been performed.",
"   </p>",
"   <p>",
"    BPAP appears to be effective, even in the presence of a small leak at the patient interface, because the inspiratory airflow will continue until the target pressure is reached. This coincides with delivery of the augmented tidal volume, assuming that severe upper airway obstruction and decreased respiratory system compliance are absent. If there is severe upper airway obstruction or decreased respiratory system compliance, the target pressure may be reached prior to delivery of the desired tidal volume, resulting in hypoventilation. In the case of severe upper airway obstruction, the EPAP and IPAP can be simultaneously increased. This relieves the upper airway obstruction while maintaining the gradient between the two pressures and allowing persistent augmentation of the tidal volume. In the case of decreased respiratory system compliance, the IPAP can be further increased once upper airway obstruction is relieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Volume cycled ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with OHS, upper airway obstruction or decreased respiratory system compliance may be so severe that sufficient alveolar ventilation cannot be achieved with CPAP or BPAP. VCPPV can be considered in this situation. VCPPV insures adequate ventilation by generating pressures high enough to overcome the physiologic limitations presented by the patient. Although this modality may be useful during an episode of acute decompensation, the high interface pressures required limit acceptance of this mode as chronic therapy. Short-term nocturnal VCPPV has been reported to improve daytime respiratory failure, with most patients eventually able to return to long-term CPAP or BPAP therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/20\">",
"     20",
"    </a>",
"    ]. An improved nocturnal ventilatory drive is the presumed mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hybrid modes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Average volume-assured pressure support (AVAPS) is a hybrid mode of NPPV, with features of standard BPAP and VCPPV. In a cross-over study of ten patients with OHS who failed CPAP therapy, BPAP alone was compared to AVAPS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/21\">",
"     21",
"    </a>",
"    ]. Both types of positive pressure ventilation improved oxygenation, sleep quality, and quality of life. However, AVAPS appeared to confer greater improvement in ventilation. Thus, AVAPS may be an acceptable alternative to BPAP and may be useful when rapid improvement of hypercapnia is necessary to prevent further decompensation of OHS. Further study is necessary to further clarify the benefits and role of AVAPS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5745012\">",
"    <span class=\"h1\">",
"     INITIATING NONINVASIVE POSITIVE PRESSURE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure therapy is indicated for patients with OHS because untreated disease may result in progressive hypercapnia, hypoxemia, and numerous adverse effects, including poor neurocognitive function, pulmonary hypertension, and cor pulmonale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5745019\">",
"    <span class=\"h2\">",
"     Acute decompensated OHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with an acute decompensation of OHS should have noninvasive positive pressure ventilation (NPPV) initiated expeditiously in a monitored inpatient setting, assuming that they are acceptable candidates for this therapy (able to cooperate, protect their airway, hemodynamically stable, arterial pH greater than 7.20). Bilevel positive airway pressure (BPAP) is the mode of NPPV that is generally tried first, with volume cycle positive pressure ventilation (VCPPV) reserved for when sufficient alveolar ventilation cannot be achieved with BPAP. Continuous positive airway pressure (CPAP) should not be used in this setting.",
"   </p>",
"   <p>",
"    There is no universal strategy for determining the initial settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For BPAP, one reasonable approach is to begin with inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) settings of 4 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O and then increase the IPAP every several minutes in increments of 2 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O until the patient appears more comfortable and there is an acceptable respiratory rate (eg, &lt;30 breaths per minute), oxyhemoglobin saturation (eg, &ge;90 percent), heart rate (eg, &le;100 beats per minute), and degree of ventilation (eg, pH &gt;7.30 on serial arterial blood gases). The inspired oxygen concentration should be titrated to maintain adequate oxyhemoglobin saturation (eg, &ge;90 percent) once the other settings have been determined. Failure of oxygenation to improve quickly may require further increases in EPAP. IPAP is generally increased simultaneously in order to maintain a pressure gradient between EPAP and IPAP that is sufficient to decrease work of breathing. Frequent arterial blood gases may be required to verify that improvement in arterial gas exchange is occurring.",
"     </li>",
"     <li>",
"      For VCPPV, the ventilator mode, respiratory rate, tidal volume, inspired oxygen concentration, and end-expiratory pressure must be selected. An assist-control mode is typically used to fully augment spontaneous respiratory efforts. The largest tidal volume that consistently maintains an airway pressure less than 30 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O is generally chosen, and the respiratory rate is then set to achieve a minute ventilation of 6 to 10",
"      <span class=\"nowrap\">",
"       L/min.",
"      </span>",
"      The respiratory rate can be adjusted as needed to achieve the ventilatory goals (eg, pH &gt;7.30 on serial arterial blood gases). The inspired oxygen concentration should be titrated to maintain adequate oxyhemoglobin saturation (eg, &ge;90 percent) and the end-expiratory pressure should be equivalent to the prior CPAP or EPAP settings. High interface pressures may cause sleep fragmentation, discomfort, intolerance, or an interface leak when VCPPV begins. In this situation, reducing the tidal volume and raising the respiratory rate will decrease the interface pressure while maintaining the desired minute ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective series of patients having an acute ventilatory decompensation of OHS, use of NPPV successfully averted endotracheal intubation in all patients and was associated with enhanced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5745117\">",
"    <span class=\"h2\">",
"     Chronic compensated OHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with chronic compensated OHS or who have been stabilized after an acute decompensation should undergo nocturnal polysomnography. Polysomnography detects coexisting obstructive sleep apnea (OSA), which guides the initial mode of therapy. It also allows the titration of positive airway pressure device settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with both OHS and OSA &ndash; Patients with OHS and OSA can be initially treated with nocturnal CPAP [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/9\">",
"       9",
"      </a>",
"      ]. Beginning at a level of 4 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O, the CPAP is increased in small increments (eg, 2 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) until obstructive events are eliminated [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/22\">",
"       22",
"      </a>",
"      ]. Patients who have persistent alveolar hypoventilation despite the elimination of obstructive events should be converted from CPAP to NPPV. This conversion is generally done using BPAP because the CPAP settings can be used as the starting point for the titration of BPAP. Beginning with IPAP and EPAP settings identical to the CPAP level at which obstructive events were eliminated, the IPAP is increased in small increments (eg, 2 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) until alveolar ventilation is sufficiently augmented [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/22\">",
"       22",
"      </a>",
"      ]. A back-up respiratory rate can be set to augment spontaneous respiratory efforts if necessary. Patients who fail BPAP may try VCPPV, which is initiated as described above. (See",
"      <a class=\"local\" href=\"#H5745019\">",
"       'Acute decompensated OHS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with OHS only &ndash; Patients with OHS alone should be treated with nocturnal NPPV because CPAP is unlikely to be effective in the absence of OSA. Nocturnal NPPV is generally initiated using the BPAP mode. Beginning with IPAP and EPAP settings of 4 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O, the IPAP is increased in increments of 2 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O until alveolar ventilation is sufficiently augmented [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/22\">",
"       22",
"      </a>",
"      ]. A back-up respiratory rate can be set to augment spontaneous respiratory efforts if necessary, although chronic use of this function may cause",
"      <span class=\"nowrap\">",
"       patient/ventilator",
"      </span>",
"      asynchrony or periodic breathing, resulting in disrupted sleep continuity or architecture in OHS patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients who fail BPAP may try VCPPV, which is initiated as described above. (See",
"      <a class=\"local\" href=\"#H5745019\">",
"       'Acute decompensated OHS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of which mode is used, clinical decisions are made according to whether the alveolar ventilation has been sufficiently augmented. However, this is difficult to determine. Blood gas analysis is the gold standard method of assessing alveolar ventilation. However, overnight blood gas analysis requires placement of an indwelling arterial catheter or multiple arterial blood draws, both of which are impractical in most sleep laboratories. The indicator of hypoventilation that is most commonly used is oxyhemoglobin desaturation unrelated to obstructive events. Transcutaneous measurement of arterial carbon dioxide (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/9,24\">",
"     9,24",
"    </a>",
"    ], calibrated respiratory inductance plethysmography, or end tidal CO",
"    <sub>",
"     2",
"    </sub>",
"    are alternative techniques, but they are controversial because their accuracy is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once nocturnal positive pressure therapy has been initiated, periodic awake arterial blood gases are useful to verify that alveolar hypoventilation has improved. Repeat polysomnography should be considered in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are symptoms or signs suggestive of persistent alveolar hypoventilation (eg, nocturnal dyspnea, a sensation of smothering at night, chronic morning headaches, failure of awake blood gases to improve) despite noninvasive positive pressure therapy. Persistent alveolar hypoventilation suggests that the type or level of positive pressure therapy may need to be changed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Awake arterial blood gases suggest improved alveolar ventilation. The purpose of polysomnography in this situation is to determine if the level of positive pressure support can be reduced, since this might improve long-term adherence to therapy. Therapy in some NPPV patients may also be able to be converted to CPAP and nocturnal oxygen supplementation may be able to be reduced or discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Factors contributing to the severity of OHS (eg, body mass, hypothyroidism, heavy ethanol consumption, or sedative use) have been reduced or eliminated. An associated reduction or elimination of alveolar hypoventilation may permit reduction or elimination of positive pressure therapy. In the case of body mass, weight loss of 50 to 100 pounds is generally required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia is common in patients with OHS, especially those with coexisting OSA. Supplemental oxygen should be administered whenever positive pressure therapy alone is insufficient to eliminate hypoxemia. Supplemental oxygen during sleep is titrated during polysomnography to eliminate hypoxemia or severe oxyhemoglobin desaturation after the optimal settings of positive pressure therapy have been established. Daytime supplemental oxygen can be titrated using oximetry at rest and with exertion.",
"   </p>",
"   <p>",
"    The supplemental oxygen is typically added to the respiratory circuit near its connection to the positive airway pressure device. Since the device generates varying degrees of air flow through the tubing that may cause a dilutional effect on the oxygen added to the circuit, the flow of supplemental oxygen may need to be adjusted if the settings are changed. Periodic repeat awake and nocturnal evaluations are necessary to insure that ongoing supplemental oxygen therapy is necessary and the prescription is correct. The need for supplemental oxygen frequently decreases as the patient's cardiopulmonary status improves with nocturnal positive pressure therapy.",
"   </p>",
"   <p>",
"    Supplemental oxygen alone (without positive pressure therapy) is inadequate therapy for OHS. Although it may improve nocturnal oxyhemoglobin desaturation, it does not relieve upper airway obstruction or augment ventilation, and it may acutely worsen carbon dioxide retention in patients with OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12375/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity Hypoventilation Syndrome (OHS) exists when there is obesity and alveolar hypoventilation during wakefulness which cannot be attributed to pulmonary parenchymal or other thoracic pathology. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two major categories of positive pressure therapy that are used to treat patients with OHS: continuous positive airway pressure (CPAP) and noninvasive positive pressure ventilation (NPPV). The latter includes bilevel positive airway pressure (BPAP) and volume cycled positive pressure ventilation (VCPPV). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Modes of noninvasive positive pressure therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with OHS receive nocturnal positive pressure therapy to reduce daytime sleepiness and improve alveolar ventilation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This recognizes that progressive alveolar hypoventilation may cause hypoxemia that is sufficient to cause clinically important adverse effects. (See",
"      <a class=\"local\" href=\"#H5745012\">",
"       'Initiating noninvasive positive pressure therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that supplemental oxygen be administered to patients with OHS if positive pressure therapy alone is insufficient to eliminate hypoxemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Supplemental oxygen during sleep can be added to the positive pressure system and titrated after the optimal settings of positive pressure therapy have been established. Daytime supplemental oxygen can be titrated using oximetry at rest and with exertion. Supplemental oxygen alone is insufficient therapy for OHS. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Supplemental oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an acute decompensation of OHS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest expeditious initiation of NPPV, rather than CPAP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). NPPV can be administered as BPAP or VCPPV, although BPAP is generally preferred unless it is insufficient to maintain an open upper airway or to overcome the decreased respiratory system compliance. (See",
"      <a class=\"local\" href=\"#H5745019\">",
"       'Acute decompensated OHS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with chronic compensated OHS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A polysomnogram is usually performed to detect coexisting obstructive sleep apnea (OSA, a disorder characterized by obstructive apneas and hypopneas) and to guide the titration of the positive airway pressure device settings. (See",
"      <a class=\"local\" href=\"#H5745117\">",
"       'Chronic compensated OHS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with OHS alone be initially treated with nocturnal NPPV, rather than CPAP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5745117\">",
"       'Chronic compensated OHS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with OHS plus OSA be initially treated with nocturnal CPAP, rather than NPPV (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients should be converted to nocturnal NPPV if they do not tolerate CPAP therapy or have persistent alveolar hypoventilation despite CPAP therapy. (See",
"      <a class=\"local\" href=\"#H5745117\">",
"       'Chronic compensated OHS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      After positive pressure therapy is initiated during sleep, periodic awake arterial blood gases are useful to verify that alveolar hypoventilation has improved. Repeat polysomnography should be considered in special situations. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/1\">",
"      Olson AL, Zwillich C. The obesity hypoventilation syndrome. Am J Med 2005; 118:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/2\">",
"      Sullivan CE, Berthon-Jones M, Issa FG. Remission of severe obesity-hypoventilation syndrome after short-term treatment during sleep with nasal continuous positive airway pressure. Am Rev Respir Dis 1983; 128:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/3\">",
"      Leech JA, Onal E, Lopata M. Nasal CPAP continues to improve sleep-disordered breathing and daytime oxygenation over long-term follow-up of occlusive sleep apnea syndrome. Chest 1992; 102:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/4\">",
"      Rapoport DM, Sorkin B, Garay SM, Goldring RM. Reversal of the \"Pickwickian syndrome\" by long-term use of nocturnal nasal-airway pressure. N Engl J Med 1982; 307:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/5\">",
"      Berger KI, Ayappa I, Chatr-Amontri B, et al. Obesity hypoventilation syndrome as a spectrum of respiratory disturbances during sleep. Chest 2001; 120:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/6\">",
"      Berthon-Jones M, Sullivan CE. Time course of change in ventilatory response to CO2 with long-term CPAP therapy for obstructive sleep apnea. Am Rev Respir Dis 1987; 135:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/7\">",
"      P&eacute;rez de Llano LA, Golpe R, Piquer MO, et al. Clinical heterogeneity among patients with obesity hypoventilation syndrome: therapeutic implications. Respiration 2008; 75:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/8\">",
"      Banerjee D, Yee BJ, Piper AJ, et al. Obesity hypoventilation syndrome: hypoxemia during continuous positive airway pressure. Chest 2007; 131:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/9\">",
"      Piper AJ, Wang D, Yee BJ, et al. Randomised trial of CPAP vs bilevel support in the treatment of obesity hypoventilation syndrome without severe nocturnal desaturation. Thorax 2008; 63:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/10\">",
"      Masa JF, Celli BR, Riesco JA, et al. The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation. Chest 2001; 119:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/11\">",
"      P&eacute;rez de Llano LA, Golpe R, Ortiz Piquer M, et al. Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. Chest 2005; 128:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/12\">",
"      Chouri-Pontarollo N, Borel JC, Tamisier R, et al. Impaired objective daytime vigilance in obesity-hypoventilation syndrome: impact of noninvasive ventilation. Chest 2007; 131:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/13\">",
"      Cuvelier A, Muir JF. Acute and chronic respiratory failure in patients with obesity-hypoventilation syndrome: a new challenge for noninvasive ventilation. Chest 2005; 128:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/14\">",
"      Priou P, Hamel JF, Person C, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest 2010; 138:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/15\">",
"      Waldhorn RE. Nocturnal nasal intermittent positive pressure ventilation with bi-level positive airway pressure (BiPAP) in respiratory failure. Chest 1992; 101:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/16\">",
"      Laursen SB, Dreijer B, Hemmingsen C, Jacobsen E. Bi-level positive airway pressure treatment of obstructive sleep apnoea syndrome. Respiration 1998; 65:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/17\">",
"      Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/18\">",
"      Redolfi S, Corda L, La Piana G, et al. Long-term non-invasive ventilation increases chemosensitivity and leptin in obesity-hypoventilation syndrome. Respir Med 2007; 101:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/19\">",
"      Heinemann F, Budweiser S, Dobroschke J, Pfeifer M. Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome. Respir Med 2007; 101:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/20\">",
"      Piper AJ, Sullivan CE. Effects of short-term NIPPV in the treatment of patients with severe obstructive sleep apnea and hypercapnia. Chest 1994; 105:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/21\">",
"      Storre JH, Seuthe B, Fiechter R, et al. Average volume-assured pressure support in obesity hypoventilation: A randomized crossover trial. Chest 2006; 130:815.",
"     </a>",
"    </li>",
"    <li>",
"     Sanders, MH, Stiller, RA. Positive airway pressure in the treatment of sleep-related breathing disorders. In: Sleep Disorders Medicine, 1st, Chokroverty, S (Eds), Butterworth-Heinemann, Boston 1994. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/23\">",
"      Guo YF, Sforza E, Janssens JP. Respiratory patterns during sleep in obesity-hypoventilation patients treated with nocturnal pressure support: a preliminary report. Chest 2007; 131:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/24\">",
"      Storre JH, Steurer B, Kabitz HJ, et al. Transcutaneous PCO2 monitoring during initiation of noninvasive ventilation. Chest 2007; 132:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12375/abstract/25\">",
"      Masa JF, Celli BR, Riesco JA, et al. Noninvasive positive pressure ventilation and not oxygen may prevent overt ventilatory failure in patients with chest wall diseases. Chest 1997; 112:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7714 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12375=[""].join("\n");
var outline_f12_5_12375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MODES OF NONINVASIVE POSITIVE PRESSURE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Continuous positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Noninvasive positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bilevel positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Volume cycled ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hybrid modes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5745012\">",
"      INITIATING NONINVASIVE POSITIVE PRESSURE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5745019\">",
"      Acute decompensated OHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5745117\">",
"      Chronic compensated OHS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7714\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7714|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/53/27483\" title=\"table 1\">",
"      Administering positive pressure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=related_link\">",
"      Pathogenesis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=related_link\">",
"      Treatment of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12376="Early and late hemodialysis arteriovenous fistula failure";
var content_f12_5_12376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early and late hemodialysis arteriovenous fistula failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12376/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12376/contributors\">",
"     Gerald A Beathard, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12376/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12376/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12376/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/5/12376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemodialysis arteriovenous fistula (AVF) is associated with fewer complications than those seen with other types of vascular access. However, they do occur and must be dealt with effectively.",
"   </p>",
"   <p>",
"    The failure of an AVF may be defined as either early or late failure. The distinction is made because there are certain unique lesions that are seen in the early category. Unfortunately, these lesions are also major causes of late failure, principally because they were not diagnosed and corrected during the early period. Nevertheless, the early and late distinction has merit.",
"   </p>",
"   <p>",
"    Early and late AVF failure and their management will be reviewed here. Other types of AVF dysfunction and their management are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY AVF FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An AVF that is never usable for dialysis or fails within three months of initial use is classified as an early failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1\">",
"     1",
"    </a>",
"    ]. Early AVF failure is common, with an incidence in the range of 20 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. Salvage of these cases is extremely important to increasing the number of AVFs in our hemodialysis population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of early failure can be classified as either inflow or outflow problems. In most cases, these problems can be obviated by proper patient evaluation, including vascular mapping prior to an attempt at access creation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37210?source=see_link\">",
"     \"Creating an arteriovenous fistula for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases that have been properly evaluated prior to access creation, the two most common causes of early AVF failure are inflow problems due to juxta-anastomotic stenosis and outflow problems due to the presence of accessory veins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The juxta-anastomotic stenosis (JAS) occurs in the segment of vein that is immediately adjacent to the anastomosis.",
"     </li>",
"     <li>",
"      The vein that is to become an AVF may have side branches. These side branches (usually cephalic) are referred to as accessory veins, which represent normal anatomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two lesions frequently occur together [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. In a study of 100 patients who met the definition of early AVF failure, 78 percent of failures were due in part to venous stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1\">",
"     1",
"    </a>",
"    ]. Additional details included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 43 percent of cases, the lesion was in the juxta-anastomotic location, which was the only lesion present in 15 percent. In 24 percent, the juxta-anastomotic stenosis was associated with an accessory vein, in 6 percent with a proximal stenosis, and in 4 percent with both.",
"     </li>",
"     <li>",
"      An accessory vein was present in 46 percent of cases. In 12 percent of the cases, this was the only lesion present. In 24 percent of the cases, this anomaly was associated with JAS, in 6 percent with proximal stenosis, and in 4 percent with both.",
"     </li>",
"     <li>",
"      A proximal stenosis lesion was present in the AVF in 36 percent. In 6 percent, it was associated with an accessory vein, in 6 percent with a JAS, and in 4 percent with both.",
"     </li>",
"     <li>",
"      The definition of arterial anastomosis stenosis was met in 38 percent of the cases, always in association with JAS. In four cases, a stenotic lesion was present in the artery above the anastomosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Inflow problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good blood inflow must be present for an AVF to develop and function adequately for hemodialysis. Both maturation and adequacy of flow are dependent upon pressure and volume of flow. Abnormalities of the feeding artery can result in early failure of the access. Anomalies, such as an artery that is too small for the creation of a functional access or the presence of arterial disease such as atherosclerosis, can prevent the development of an adequate AVF or result in its early demise. Both of these problems should be preventable with proper patient evaluation prior to access placement.",
"   </p>",
"   <p>",
"    The unique problem that results in early access failure due to inflow difficulties is, as previously mentioned, juxta-anastomotic stenosis. This lesion occurs in the segment of vein that is immediately adjacent to the anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the etiology of juxta-anastomotic stenosis is not clear, this lesion involves the segment of vein that is mobilized and manipulated by the surgeon in creating the AVF. It may be related to stretching, torsion, or other types of trauma. This segment is often skeletonized in the process of mobilizing it for the creation of the AVF. This causes a loss of the vasa venosum, which supplies blood to the vein. The effect of the lesion is to obstruct AVF inflow. Since it occurs early, it results in early access failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Outflow problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate, low resistance blood outflow is required for an AVF to develop and function adequately for hemodialysis. The absence of good outflow can result in failure of the access.",
"   </p>",
"   <p>",
"    Anomalies that lead to outflow problems include veins that are too small for AVF development, veins that are fibrotic or stenotic due to past trauma, such as venipuncture, and the presence of accessory veins. The first two of these should be preventable by proper patient evaluation prior to access placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37210?source=see_link\">",
"     \"Creating an arteriovenous fistula for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is an overview of accessory veins. The optimum anatomy for the creation of a AVF is a single vein without side branches. Unfortunately, this is not always the case. The vein that is to become an AVF may have side branches, which are referred to as accessory veins (usually cephalic). These represent normal anatomy. They must be distinguished from collateral veins that represent pathological anatomy, which are always associated with a down stream (antegrade) stenosis.",
"   </p>",
"   <p>",
"    Frequently, the presence of accessory veins is recognized and dealt with by the surgeon at the time of AVF creation; however, this is not always the case. In addition, all of the veins receiving the drainage from the newly created anastomosis enlarge. A small accessory vein, not thought to be significant at the time of creation, may become enlarged with time.",
"   </p>",
"   <p>",
"    In ideal situations, the presence of an accessory vein may be viewed as an advantage, as the patient may develop an additional venous channel suitable for cannulation (a double AVF). However, under less than optimal conditions, its presence can result in early AVF failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This occurs because AVF development is dependent upon flow and pressure. Pressure necessary for AVF development is dependent upon the inflow pressure and the upstream resistance of the draining vein. Down stream (antegrade) resistance is decreased if the vessel branches because of the increased effective cross-sectional diameter represented by multiple vessels. In addition, flow that should be limited to a single channel is partitioned into two or more channels, each receiving less than the total.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of early failure are poor flow, thrombosis, and failure of the access to develop adequately for cannulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of early AVF failure is diagnosed by careful physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41443?source=see_link\">",
"     \"Physical examination of the hemodialysis arteriovenous fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Juxta-anastomotic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juxta-anastomotic stenosis can be easily diagnosed by physical examination. Normally, a very prominent thrill is present at the anastomosis. In the absence of abnormalities, the pulse is soft and easily compressible.",
"   </p>",
"   <p>",
"    With stenosis, a water-hammer pulse is felt at the anastomosis. The thrill, which is normally continuous, is diminished and generally only present in systole. As one moves up the vein from the anastomosis with the palpating finger, the pulse goes away rather abruptly as the site of stenosis is encountered. Above this level, the pulse is very weak and the vein is poorly developed. The stenosis itself can frequently be felt as an abrupt diminution in the size of the vein, almost like a shelf. Once these typical physical findings are detected, the cause for poor fistula development becomes obvious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Accessory veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory veins, which may be single or multiple, can be easily diagnosed by physical examination. Frequently, these veins are visible. If not, they can be detected by palpating the fistula. Normally, the thrill that is palpable over the arterial anastomosis disappears when the downstream fistula is manually occluded; this causes flow to stop.",
"   </p>",
"   <p>",
"    If it does not disappear, an outflow channel (accessory vein) is present below the point of occlusion. Palpation of the fistula below the occlusion point will generally reveal the location of the accessory vein by the presence of a thrill over its trunk. As long as the main channel can be identified for occlusion, the entire length of the vein can be evaluated by moving the point of fistula occlusion progressively upward.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Juxta-anastomotic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juxta-anastomotic stenosis is amenable to treatment. Generally, it can be successfully treated by percutaneous angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1,11,13\">",
"     1,11,13",
"    </a>",
"    ] or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/12\">",
"     12",
"    </a>",
"    ]. Although there have been no prospective studies to compare these two modalities, most of the published series have used angioplasty and have had a high success rate (&gt;90 percent). This, along with the ease with which treatment can be affected in the outpatient setting, has led many to consider this modality as the treatment of choice. We therefore suggest the use of angioplasty rather than surgery in patients with juxta-anastomotic stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Accessory veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all accessory veins need to be obliterated. The significance of the additional venous structure can be judged by its size and apparent blood flow. Small accessory veins seldom contribute significantly to the AVF's failure to develop.",
"   </p>",
"   <p>",
"    In general, an accessory vein that is less than one-fourth the diameter of the main AVF is unlikely to prove to be significant. Palpation of the upper AVF when the accessory vein is manually occluded will also aid in determining the side branch's significance. If it is affecting the AVF, an apparent augmentation should be evident when it is occluded. These veins can be obliterated to convert the branched, unusable AVF into a functional AVF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1,11,13,14\">",
"     1,11,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Side branch and stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a downstream (antegrade) stenosis, the side branch is either a collateral that has developed because of the stenosis or an accessory (meaning that it is a normal venous structure) that is being augmented by the presence of the stenosis. There is no way to distinguish between these two possibilities. In either case, the significance of a side branch associated with a downstream stenosis cannot be evaluated adequately until the stenosis has been successfully treated.",
"   </p>",
"   <p>",
"    When presented with the combination of a large side branch associated with a down stream stenosis, we suggest first treating the stenosis and then determining the significance of the side branch. It many instances, it will be seen to have disappeared. This approach is based entirely on clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Outcome studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of early AVF failure can be treated with a high expectation of success [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1,11,14,15\">",
"     1,11,14,15",
"    </a>",
"    ]. However, no prospective randomized studies have examined the effectiveness of different modalities. In the prospective non-controlled report of 100 cases of early AVF failure previously mentioned, each patient was first evaluated angiographically to identify the anatomy of their AV fistula and detect abnormalities that might be present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1\">",
"     1",
"    </a>",
"    ]. Stenotic lesions were then treated with angioplasty, and accessory veins thought to be significant were obliterated. Angioplasty was performed in 72 percent of the cases with a 98 percent success rate. Angioplasty of the arterial anastomosis was performed in 38 cases with a 100 percent success rate. Accessory vein obliteration was performed in 46 percent of the patients with a 100 percent success rate.",
"   </p>",
"   <p>",
"    The overall complication rate in this series was 4 percent; of these, 3 percent were minor and 1 percent were major. It was possible to initiate dialysis using the AVF in 92 percent of the cases. Actuarial life-table analysis looking at primary patency showed that 84 percent were functional at three months, 72 percent at six months, and 68 percent at 12 months.",
"   </p>",
"   <p>",
"    Many early failure cases also require a staged procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 63 AVFs required 209 procedures (3.3 procedures per AVF) for salvage [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 154 AVFs created in 146 patients, only 112 (73 percent) were ultimately used successfully for hemodialysis. One hundred and thirteen procedures were performed in 65 of these cases (1.7 procedures per AVF) in order to promote maturation. Only 48 of these 65 non-maturing AVFs (74 percent) became functional [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LATE AVF FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late AVF failure is defined as failure that occurs after three months of use. It is important to realize that the lesions typical of early failure are also commonly seen during this later period because they were not addressed in a timely fashion. It is also possible that these lesions of early failure have progressed in their ability to cause dysfunction.",
"   </p>",
"   <p>",
"    The lesions most typical of this later period are acquired venous and arterial stenoses. These lesions are manifest as pathological changes in the AVF from increased pressure and decreased flow, leading to inadequate dialysis and eventually thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Venous stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous stenosis does not occur in the AVF with the same degree of frequency as is seen with synthetic grafts. Nevertheless, it is the most common cause of late AVF loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. In one study, for example, 63 mature fistulas required 209 procedures to maintain patency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/14\">",
"     14",
"    </a>",
"    ]. Of these, 174 were venous angioplasty procedures, which means that 83 percent of the total procedures performed were for venous stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/14\">",
"     14",
"    </a>",
"    ]. For this reason, the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    Clinical Practice Guidelines recommends that each dialysis facility have in place an organized program for the prospective diagnosis of venous stenosis by means of monitoring and surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike grafts, venous stenosis associated with the AVF generally develops at areas of surgical vein mobilization (swing-point) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/17\">",
"     17",
"    </a>",
"    ], vein bifurcation, pressure points, and in association with venous valves. The development of collateral veins is frequent and often preserves flow in the access so that thrombosis occurs late.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Screening and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that all hemodialysis facilities have a system designed to detect venous stenosis so that it can be diagnosed and treated prospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/15\">",
"     15",
"    </a>",
"    ]. Monitoring performed by physical examination should be performed on a weekly basis. Surveillance testing should be performed on a regularly scheduled basis.",
"   </p>",
"   <p>",
"    For surveillance of fistulas, the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group prefer the following modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct flow measurements",
"     </li>",
"     <li>",
"      Physical examination &mdash; Physical findings suggestive of stenosis include persistent arm swelling, prolonged bleeding after needle withdrawal, collateral veins, and altered features of the pulse or thrill.",
"     </li>",
"     <li>",
"      Duplex ultrasonography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group also suggest that it is acceptable to use recirculation (via a non-urea-based dilutional method) or static pressures (either direct or derived) for surveillance of fistulas.",
"   </p>",
"   <p>",
"    Although most of the studies have primarily evaluated patients with AV grafts, some data also suggest that blood flow measurements are valuable in patients with native AV fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In a 2008 systematic review, four randomized controlled trials evaluated access flow- or ultrasound-based monitoring in native AV fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/19\">",
"     19",
"    </a>",
"    ]. These modalities significantly decreased the risk of access thrombosis (RR of 0.45, 95% CI 0.28-0.77).",
"   </p>",
"   <p>",
"    The question of which of the available modalities is preferred often arises. A great deal of the answer to this query lies in the experience of the personnel involved. Physical examination is inexpensive and accurate. It is easily learned but does require some training. We feel that it has many advantages.",
"   </p>",
"   <p>",
"    Physical examination has a relatively high degree of accuracy in detecting the pathology associated with a dysfunctional access. This has been shown true for both synthetic grafts and fistulas. The first report of the ability of this modality to predict venous stenosis reported 85 percent accuracy when correlated with angiography in synthetic grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/20\">",
"     20",
"    </a>",
"    ]. Subsequent studies in grafts showed a high degree of correlation between physical examination and ultrasound with volume flow measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/20\">",
"     20",
"    </a>",
"    ]; this approach was significantly better than pressure measurements in predicting the success of just completed interventional procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report involving only fistulas, the accuracy of an experienced interventionalist (IN) and a nephrology fellow (NF) with one month of training in physical examination of dialysis access was compared [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/22\">",
"     22",
"    </a>",
"    ]. Forty-five and 142 consecutive cases of arteriovenous fistula dysfunction were examined by the NF and IN, respectively. Evaluation of the data revealed that, for outflow stenosis, the level of accuracy for NF was 81 percent, while that for IN was 89 percent. For inflow stenosis, NF was 80 percent accurate and IN was 83 percent. NF performed significantly better than IN regarding central vein stenosis, 79 versus 11 percent.",
"   </p>",
"   <p>",
"    When abnormalities are found in any of the monitoring or surveillance parameters, the patient should be referred for further evaluation and treatment. When relying on such techniques as flow measurement, one should not respond to a single isolated abnormal value; the aberration must be persistent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that clinicians use the following criteria for additional diagnostic testing and possible treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With all techniques, findings with prospective trend analysis consistent with stenosis, rather than a single isolated value",
"     </li>",
"     <li>",
"      Persistent abnormalities with any of the techniques",
"     </li>",
"     <li>",
"      Access flow rate less than 400 to 500",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      Venous segment static pressure ratio greater than 0.5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with these criteria and suggest using angiography for further diagnostic testing among those with such abnormalities. With angiography, a stenotic lesion is recognized by comparison with the adjacent normal vein or fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The entire venous system associated with the access should be examined angiographically, as well as the anastomosis and adjacent artery. More than one lesion can be expected in at least one-third of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective treatment of stenosis before thrombosis can occur is important and will materially prolong access survival. Although not supported by well-designed prospective studies, we suggest that only lesions showing 50 percent or greater stenosis in conjunction with clinical or physiological abnormalities be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is performed either by percutaneous transluminal angioplasty (PTA) or surgical revision. Although there have been no direct comparisons between PTA and surgical revision, uncontrolled studies have reported that PTA has a greater than 95 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/27\">",
"     27",
"    </a>",
"    ]. This success rate combined with superior convenience and less morbidity compared with surgery has resulted in PTA becoming the treatment of choice for these lesions. Long-term primary patency rates have been in the range of 84 percent at three months, 57 to 67 percent at six months, and 35 to 51 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/27\">",
"     27",
"    </a>",
"    ]. It is important to note that the stenosis, as well as the clinical parameters used to detect it, should return to acceptable limits following intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Arterial stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many dialysis patients either have significant vascular disease when they begin dialysis or are predisposed to its development. Arterial lesions that develop or advance once dialysis is initiated can jeopardize the functioning AVF. The incidence of arterial problems (anastomosis and feeding artery) in dysfunctional AVFs has been reported to be as high as 15 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Diagnosis and screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for arterial stenosis or inflow stenosis is generally an important part of access management. Any time blood flow surveillance detects a decreased flow, such a problem is a possible cause. However, the flow abnormality detected is not specific for this location. With ultrasonography, the artery and its anastomosis can be directly examined and evaluated as part of the study. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Screening and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nevertheless, we feel that physical examination is the easiest and best method for monitoring the patient's fistula for inflow problems. The technique of evaluating pulse augmentation is easily learned, easily applied, and quickly accomplished. It has a high degree of accuracy for this anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/22,30\">",
"     22,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41443?source=see_link\">",
"     \"Physical examination of the hemodialysis arteriovenous fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Presented with a clinical picture of fistula dysfunction and this physical finding, the patient should be referred for angiography with a high level of suspicion of an inflow problem. The diagnosis of an inflow problem is dependent upon angiographic demonstration of the lesion. The location of the problem may be anywhere within the feeding arterial system or the anastomosis.",
"   </p>",
"   <p>",
"    Diagnosis is based upon a comparison of the narrowed segment within the artery to the immediately adjacent normal artery. In the case of anastomosis, the diameter of the orifice is compared to the adjacent normal artery. It must be less than 50 percent to qualify as stenotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that have evaluated the efficacy of surgery in this setting. By comparison, these arterial problems frequently can be treated successfully by angioplasty. In a study of 101 cases with fistula dysfunction due to either poor flow or thrombosis, 8 percent were found to have arterial lesions and 21 percent had stenosis at the anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/28\">",
"     28",
"    </a>",
"    ]. Five of the arterial lesions were located adjacent to the arterial anastomosis. The remaining three cases were located upstream from the fistula. Problems were more frequent in the forearm than in upper arm fistulas. Treatment resulted in a doubling of blood flow. Doubling of flow following treatment of such lesions has also been reported by other investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/29,31\">",
"     29,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to qualify for treatment by angioplasty, the degree of stenosis observed must be 50 percent or greater and is associated with hemodynamic, functional, or clinical abnormalities such as a previous thrombotic episode, abnormal physical findings, or decreased access flow [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some instances, these arterial lesions can predispose to a steal syndrome. This is most commonly associated with radial-cephalic fistulas. The majority of patients with radial-cephalic fistulas will have significant blood flow to the access through the palmar arch from the ulnar artery (physiologic steal) but will be asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Only a small portion (1 percent or less ) will develop symptoms of this syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although AVFs have only one-sixth the thrombosis rate of grafts, thrombosis is a common mechanism for late AVF failures. From a clinical perspective, a fistula is labeled as a thrombosed fistula when it has no detectable flow in the dialysis facility. In fact, many, if not most, actually have no thrombus; they simply have flow that is so diminished that it is no longer detectable, or they have complete obstruction of the main channel and all the flow (diminished) is going through collaterals.",
"   </p>",
"   <p>",
"    There are two reasons for these observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This is a native vein and, unlike a synthetic graft, it can tolerate very low flow without thrombosing.",
"     </li>",
"     <li>",
"      It is capable of forming collaterals that preserve flow as the main channel becomes increasingly stenotic. In addition, since the fistula can remain patent longer with decreasing flow than can a synthetic graft, the stenotic lesions that are seen are frequently much more severe. This is not to say that the fistula clinically diagnosed as being thrombosed never has thrombus. In fact, the thrombus load in some of these cases can be quite large. This is more likely to be seen in the upper arm fistulas and in what has come to be referred to as a \"mega-fistula\" (ie, one that is markedly dilated, tortuous, with multiple aneurysms).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Problems on the arterial side of the AVF affecting inflow have been reported in as many as 40 percent of cases of AVF dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/28\">",
"     28",
"    </a>",
"    ]. Due to this degree of frequency, it is important that all cases be evaluated angiographically for such a problem. This can be done easily at the time of the thrombectomy by comparing the diameter of the arterial anastomosis with the diameter of the adjacent normal artery. If it is less than 50 percent, we consider it stenotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies reported relatively poor results with the treatment of thrombosed AVFs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/37\">",
"     37",
"    </a>",
"    ]. The popular opinion was that a thrombosed AVF should be referred for surgical revision, often replacement with a graft.",
"   </p>",
"   <p>",
"    However, subsequent uncontrolled prospective reports have documented excellent success with both endovascular and surgical approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/1,27,37-40\">",
"     1,27,37-40",
"    </a>",
"    ]. Initial success in the treatment of thrombosed AVFs has ranged from 88 to 94 percent. With endovascular therapy, long-term primary patency with endovascular therapy has been reported in the range of 63 to 89 percent at three months, 52 to 74 percent at six months, and 27 to 47 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/27,39\">",
"     27,39",
"    </a>",
"    ]. The largest report of treated thrombosed fistulas consists of a cohort of 228 cases treated endovascularly with a 78 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is not a great deal of information available on the surgical treatment of a thrombosed fistula:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report describing a surgical approach to the thrombosed fistula, investigators describe a technique that combines both surgical and endovascular techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/37\">",
"       37",
"      </a>",
"      ]. Only 10 cases were treated over a period of three years. A 70 percent success rate was reported with a six-month primary and secondary patency of 51 and 69 percent, respectively.",
"     </li>",
"     <li>",
"      In another report, a cohort of 32 thrombosed fistulas were treated surgically with an 84 percent success rate [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12376/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In view of the complex anatomy often presented by these cases with severe stenotic lesions, often multiple, and multiple collaterals, image-guided treatment is critical. For this reason, we prefer endovascular treatment to a surgical approach.",
"   </p>",
"   <p>",
"    The initial technical success rate for treating a thrombosed fistula is not as good as that seen for thrombosed grafts managed by either endovascular or surgical means (in the mid-90 percent range). However, the primary and secondary patency rates are definitely better with fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hemodialysis arteriovenous fistula (AVF) that is never usable for dialysis or fails within three months of initial use is classified as an early failure. In cases that have been properly evaluated prior to access creation, the two most common causes of early AVF failure are inflow problems due to juxta-anastomotic stenosis and outflow problems due to the presence of accessory veins. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of early AVF failure is diagnosed by careful physical examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41443?source=see_link\">",
"       \"Physical examination of the hemodialysis arteriovenous fistula\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with early AVF failure due to juxta-anastomotic stenosis, we suggest the use of angioplasty rather than surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Among those with early AVF failure due to an accessory vein, the culprit vein can be obliterated. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late AVF failure is defined as failure that occurs after three months of use. The lesions most typical of this later period are acquired venous (most common) and arterial stenoses. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Late AVF failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To screen for venous stenosis, we prefer the use of direct flow measurements or physical examination. Among those with abnormalities suggestive of venous stenosis, we use angiography for diagnostic testing. Among patients with lesions showing 50 percent or greater stenosis in conjunction with clinical or physiological abnormalities, we suggest the use of percutaneous transluminal angioplasty (PTA) rather than surgical revision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Venous stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To screen for arterial stenosis, we prefer the use of the physical examination. Among patients with late AVF failure, the presence of poor pulse augmentation within the access is indicative of an inflow problem. Such patients should be referred for an angiogram. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Arterial stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with 50 percent or greater arterial stenosis associated with hemodynamic, functional, or clinical abnormalities such as a previous thrombotic episode, abnormal physical findings, or decreased access flow, we suggest the use of PTA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/1\">",
"      Beathard GA, Arnold P, Jackson J, et al. Aggressive treatment of early fistula failure. Kidney Int 2003; 64:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/2\">",
"      Gibson KD, Caps MT, Kohler TR, et al. Assessment of a policy to reduce placement of prosthetic hemodialysis access. Kidney Int 2001; 59:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/3\">",
"      Allon M, Lockhart ME, Lilly RZ, et al. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001; 60:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/4\">",
"      Oliver MJ, McCann RL, Indridason OS, et al. Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int 2001; 60:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/5\">",
"      Sedlacek M, Teodorescu V, Falk A, et al. Hemodialysis access placement with preoperative noninvasive vascular mapping: comparison between patients with and without diabetes. Am J Kidney Dis 2001; 38:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/6\">",
"      Huber TS, Ozaki CK, Flynn TC, et al. Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. J Vasc Surg 2002; 36:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/7\">",
"      Robbin ML, Chamberlain NE, Lockhart ME, et al. Hemodialysis arteriovenous fistula maturity: US evaluation. Radiology 2002; 225:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/8\">",
"      Ives CL, Akoh JA, George J, et al. Pre-operative vessel mapping and early post-operative surveillance duplex scanning of arteriovenous fistulae. J Vasc Access 2009; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/9\">",
"      Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008; 299:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/10\">",
"      Weber CL, Djurdjev O, Levin A, Kiaii M. Outcomes of vascular access creation prior to dialysis: building the case for early referral. ASAIO J 2009; 55:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/11\">",
"      Beathard GA, Settle SM, Shields MW. Salvage of the nonfunctioning arteriovenous fistula. Am J Kidney Dis 1999; 33:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/12\">",
"      Romero A, Polo JR, Garcia Morato E, et al. Salvage of angioaccess after late thrombosis of radiocephalic fistulas for hemodialysis. Int Surg 1986; 71:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/13\">",
"      Nassar GM, Nguyen B, Rhee E, Achkar K. Endovascular treatment of the \"failing to mature\" arteriovenous fistula. Clin J Am Soc Nephrol 2006; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/14\">",
"      Falk A. Maintenance and salvage of arteriovenous fistulas. J Vasc Interv Radiol 2006; 17:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/15\">",
"      NKF-K/DOQI Clinical Practice Guidelines For Vascular Access. Clinical Practice Guideline 4: Detection of access dysfunction: monitoring, surveillance, and diagnostic testing. Am J Kidney Dis 2006; 48(Suppl 1):S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/16\">",
"      Roy-Chaudhury P, Spergel LM, Besarab A, et al. Biology of arteriovenous fistula failure. J Nephrol 2007; 20:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/17\">",
"      Falk A, Teodorescu V, Lou WY, et al. Treatment of \"swing point stenoses\" in hemodialysis arteriovenous fistulae. Clin Nephrol 2003; 60:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/18\">",
"      Tonelli M, Jindal K, Hirsch D, et al. Screening for subclinical stenosis in native vessel arteriovenous fistulae. J Am Soc Nephrol 2001; 12:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/19\">",
"      Tonelli M, James M, Wiebe N, et al. Ultrasound monitoring to detect access stenosis in hemodialysis patients: a systematic review. Am J Kidney Dis 2008; 51:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/20\">",
"      Beathard, GA. Physical examination of AV grafts. Semin Dial 1992; 5:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/21\">",
"      Trerotola SO, Scheel PJ Jr, Powe NR, et al. Screening for dialysis access graft malfunction: comparison of physical examination with US. J Vasc Interv Radiol 1996; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/22\">",
"      Leon C, Asif A. Physical examination of arteriovenous fistulae by a renal fellow: does it compare favorably to an experienced interventionalist? Semin Dial 2008; 21:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/23\">",
"      Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int 1992; 42:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/24\">",
"      Gray RJ. Percutaneous intervention for permanent hemodialysis access: a review. J Vasc Interv Radiol 1997; 8:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/25\">",
"      Vesely, TM. Percutaneous transluminal angioplasty for the treatment of failing hemodialysis grafts and fistulae. Semin Dial 1998; 11:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/26\">",
"      NKF-K/DOQI Clinical Practice Guidelines For Vascular Access. Clinical Practice Guideline 5: Treatment of fistula complications. Am J Kidney Dis 2006; 48(Suppl 1):S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/27\">",
"      Turmel-Rodrigues L, Pengloan J, Baudin S, et al. Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant 2000; 15:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/28\">",
"      Asif A, Gadalean FN, Merrill D, et al. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int 2005; 67:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/29\">",
"      Duijm LE, Liem YS, van der Rijt RH, et al. Inflow stenoses in dysfunctional hemodialysis access fistulae and grafts. Am J Kidney Dis 2006; 48:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/30\">",
"      Leon C, Orozco-Vargas LC, Krishnamurthy G, et al. Accuracy of physical examination in the detection of arteriovenous graft stenosis. Semin Dial 2008; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/31\">",
"      Duijm LE, van der Rijt RH, Cuypers PW, et al. Outpatient treatment of arterial inflow stenoses of dysfunctional hemodialysis access fistulas by retrograde venous access puncture and catheterization. J Vasc Surg 2008; 47:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/32\">",
"      NKF-K/DOQI Clinical Practice Guidelines For Vascular Access: Update 2006. Clinical Practice Guideline 6: Treatment of arteriovenous graft complications, 6.4 treatment of stenosis without thrombosis. Am J Kidney Dis 2006; 48(Suppl 1):S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/33\">",
"      Kwun, KB, Schanzer, H, Finkler, N, et al. Hemodynamic evaluation of angioaccess procedures for hemodialysis. Vasc Surg 1979; 13:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/34\">",
"      Ballard JL, Bunt TJ, Malone JM. Major complications of angioaccess surgery. Am J Surg 1992; 164:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/35\">",
"      Morsy AH, Kulbaski M, Chen C, et al. Incidence and characteristics of patients with hand ischemia after a hemodialysis access procedure. J Surg Res 1998; 74:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/36\">",
"      Goff CD, Sato DT, Bloch PH, et al. Steal syndrome complicating hemodialysis access procedures: can it be predicted? Ann Vasc Surg 2000; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/37\">",
"      Palmer RM, Cull DL, Kalbaugh C, et al. Is surgical thrombectomy to salvage failed autogenous arteriovenous fistulae worthwhile? Am Surg 2006; 72:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/38\">",
"      Schon D, Mishler R. Salvage of occluded autologous arteriovenous fistulae. Am J Kidney Dis 2000; 36:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/39\">",
"      Schon D, Mishler R. Pharmacomechanical thrombolysis of natural vein fistulas: reduced dose of TPA and long-term follow-up. Semin Dial 2003; 16:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/40\">",
"      Lipari G, Tessitore N, Poli A, et al. Outcomes of surgical revision of stenosed and thrombosed forearm arteriovenous fistulae for haemodialysis. Nephrol Dial Transplant 2007; 22:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12376/abstract/41\">",
"      Beathard GA, Litchfield T, Physician Operators Forum of RMS Lifeline, Inc. Effectiveness and safety of dialysis vascular access procedures performed by interventional nephrologists. Kidney Int 2004; 66:1622.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1957 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-ACD0464BDC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12376=[""].join("\n");
var outline_f12_5_12376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY AVF FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Inflow problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Outflow problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Juxta-anastomotic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Accessory veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Juxta-anastomotic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Accessory veins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Side branch and stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Outcome studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LATE AVF FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Venous stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Screening and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Arterial stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37210?source=related_link\">",
"      Creating an arteriovenous fistula for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41443?source=related_link\">",
"      Physical examination of the hemodialysis arteriovenous fistula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12377="Nifedipine: Drug information";
var content_f12_5_12377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nifedipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/27/31157?source=see_link\">",
"    see \"Nifedipine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"    see \"Nifedipine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adalat&reg; CC;",
"     </li>",
"     <li>",
"      Afeditab&reg; CR;",
"     </li>",
"     <li>",
"      Nifediac CC&reg;;",
"     </li>",
"     <li>",
"      Nifedical XL&reg;;",
"     </li>",
"     <li>",
"      Procardia XL&reg;;",
"     </li>",
"     <li>",
"      Procardia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adalat&reg; XL&reg;;",
"     </li>",
"     <li>",
"      Apo-Nifed PA&reg;;",
"     </li>",
"     <li>",
"      Mylan-Nifedipine Extended Release;",
"     </li>",
"     <li>",
"      Nu-Nifed;",
"     </li>",
"     <li>",
"      Nu-Nifedipine-PA;",
"     </li>",
"     <li>",
"      PMS-Nifedipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dosage adjustments should occur at 7- to 14-day intervals, to allow for adequate assessment of new dose; when switching from immediate release to sustained release formulations, use same total daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic stable or vasospastic angina:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Initial: 10 mg 3 times/day; usual dose: 10-20 mg 3 times/day; coronary artery spasm may require up to 20-30 mg 3-4 times/day; single doses &gt;30 mg and total daily doses &gt;120 mg are rarely needed; maximum: 180 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Do not use for acute anginal episodes; may precipitate myocardial infarction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Initial: 30 or 60 mg once daily; maximum: 120-180 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Extended release: Initial: 30 or 60 mg once daily; maximum: 90-120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      High altitude pulmonary edema (unlabeled use; Luks, 2010):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention: Extended release: 30 mg every 12 hours starting the day before ascent and may be discontinued after staying at the same elevation for 5 days or if descent initiated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: Extended release: 30 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pulmonary hypertension (unlabeled use; Galie, 2004):",
"     </b>",
"     Oral: Extended release: Initial: 30 mg twice daily; may increase cautiously to 120-240 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Raynaud&rsquo;s phenomenon (unlabeled use; Wigley, 2002):",
"     </b>",
"     Oral: Extended release: Dosage range: 30-120 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F201425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"      see \"Nifedipine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      High altitude pulmonary edema (unlabeled use; Pollard, 2001):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment with NIFEdipine is only necessary if response to oxygen and/or descent is unsatisfactory; extended release preparation is preferred, but with proper dose and frequency adjustment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 0.5 mg/kg/dose (maximum: 20 mg/dose) every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Oral: Children 1-17 years: Extended release tablet: Initial: 0.25-0.5 mg/kg/day once daily or in 2 divided doses; maximum: 3 mg/kg/day up to 120 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10293332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis effects: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F201406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clearance of nifedipine is reduced in cirrhotic patients leading to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procardia&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 30 mg, 60 mg, 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adalat&reg; CC: 30 mg, 60 mg, 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afeditab&reg; CR: 30 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nifediac CC&reg;: 30 mg [DSC], 60 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nifediac CC&reg;: 90 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nifedical XL&reg;: 30 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procardia XL&reg;: 30 mg, 60 mg, 90 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: In general, may be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Tablets should be swallowed whole; do not crush, split, or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adalat&reg; CC, Afeditab&reg; CR, Nifediac CC&reg;: Administer on an empty stomach (per manufacturer). Other extended release products may not have this recommendation; consult product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of chronic stable or vasospastic angina; treatment of hypertension (sustained release products only)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7280204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of pulmonary hypertension, preterm labor, and Raynaud&rsquo;s phenomenon; prevention and treatment of high altitude pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NIFEdipine may be confused with niCARdipine, niMODipine, nisoldipine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Procardia XL&reg; may be confused with Cartia XT&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depin [India] may be confused with Depen brand name for penicillamine [U.S.]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nipin [Italy and Singapore] may be confused with Nipent brand name for pentostatin [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (10% to 25%; extended release products 3% to 4%), peripheral edema (dose related 7% to 30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness/lightheadedness/giddiness (10% to 27%), headache (10% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/heartburn (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (&le;2% to 7%), transient hypotension (dose related 5%), CHF (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness/mood changes (&le;2% to 7%), fatigue (6%), shakiness (&le;2%), jitteriness (&le;2%), sleep disturbances (&le;2%), difficulties in balance (&le;2%), fever (&le;2%), chills (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (&le;2%), pruritus (&le;2%), urticaria (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Sexual difficulties (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (&le;2%), constipation (&le;2%), cramps (&le;2%), flatulence (&le;2%), gingival hyperplasia (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps/tremor (&le;2% to 8%), weakness (&lt;3%), inflammation (&le;2%), joint stiffness (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough/wheezing (6%), nasal congestion/sore throat (&le;2% to 6%), chest congestion (&le;2%), dyspnea (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, allergic hepatitis, alopecia, anemia, angina, angioedema, aplastic anemia, arrhythmia, arthritis with positive ANA, bezoars (Procardia XL&reg;), cerebral ischemia, depression, dysosmia, epistaxis, EPS, erectile dysfunction, erythema multiforme, erythromelalgia, exanthematous pustulosis, exfoliative dermatitis, facial edema, gastroesophageal reflux, gastrointestinal obstruction (Procardia XL&reg;), gastrointestinal ulceration (Procardia XL&reg;), gynecomastia, hematuria, ischemia, leukopenia, lip cancer (Friedman, 2012), memory dysfunction, migraine, myalgia, myoclonus, nocturia, paranoid syndrome, parotitis, periorbital edema, photosensitivity, polyuria, purpura, Stevens-Johnson syndrome, syncope, tachycardia, taste perversion, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient blindness, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported with use of sublingual short-acting nifedipine: Acute MI, cerebrovascular ischemia, ECG changes, fetal distress, heart block, severe hypotension, sinus arrest, stroke, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nifedipine or any component of the formulation; concomitant use with strong CYP3A4 inducers (eg, rifampin); cardiogenic shock; immediate release preparation for treatment of urgent or emergent hypertension (Chobanian, 2003); acute MI  (Antman, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.",
"     <b>",
"      The use of immediate release nifedipine (sublingually or orally) in hypertensive emergencies and urgencies is neither safe nor effective.",
"     </b>",
"     Serious adverse events (eg, death, cerebrovascular ischemia, syncope, stroke, acute myocardial infarction, and fetal distress) have been reported.",
"     <b>",
"      Immediate release nifedipine should not be used for acute blood pressure reduction.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in myocardial ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal strictures:  Alterations in gastrointestinal anatomy (eg, severe gastrointestinal narrowing, history of GI cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) and underlying hypomotility disorders have lead to bezoar formation with extended release forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with HF; may cause worsening of symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.  Clearance of nifedipine is reduced in cirrhotic patients leading to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potential for interactions: Use with caution in patients taking CYP3A4 inhibitors; may result in increased nifedipine concentrations; monitor for adverse effects/toxicity and consider dose adjustments. Use with strong CYP3A4 inducers (eg, rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, St John&rsquo;s wort) is contraindicated due to reduced bioavailability and efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Immediate release nifedipine should be avoided in this age group due to potential to cause hypotension and risk of precipitating myocardial ischemia (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release formulation: Consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract (eg, severe gastrointestinal narrowing, colon cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) has been associated with symptoms of obstruction (pharmacobezoar).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immediate release formulation: Immediate release formulations should not be used to manage essential hypertension, adequate studies to evaluate outcomes have not been conducted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Adalat&reg; CC tablets contain lactose; do not use with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia may result in severe hypotension and/or increased fluid requirements. Consider withdrawing nifedipine (&gt;36 hours) before surgery if possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Abrupt withdrawal may cause rebound angina in patients with CAD.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May increase the serum concentration of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: May increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of NIFEdipine. Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: NIFEdipine may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May enhance the adverse/toxic effect of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of NIFEdipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: NIFEdipine may increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): NIFEdipine may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression and may increase the effects of nifedipine. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Nifedipine serum levels may be decreased if taken with food. Food may decrease the rate but not the extent of absorption of Procardia XL&reg;. Increased nifedipine concentrations resulting in therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur if nifedipine is taken by patients ingesting grapefruit. Management: Avoid grapefruit/grapefruit juice. Avoid caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease nifedipine levels. Some herbal medications (eg, licorice) may worsen hypertension; others may increase the antihypertensive effect of nifedipine (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Nifedipine crosses the placenta. Use in pregnancy only when clearly needed and when the benefits outweigh the potential hazard to the fetus. Hypotension, IUGR reported. IUGR probably related to maternal hypertension. Nifedipine has been evaluated for the treatment of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG, 2012). Nifedipine is ineffective for maintenance tocolytic therapy (ACOG, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP considers \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F201387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice with all products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Capsule is rapidly absorbed orally if it is administered without food, but may result in vasodilator side effects; if flushing is problematic, administration with low-fat meals may decrease. In general, can take with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Adalat&reg; CC, Afeditab&reg; CR, Nifediac CC&reg;: Take on an empty stomach (manufacturer recommendation). Other extended release products may not have this recommendation; consult product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (NIFEdipine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $102.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $230.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Procardia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $143.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Adalat CC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $161.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $287.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $336.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Afeditab CR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $125.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $224.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Nifediac CC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (1): $1.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (1): $2.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $256.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Nifedical XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $136.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $236.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (NIFEdipine ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $139.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $248.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $291.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (NIFEdipine ER Osmotic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $132.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $229.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $256.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Procardia XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $320.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $555.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $640.78",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F201372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, signs and symptoms of CHF, peripheral edema",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adalat (AR, AT, BE, BF, BJ, BR, CH, CI, CN, CR, CZ, DE, DK, EE, ES, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IT, JP, KE, KP, LR, LU, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NO, PA, PE, PH, PK, PL, PT, RU, SC, SD, SE, SL, SN, SV, TN, TR, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Adalat 10 (AU);",
"     </li>",
"     <li>",
"      Adalat 20 (AU);",
"     </li>",
"     <li>",
"      Adalat CR (BG, CH, GR, JP, TH);",
"     </li>",
"     <li>",
"      Adalat Crono (IT);",
"     </li>",
"     <li>",
"      Adalat GITS (CL, HK);",
"     </li>",
"     <li>",
"      Adalat GITS 30 (PH);",
"     </li>",
"     <li>",
"      Adalat L (JP);",
"     </li>",
"     <li>",
"      Adalat LA (GB, MY, SG);",
"     </li>",
"     <li>",
"      Adalat LP (FR);",
"     </li>",
"     <li>",
"      Adalat Oros (AU, BB, BM, BR, BS, BZ, CN, CO, DK, DO, EC, EE, ES, FI, GY, ID, JM, KP, NL, NO, NZ, PE, PR, PY, SE, SR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Adalat Retard (AE, AT, BF, BH, BJ, BR, CI, CN, CR, CY, CZ, DE, EG, ES, ET, GB, GH, GM, GN, GR, GT, HK, HN, ID, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, OM, PA, PE, PH, PL, PY, QA, SA, SC, SD, SL, SN, SV, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Adalate (FR);",
"     </li>",
"     <li>",
"      Addos XR (AU);",
"     </li>",
"     <li>",
"      Adefin XL (AU);",
"     </li>",
"     <li>",
"      Adifen SR (MY);",
"     </li>",
"     <li>",
"      Adipine XL (GB);",
"     </li>",
"     <li>",
"      Aprical (DE, LU);",
"     </li>",
"     <li>",
"      Atanaal Softcap (TW);",
"     </li>",
"     <li>",
"      Calcibloc (PH);",
"     </li>",
"     <li>",
"      Calcibloc OD (PH);",
"     </li>",
"     <li>",
"      Calcigard (IN, SG, TH);",
"     </li>",
"     <li>",
"      Cardifen (ZA);",
"     </li>",
"     <li>",
"      Chronadalate LP (FR);",
"     </li>",
"     <li>",
"      Citilat (IT);",
"     </li>",
"     <li>",
"      Coracten (AE, BH, CY, DE, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Coral (IT);",
"     </li>",
"     <li>",
"      Cordaflex (BG, HU);",
"     </li>",
"     <li>",
"      Cordilat (MX);",
"     </li>",
"     <li>",
"      Cordipen (SG);",
"     </li>",
"     <li>",
"      Cordipen Retard (SG);",
"     </li>",
"     <li>",
"      Cordipin (HK, HR);",
"     </li>",
"     <li>",
"      Corinfar (HU);",
"     </li>",
"     <li>",
"      Corotrend (DE);",
"     </li>",
"     <li>",
"      Depin (IN);",
"     </li>",
"     <li>",
"      Depin-E Retard (TH);",
"     </li>",
"     <li>",
"      Dignokonstant (DE);",
"     </li>",
"     <li>",
"      Dipinkor (ID);",
"     </li>",
"     <li>",
"      Duranifin (DE);",
"     </li>",
"     <li>",
"      Ecodipin (CH);",
"     </li>",
"     <li>",
"      Fenamon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Glopir (GR);",
"     </li>",
"     <li>",
"      Hexadilat (DK);",
"     </li>",
"     <li>",
"      Huma-Nifedin (HU);",
"     </li>",
"     <li>",
"      Jutadilat (DE);",
"     </li>",
"     <li>",
"      Myogard (AE, BH, CY, EG, IN, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nedipin (TW);",
"     </li>",
"     <li>",
"      Nelapine (PH);",
"     </li>",
"     <li>",
"      Nicardia CD (TH);",
"     </li>",
"     <li>",
"      Nidipin (HU);",
"     </li>",
"     <li>",
"      Nifadil (HR);",
"     </li>",
"     <li>",
"      Nifangin (FI);",
"     </li>",
"     <li>",
"      Nifar (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Nifar-GB (MX);",
"     </li>",
"     <li>",
"      Nifdemin (FI);",
"     </li>",
"     <li>",
"      Nifebene (AT);",
"     </li>",
"     <li>",
"      Nifecard (AT, HR);",
"     </li>",
"     <li>",
"      Nifecard XL (SG);",
"     </li>",
"     <li>",
"      Nifecor (DE);",
"     </li>",
"     <li>",
"      Nifedepat (DE);",
"     </li>",
"     <li>",
"      Nifedicor (IT);",
"     </li>",
"     <li>",
"      Nifedigel (MX);",
"     </li>",
"     <li>",
"      NIfedilat (ZA);",
"     </li>",
"     <li>",
"      Nifedilong (IL);",
"     </li>",
"     <li>",
"      Nifedin (IT);",
"     </li>",
"     <li>",
"      Nifedine (IN);",
"     </li>",
"     <li>",
"      Nifedipin (HR);",
"     </li>",
"     <li>",
"      Nifedipin AL (HU);",
"     </li>",
"     <li>",
"      Nifedipin Pharmavit (HU);",
"     </li>",
"     <li>",
"      Nifedipin Stada (LU);",
"     </li>",
"     <li>",
"      Nifedipin-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Nifedipresc MR (GB);",
"     </li>",
"     <li>",
"      Nifedix SR (KP);",
"     </li>",
"     <li>",
"      Nifehexal (AU, LU);",
"     </li>",
"     <li>",
"      Nifelat (AR, HK, SG, TH);",
"     </li>",
"     <li>",
"      Nifelat-Q (TH);",
"     </li>",
"     <li>",
"      Nifensar (PE);",
"     </li>",
"     <li>",
"      Nifensar Retard (PE);",
"     </li>",
"     <li>",
"      Niferon CR (KP);",
"     </li>",
"     <li>",
"      Nifeslow (LU);",
"     </li>",
"     <li>",
"      Nifestad (PH);",
"     </li>",
"     <li>",
"      Nifezzard (MX);",
"     </li>",
"     <li>",
"      Nificard (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nifipen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Niften (IE);",
"     </li>",
"     <li>",
"      Noviken LP (MX);",
"     </li>",
"     <li>",
"      Nyefax (AU);",
"     </li>",
"     <li>",
"      Nyefax Retard (NZ);",
"     </li>",
"     <li>",
"      Odipin (PH);",
"     </li>",
"     <li>",
"      Orix (GR);",
"     </li>",
"     <li>",
"      Osmo-Adalat (IL);",
"     </li>",
"     <li>",
"      Pidilat (DE);",
"     </li>",
"     <li>",
"      Pressolat (IL);",
"     </li>",
"     <li>",
"      Sepamit (JP);",
"     </li>",
"     <li>",
"      Servidipine (MY);",
"     </li>",
"     <li>",
"      Slow-Nifine (LU);",
"     </li>",
"     <li>",
"      Stada Uno (SG);",
"     </li>",
"     <li>",
"      Unidipin (HU, LU);",
"     </li>",
"     <li>",
"      Xin Ran (CL);",
"     </li>",
"     <li>",
"      Zenusin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina; also reduces peripheral vascular resistance, producing a reduction in arterial blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate release: ~20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding (concentration dependent): 92% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Capsule: 40% to 77%; Sustained release: 65% to 89% relative to immediate release capsules; bioavailability increased with significant hepatic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Healthy: 2-5 hours; Cirrhosis: 7 hours; Elderly: 7 hours (extended release tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 80% as inactive metabolites); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 127: &ldquo;Management of Preterm Labor,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2012, 119(6):1308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/22617615/pubmed\" id=\"22617615\" target=\"_blank\">",
"        22617615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Abman SH, Simonneau G, et al, &ldquo;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6):1917-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/17565025/pubmed\" id=\"17565025\" target=\"_blank\">",
"        17565025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2000, 36(3):970-1062.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/10987629/pubmed\" id=\"10987629\" target=\"_blank\">",
"        10987629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman GD, Asgari MM, Warton EM, et al, \"Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2012, 6:1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/22869299/pubmed\" id=\"22869299\" target=\"_blank\">",
"        22869299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furberg Cd, Psaty BM, and Meyer JV, &ldquo;Nifedipine: Dose-Related Increase in Mortality in Patients With Coronary Heart Disease,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 92(5):1326-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/7648682/pubmed\" id=\"7648682\" target=\"_blank\">",
"        7648682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galie N, Torbicki A, Barst R, et al, &ldquo;Guidelines on Diagnosis and Treatment of Pulmonary Arterial Hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2004, 25(24):2243-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/15589643/pubmed\" id=\"15589643\" target=\"_blank\">",
"        15589643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman E, Messerli FH, Grodzicki T, et al, &ldquo;Should a Moratorium Be Placed on Sublingual Nifedipine Capsules Given for Hypertensive Emergencies and Pseudoemergencies?&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1996, 276(16):1328-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/8861992/pubmed\" id=\"8861992\" target=\"_blank\">",
"        8861992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ishikawa K, Nakai S, Takenaka T, et al, &ldquo;Short-Acting Nifedipine and Diltiazem Do Not Reduce the Incidence of Cardiac Events in Patients With Healed Myocardial Infarction. Secondary Prevention Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(10):2368-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/9170398/pubmed\" id=\"9170398\" target=\"_blank\">",
"        9170398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luks AM, McIntosh SE, Grissom CK, et al, &ldquo;Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,&rdquo;",
"      <i>",
"       Wilderness Environ Med",
"      </i>",
"      , 2010, 21(2):146-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/20591379/pubmed\" id=\"20591379\" target=\"_blank\">",
"        20591379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Messerli FH, Kowey P, and Grodzicki T, &ldquo;Sublingual Nifedipine for Hypertensive Emergencies,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1991, 338(8771):881.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/1681227/pubmed\" id=\"1681227\" target=\"_blank\">",
"        1681227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollard AJ, Niermeyer S, Barry P, et al, &ldquo;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&rdquo;",
"      <i>",
"       High Alt Med Biol",
"      </i>",
"      , 2001, 2(3):389-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/11682018/pubmed\" id=\"11682018\" target=\"_blank\">",
"        11682018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poole-Wilson PA, Lubsen J, Kirwan BA, et al, &ldquo;Effect of Long-Acting Nifedipine on Mortality and Cardiovascular Morbidity in Patients with Stable Angina Requiring Treatment (Action Trial): Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2004, 364(9437):849-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/15351192/pubmed\" id=\"15351192\" target=\"_blank\">",
"        15351192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prisant LM and Spaulding VC, &ldquo;Antihypertensive Pharmacobezoar,&rdquo;",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2006, 8(4):296-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/16596036/pubmed\" id=\"16596036\" target=\"_blank\">",
"        16596036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Psaty BM, Heckbert SR, Koepsell TD, et al, &ldquo;The Risk of Myocardial Infarction Associated With Antihypertensive Therapies,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 274(8):620-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/7637142/pubmed\" id=\"7637142\" target=\"_blank\">",
"        7637142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scognamiglio R, Rahimtoola SH, Fasoli G, et al, &ldquo;Nifedipine in Asymptomatic Patients With Severe Aortic Regurgitation and Normal Left Ventricular Function,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(11):689-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/8058074/pubmed\" id=\"8058074\" target=\"_blank\">",
"        8058074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberschmidt AL, Kuhn-Velten WN, Juon AM, et al, &ldquo;Nifedipine Concentration in Maternal and Umbilical Cord Blood After Nifedipine Gastrointestinal Therapeutic System for Tocolysis,&rdquo;",
"      <i>",
"       BJOG",
"      </i>",
"      , 2008, 115(4):480-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/18271884 /pubmed\" id=\"18271884 \" target=\"_blank\">",
"        18271884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitbon O, Humbert M, Jais X, et al, &ldquo;Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):3105-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/15939821/pubmed\" id=\"15939821\" target=\"_blank\">",
"        15939821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/8135450/pubmed\" id=\"8135450\" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wigley FM, &ldquo;Clinical Practice. Raynaud&rsquo;s Phenomenon,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(13):1001-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/5/12377/abstract-text/11247310/pubmed\" id=\"11247310\" target=\"_blank\">",
"        11247310",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9700 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12377=[""].join("\n");
var outline_f12_5_12377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201399\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201400\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201448\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201404\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201425\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201405\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10293332\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201406\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201374\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201360\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201378\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201377\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7280204\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201456\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201446\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201381\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201364\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201443\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201369\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201395\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201370\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201385\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201409\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201387\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201384\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201372\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201388\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201363\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201380\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9700|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/27/31157?source=related_link\">",
"      Nifedipine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=related_link\">",
"      Nifedipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12378="Overview of gender development and clinical presentation of gender nonconformity in children and adolescents";
var content_f12_5_12378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of gender development and clinical presentation of gender nonconformity in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Michelle Forcier, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Johanna Olson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12378/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/5/12378/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/5/12378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H172535435\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children generally are assigned a gender at birth based upon genital anatomy or chromosomes. For most children, gender assignment correlates with gender identity, which is the innate sense of maleness or femaleness. However, some children have a gender identity that does not correlate with assigned gender. These children are called gender-nonconforming or sometimes transgender. (See",
"    <a class=\"local\" href=\"#H182326064\">",
"     'Terminology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The trajectory of gender nonconformity in childhood is unpredictable; some children with gender nonconformity will grow up to be transgender adults and some will grow up to be cis-gendered adults (ie, adults in whom gender identity matches genital anatomy). (See",
"    <a class=\"local\" href=\"#H584043130\">",
"     'Trajectory'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will provide an overview of gender development and the clinical presentation of gender nonconformity in children and adolescents. An overview of the management of gender nonconformity in children and adolescents and issues related to gender in children with disorders of sexual development are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link\">",
"     \"Overview of the management of gender nonconformity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of the infant with ambiguous genitalia\", section on 'Gender decisions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3426676\">",
"    <span class=\"h1\">",
"     CULTURAL CONTEXT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultural differences in concepts of gender, the language used to describe gender, and attitudes toward gender-nonconforming people may affect expressions of gender identity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/1\">",
"     1",
"    </a>",
"    ]. Many Western societies view gender as binary: male or female. This ideology sets an expectation that gender expression must conform to one or the other and may contribute to the pathologization of gender nonconformity. When the gender expression of a child or adolescent does not fit neatly into the societal construct of male or female in congruence with their assigned sex, the child and family may be ostracized or stigmatized.",
"   </p>",
"   <p>",
"    An alternate perspective views gender as a continuum from male to female, permitting a spectrum of gender identities with varying proportions of maleness and femaleness. Societies that view gender according to this more fluid or developmental perspective may be more accepting of gender variations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/1\">",
"     1",
"    </a>",
"    ]. Healthcare provider recognition and validation of the gender continuum and acceptance of individuals no matter where on the spectrum they identify may help to increase tolerance in families and communities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182326064\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human sexuality is a broad concept that embodies interaction among anatomy, hormones and physiology, psychology, interpersonal relationships, and sociocultural influences (",
"    <a class=\"graphic graphic_figure graphicRef87072 \" href=\"UTD.htm?1/25/1424\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Terms that may be used to describe various aspects of gender and sexuality include are listed below (",
"    <a class=\"graphic graphic_table graphicRef86993 \" href=\"UTD.htm?10/1/10269\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. These are cultural and descriptive terms, not diagnostic terms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Biologic, anatomic, or natal gender (sex)",
"      </strong>",
"      &ndash; Typically assigned according to external genitalia or chromosomes",
"     </li>",
"     <li>",
"      <strong>",
"       Gender identity &ndash;",
"      </strong>",
"      An individual's innate sense of feeling male, female, neither, or some combination of both",
"     </li>",
"     <li>",
"      <strong>",
"       Gender role behavior &ndash;",
"      </strong>",
"      Society&rsquo;s expectations of attitudes, behaviors, and personality traits typically based on biologic sex; these cultural expectations are conveyed by &ldquo;masculinity&rdquo; and &ldquo;femininity&rdquo;",
"     </li>",
"     <li>",
"      <strong>",
"       Gender expression",
"      </strong>",
"      &ndash; How gender is presented to the outside world (eg, feminine, masculine, androgynous); gender expression does not necessarily correlate with biologic gender (sex) or gender identity",
"     </li>",
"     <li>",
"      <strong>",
"       Gender nonconformity &ndash;",
"      </strong>",
"      Variation from the cultural norm in gender expression or gender role behavior (eg, in choices of toys, playmates, etc); other terms used similarly include &ldquo;gender variance&rdquo; or &ldquo;gender atypicality&rdquo;",
"     </li>",
"     <li>",
"      <strong>",
"       Gender discordance &ndash;",
"      </strong>",
"      Discrepancy between anatomic sex and gender identity",
"     </li>",
"     <li>",
"      &ldquo;",
"      <strong>",
"       Transgender",
"      </strong>",
"      &rdquo; &ndash; Umbrella term that is used to describe individuals with gender nonconformity; it includes individuals whose gender identity is different from their biologic sex",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      whose gender expression does not fall within stereotypical definitions of masculinity and femininity",
"     </li>",
"     <li>",
"      <strong>",
"       Gender dysphoria &ndash;",
"      </strong>",
"      Distress or discomfort that occurs if gender identity and anatomic sex are not completely congruent; not all gender discordant individuals experience gender dysphoria",
"     </li>",
"     <li>",
"      <strong>",
"       Transsexuals &ndash;",
"      </strong>",
"      Gender discordant people who make changes to their perceived gender",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anatomic sex in order to conform with their gender identity through strategies such as dress, grooming, hormones,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery",
"     </li>",
"     <li>",
"      <strong>",
"       Sexual orientation &ndash;",
"      </strong>",
"      An individual's pattern of physical and emotional arousal (including fantasies, activities, and behaviors) and the gender(s) of persons to whom an individual is physically or sexually attracted (homosexual, heterosexual, bisexual); sexual orientation is an entirely different construct than gender identity, but is often confused with it",
"     </li>",
"     <li>",
"      <strong>",
"       Sexual behaviors &ndash;",
"      </strong>",
"      Specific behaviors involving sexual activities that are useful for screening and risk assessment; many youth reject traditional labeling (homo-, hetero-, bisexual) but still have same sex partners &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the care for gender discordant individuals becomes increasingly common, sophisticated, and detailed, professionals and the community struggle to keep pace providing a sensitive and descriptive lexicon. As an example, many in the transgender community now use the terms &ldquo;affirmed female&rdquo; or &ldquo;trans-woman&rdquo; and &ldquo;affirmed male&rdquo; or &ldquo;trans-man&rdquo; to describe genotypic males with a female gender identity and genotypic females with a male gender identity, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/7\">",
"     7",
"    </a>",
"    ]. Gender discordant individuals may choose different terms than those listed above to describe themselves (eg, &ldquo;bigender&rdquo;, &ldquo;genderqueer&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/1\">",
"     1",
"    </a>",
"    ]. The terms that are used by professionals are less important than being sensitive to the individual patient&rsquo;s psychosexual profile and desired paradigm.",
"   </p>",
"   <p>",
"    Gender nonconformity is captured in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) as &ldquo;gender identity disorder&rdquo; (GID) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/8\">",
"     8",
"    </a>",
"    ]. Core components of the DSM-IV diagnosis of GID include long-standing discomfort with assigned gender; interference with activities of daily living; and no other illness, physical or psychiatric, that would confuse the diagnosis.",
"   </p>",
"   <p>",
"    Although the DSM-IV criteria for GID may provide some insight into the experience of some gender-nonconforming persons, there are many gender-nonconforming persons for whom a diagnosis of GID is neither accurate nor appropriate. The ongoing debate about whether or not gender nonconformity should be considered a &ldquo;disorder&rdquo; is beyond the scope of this topic review [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Viewing gender nonconformity from the developmental or fluid perspective of a gender continuum, rather than the pathologic perspective of a disorder, promotes understanding that all children may experience gender-nonconforming play and experimentation and may help to reassure families and professionals that exploring gender is a normal component of sexual development for many youth. (See",
"    <a class=\"local\" href=\"#H3426676\">",
"     'Cultural context'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H511653355\">",
"    <span class=\"h1\">",
"     GENDER DEVELOPMENT IN CHILDHOOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear exactly how young children learn about gender [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/12\">",
"     12",
"    </a>",
"    ]. Nonetheless, they are aware of gender differences in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/13\">",
"     13",
"    </a>",
"    ]. At about two-and-one-half years of age, they have the ability to label faces as male or female. Children between two and four years of age begin to understand gender differences, use gendered pronouns such as &ldquo;him&rdquo; and &ldquo;her&rdquo;, and can identify their own gender. By this age, most children also play with toys and games that correlate with their anatomic sex [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/14\">",
"     14",
"    </a>",
"    ]. Initially, children may view gender as subject to variation and change; by five to six years of age, their view of gender becomes more constant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Young children assume gender stereotypes for themselves and others; preschoolers begin sex segregation, playing more with same-sex peers, and furthering generalizable social constructs and gender-conforming roles and rules [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ]. In the school-age years, children may relax gender rules and regard gendered activities with more flexibility and choice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/16\">",
"     16",
"    </a>",
"    ]. However, peer groups generally continue to be same-sex; following rules, fitting in, and peer group acceptance is important in school-aged children.",
"   </p>",
"   <p>",
"    Exploring sexuality, including gender and sexual behaviors is a normal part of child development [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. At some point in childhood, many children experiment with gender expression and roles (eg, interest in cross-gender toys and games, cross-dressing) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. However, for unknown and probably multifactorial biologic and psychosocial reasons, in some children, cross-gender behavior and expression is more consistent, persistent, and insistent than it is among their peers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. These are not choices per se, but reflect an innate preference of the child. (See",
"    <a class=\"local\" href=\"#H182326331\">",
"     'During childhood'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532114114\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal epidemiologic studies on gender nonconformity are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/1\">",
"     1",
"    </a>",
"    ]. Accurate estimation of prevalence is hampered by the social stigma of gender nonconformity and lack of a standardized definition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/23\">",
"     23",
"    </a>",
"    ]. Estimates range widely depending upon the definition and the population studied.",
"   </p>",
"   <p>",
"    Review of the available research highlights two key points: 1) the number of children and adolescents presenting to multidisciplinary clinics for evaluation and management of gender identity issues is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]; and 2) while many children and adolescents sometimes behave like the opposite sex, a significantly smaller number of them will go on to desire physical or social transition to the opposite sex in adolescence or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/12,25\">",
"     12,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 10 studies from eight countries focusing on individuals who present for gender-transition care at specialist centers, the prevalence ranged from 1:11,900 to 1:45,000 for transgender females (genotypic males) and 1:30,400 to 1:200,000 for transgender males (genotypic females) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Responses to two questions (&ldquo;behaves like opposite sex&rdquo; and &ldquo;wishes to be opposite sex&rdquo;) on the Child Behavior Checklist (a 118-question parent-report behavior screen) have been used to estimate the prevalence of gender nonconformity among children in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In population-based studies using these questions, parents of children (ranging in age from 4 to 18 years) reported that between 2 to 4 percent of boys and 3 to 10 percent of girls sometimes behaved like the opposite sex; wishing to be the opposite sex was reported less frequently (0 to 1 percent in boys and 1 to 4 percent in girls) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/21,25,27,28\">",
"       21,25,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a longitudinal study, reports of behaving like the opposite sex or wishing to be the opposite sex decreased slightly between 7 and 10 years of age (from 3.2 to 2.4 percent in boys and 5.2 to 3.3 percent in girls) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a self-report survey, 5 to 13 percent of teenage boys and 20 to 26 percent of teenage girls reported cross-gender behavior some of the time and 2 to 5 percent of boys and 15 to 16 percent of girls reported sometimes wishing to be the opposite sex [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/25,29\">",
"       25,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a 2011 population based survey, 1.3 percent of middle school students (grades six through eight) in San Francisco self-identified as transgender when asked, &ldquo;What is your gender?&rdquo; and were provided with the following responses: &ldquo;female&rdquo;, &ldquo;male&rdquo;, and &ldquo;transgender&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/30\">",
"     30",
"    </a>",
"    ]. The proportion of youth who self-identified as transgender increased with increasing age (0.6 percent at age 11 or younger and 1.7 percent at age 13).",
"   </p>",
"   <p>",
"    In clinically referred populations of gender-dysphoric prepubertal children, the genotypic male-to-female ratio ranges from 3:1 to 6:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/31\">",
"     31",
"    </a>",
"    ]. Among children older than 12 years, the genotypic male-to-female ratio is closer to 1:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/24,32\">",
"     24,32",
"    </a>",
"    ]. Changes in the genotypic male-to-female ratio may reflect a broader range of acceptable gender behaviors in genotypic females (ie, &ldquo;tomboys&rdquo;) than in genotypic males [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/7,32\">",
"     7,32",
"    </a>",
"    ]. It may also reflect the effects of puberty, development of secondary sexual characteristics, and menstruation that occurs with adolescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462800710\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender-nonconforming children may present in a variety of ways depending upon their personalities, the flexibility of their environment, and their culture. (See",
"    <a class=\"local\" href=\"#H3426676\">",
"     'Cultural context'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182326331\">",
"    <span class=\"h2\">",
"     During childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children with gender nonconformity may prefer clothing, hairstyles, toys, activities, and playmates that usually are reserved for the opposite sex [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/24,33-35\">",
"     24,33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gender-nonconforming genotypic males describe their interest in dolls, dresses, wigs, makeup, and often feminine characters as role models. They may urinate in the sitting position or choose to play with &ldquo;female&rdquo; toys when given a choice.",
"     </li>",
"     <li>",
"      Gender-nonconforming genotypic females may despise girls&rsquo; clothing, prefer short haircuts, role-play in traditionally male roles during dramatic play, and participate in more physical activities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Demonstration of gender-nonconforming behaviors and expression is not a choice per se; it reflects an innate preference of the child. However, strong social pressures to conform with same-sex gender stereotypes may suppress the child&rsquo;s desire to express himself or herself in cross-gendered way [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/9,36\">",
"     9,36",
"    </a>",
"    ]. The child&rsquo;s parents and the child himself or herself may try to reshape and redirect gendered interests to be more socially acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H83439611#H83439611\">",
"     \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Mental health interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Young children who are gender nonconforming generally are not gender dysphoric because they lack a clear understanding that their internal gender identity does not match their genitals. They may develop gender dysphoria as they begin to understand the constancy of assigned gender. However, gender dysphoria is unlikely to be recognized if the child is unable or unwilling to express it through activity or verbalization. Children who do not have the language or sophistication to express gender concerns may present in other ways (eg, mood or behavior problems).",
"   </p>",
"   <p>",
"    The majority of prepubertal children with gender nonconformity do not continue to have a cross-gender identity during adolescence. Although it is impossible to predict the trajectory of gender nonconformity for an individual child, one characteristic that may distinguish long-term gender variance from a passing phase is the desire for genitals that correspond with gender identity. Gender-nonconforming genotypic males sometimes try to hide, or even cut off their penises. Gender-nonconforming genotypic females may ask for a penis from their parents, or pray that they wake up with one. Some children tell their parents that a mistake was made, and they are in the wrong body. Consistent, persistent, and insistent gender-nonconforming behaviors and expression in prepubertal children appear to be associated with continued gender dysphoria after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/34,37,38\">",
"     34,37,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H584043130\">",
"     'Trajectory'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182326285\">",
"    <span class=\"h2\">",
"     During adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical changes of puberty usually are exceptionally difficult for gender-nonconforming youth. The development of unwanted secondary sexual characteristics is described by many as a betrayal of one&rsquo;s body, the final confirmation that they must live in an adult version of a body that is not reflective of their true self. In the authors&rsquo; experience, many transgender adolescents have difficulty functioning academically and socially as puberty ensues.",
"   </p>",
"   <p>",
"    For various reasons, some gender-nonconforming individuals may present in adolescence. Transgender youth who have lived &ldquo;gender neutral&rdquo; childhoods may only realize that they are transgender at the onset of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/24\">",
"     24",
"    </a>",
"    ]. Others, who suppressed feelings and expression of gender nonconformity during childhood, may experience feelings of gender nonconformity with increased intensity during pubertal development. For such youth, the addition of the incongruence of genotypic sex to the physical, social, and emotional changes of adolescence can be overwhelming, leading to isolation, anxiety, depression, suicidality, and dangerous behavior (eg, illicit drug use, unprotected sexual activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/23,39-44\">",
"     23,39-44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H492231856\">",
"     'Associated concerns'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Gender dysphoria that intensifies with the onset of puberty rarely subsides [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/22,24,45\">",
"     22,24,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492231856\">",
"    <span class=\"h2\">",
"     Associated concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to children and adolescents with gender nonconformity plays an important role in their psychological, social, and sexual development. Those who experience fear of and contempt toward their physical self, instinctual behavior, and sexual maturation may develop functional or mental health problems [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children and adolescents with gender nonconformity are at risk for multiple psychosocial problems including [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/23,39-44,46\">",
"     23,39-44,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor relationships with parents, family rejection, and loss of financial support",
"     </li>",
"     <li>",
"      Social isolation and peer rejection",
"     </li>",
"     <li>",
"      Verbal and physical victimization",
"     </li>",
"     <li>",
"      Decreased sense of well-being and self-esteem",
"     </li>",
"     <li>",
"      School problems",
"     </li>",
"     <li>",
"      Symptoms of depression and anxiety",
"     </li>",
"     <li>",
"      Self-harm and suicidality",
"     </li>",
"     <li>",
"      Homelessness and sexual exploitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Feeling uncomfortable with one&rsquo;s body and outside the gender norms may contribute to a child&rsquo;s feeling isolated, not fitting in with any particular peer group. The segregation according to anatomic sex that occurs in the early school years (teams, bathrooms, etc) may be emotionally challenging for the gender-nonconforming child [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/3\">",
"     3",
"    </a>",
"    ]. Children and adolescents who openly express their desire for toys and clothing that do not correlate with their assigned gender may be ostracized, criticized, and victimized by those around them [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/3,47\">",
"     3,47",
"    </a>",
"    ]. This may contribute to damaged self-esteem, poor adjustment, and the development of internalizing (eg, depression, anxiety)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    externalizing symptoms (eg, aggression, hyperactivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/15,48\">",
"     15,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family rejection has negative health outcomes in lesbian, gay, and bisexual youth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/49\">",
"     49",
"    </a>",
"    ]; in clinical experience, this is also true for transgender youth. Self-harm (eg, cutting and burning), suicidal thoughts, and suicidal attempts are common among gender-nonconforming youth. In a cohort of 97 consecutive patients with gender identity disorders referred to a multidisciplinary gender management clinic, 43 had a history of psychiatric diagnosis or mental health issues, including 25 with depression, 20 with self-mutilation, and 9 with suicide attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/24\">",
"     24",
"    </a>",
"    ]. In another observational study, 25 of 55 (45 percent) transgender youth reported that they had thought seriously about taking their lives and 14 (26 percent) had attempted suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/39\">",
"     39",
"    </a>",
"    ]. In comparison, in the 2011 Youth Risk Behavior Survey, approximately 16 percent of high school students reported that they had thought seriously about taking their lives, and 8 percent had attempted suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gender-nonconforming youth from conservative families or who live in socially rigid environments may be bullied, harassed, ostracized, discriminated against, physically assaulted, or even killed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In a longitudinal cohort survey, gender nonconformity before 11 years of age was associated with self-reported increased risk of childhood sexual, physical, and psychological abuse and lifetime risk of post-traumatic stress disorder at age 19 to 27 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/53\">",
"     53",
"    </a>",
"    ]. The increased risk of post-traumatic stress disorder was partially mediated by abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many youth seeking care in the authors&rsquo; transgender clinics were forced to leave home because of gender nonconformity. Homelessness and lack of financial support are associated with other health risks (eg, engagement in sex work, increasing the risk of HIV and other sexually transmitted infections) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9259173\">",
"    <span class=\"h2\">",
"     Disclosure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age at which a transgendered individual (",
"    <a class=\"graphic graphic_table graphicRef86993 \" href=\"UTD.htm?10/1/10269\">",
"     table 1",
"    </a>",
"    ) fully acknowledges his or her gender identity varies from mid-childhood to middle age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/57\">",
"     57",
"    </a>",
"    ]. In retrospect, many youth acknowledge that early in childhood they felt as if something was &ldquo;different&rdquo; about them compared with their peers, but they did not have the words or concepts to describe the discordance between their body and their identity. Many youth begin to recognize this discordance and transgender identity as they listen to and observe other transgender persons in the media or social networking sites. In addition, delayed acknowledgment may be related to a fear of stigmatization, victimization, or rejection by family, friends, and employers. Some youth may internalize negative and rejecting social messages and are themselves transphobic, creating further psychological dissonance. Other barriers to disclosure include concerns about confidentiality or decreased access to care.",
"   </p>",
"   <p>",
"    Specific concerns related to disclosure depend upon the timing of disclosure and social milieu. For a young person who is coming out and disclosing for the first time as a teenager, there are very real and concerning dangers. Planning for both safety and social support are critical to disclosure and transitioning. (See",
"    <a class=\"local\" href=\"#H492231856\">",
"     'Associated concerns'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Mental health therapists and medical providers can assist youth in developing a safety plan around disclosure (",
"    <a class=\"graphic graphic_table graphicRef87390 \" href=\"UTD.htm?13/29/13789\">",
"     table 2",
"    </a>",
"    ). Youth may want to work in conjunction with advocacy organizations (eg,",
"    <a class=\"external\" href=\"file://www.genderspectrum.org/\">",
"     Gender Spectrum",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.imatyfa.org/\">",
"     TransYouth Family Allies",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.transyouthequality.org/\">",
"     Trans Youth Equality Foundation",
"    </a>",
"    ) to facilitate disclosure to family members, friends, schools, and other organizations with whom the youth and family have contact. It is important for youth and providers to avoid making assumptions about who will or will not be supportive in the disclosure process. Many gender-nonconforming youth are surprised by family members and friends who become truly supportive and allies; many are devastated by the variety of responses that invalidate or deny their true identity. It is also important to explore networks and allies for parents as they proceed through their own cognitive, emotional, and social processing of their child&rsquo;s &ldquo;new&rdquo; identity. Social, religious, and emotional support may help parents and families who are struggling with these changes. (See",
"    <a class=\"local\" href=\"#H462800773\">",
"     'Role of the medical provider'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H462800780\">",
"     'Role of the mental health provider'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many young people disclose to their parents in a letter. Some parents find out about their child&rsquo;s true gender identity from social networking sites. The choice of how to disclose to one&rsquo;s parents largely depends upon the existing relationship between parent(s) and the child. Writing a letter allows a young person to fully plan out what words to use, and also does not require the young person to witness the parent&rsquo;s reaction. Because reactions from parents vary widely from overwhelming sadness, to disappointment, to anger and outrage, letter writing has become a popular strategy for disclosure.",
"   </p>",
"   <p>",
"    The Internet has provided some young people with a virtual environment in which to &ldquo;practice&rdquo; disclosure and live as one&rsquo;s true self with less risk of harm. This is probably why many young people initially disclose on a social media site (eg, Facebook). The disadvantage of disclosing first to one&rsquo;s cyberfriends is that parents may discover the information inadvertently, and feel angry or hurt that their child has not shared the information with them. In many instances, parents or caregivers are most concerned about how they will be perceived as parents by family members, friends, and even strangers. While ultimately most parents care about the happiness of their child, this initial hurdle often causes great distress for the family. Disclosure decision-making strategies may benefit from the involvement of an experienced mental health therapist. (See",
"    <a class=\"local\" href=\"#H462800780\">",
"     'Role of the mental health provider'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584043130\">",
"    <span class=\"h1\">",
"     TRAJECTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9259024\">",
"    <span class=\"h2\">",
"     Prepubertal children",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is impossible to predict with certainty whether gender nonconformity in an individual child will persist into adolescence or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/27,58\">",
"     27,58",
"    </a>",
"    ]. Review of the evidence from prospective and retrospective follow-up studies suggests that gender dysphoria in prepubertal children persists into",
"    <span class=\"nowrap\">",
"     adolescence/adulthood",
"    </span>",
"    in a minority of children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/22,38\">",
"     22,38",
"    </a>",
"    ]. However, children with consistent, persistent, and insistent nonconforming behaviors and expression may to be more likely to maintain nonconforming gender identity in the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/34,37,38\">",
"     34,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 77 children referred for gender dysphoria at age 5 to 12 years and followed up at a mean of 10.4 years later, gender dysphoria persisted in 27 percent and was no longer present in 43 percent (30 percent were lost to follow-up) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another long-term study, 3 of 25 genotypic females with gender identity disorder or subthreshold gender identity disorder at age 3 to 12 years continued to have gender dysphoria at a mean follow-up of 23.2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with gender identity, the trajectory of sexual orientation is impossible to predict in an individual patient. Predicting the trajectory of sexual orientation is complicated by the lack of clarity about what is meant by &ldquo;heterosexual&rdquo; or &ldquo;homosexual&rdquo; in gender-nonconforming youth (ie, is the categorization made according to natal gender or gender identity?).",
"   </p>",
"   <p>",
"    Longitudinal studies (most of which were performed in genotypic males) suggest that among individuals with gender nonconformity in childhood who eventually affirm a gender identity congruent with anatomic gender, there is an increased likelihood of attraction to sexual partners of the same anatomic sex or to partners of both sexes compared with individuals without gender nonconformity during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/27,38,59\">",
"     27,38,59",
"    </a>",
"    ]. In the author&rsquo;s (JO&rsquo;s) experience, approximately one-half of genotypic females with a male gender identity report being attracted exclusively to female partners and one-half of genotypic males with a female gender identity report being attracted exclusively to male partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9259031\">",
"    <span class=\"h2\">",
"     After puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to prepubertal gender nonconformity, gender dysphoria that intensifies with the onset of puberty rarely subsides [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/22,24,45\">",
"     22,24,45",
"    </a>",
"    ]. In prospective follow-up of a cohort 70 gender dysphoric youth who underwent suppression of endogenous puberty with gonadotropin releasing hormone analogs (to prevent the development of unwanted secondary sexual characteristics), all of the patients elected to proceed with cross-gender hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462800773\">",
"    <span class=\"h1\">",
"     ROLE OF THE MEDICAL PROVIDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care providers often are the first stop for parents with questions or concerns about gender-nonconforming behaviors. Primary care providers are in a unique position to promote health and positive outcomes for children with gender nonconformity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary care providers may play an important part in the recognition of gender nonconformity, monitoring for associated concerns, providing education and support, recognition of mental health problems and health risk behaviors, and facilitating appropriate referrals for the patient and family members [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. They also may coordinate care and provide clinical and laboratory monitoring for patients receiving hormonal interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H113274158#H113274158\">",
"     \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Overview of hormonal interventions for adolescents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individual clinicians may have different levels of comfort or expertise with gender nonconformity. Clinicians who are neither comfortable nor sufficiently knowledgeable to treat patients with gender nonconformity should refer them to more experienced colleagues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/23,57\">",
"     23,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233832\">",
"    <span class=\"h2\">",
"     Identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early identification of children who are struggling with gender identity may help to prevent adverse mental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical health consequences. Early identification permits psychosocial support for the child or adolescent and his or her family members. Family rejection has negative health consequences for transgender youth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/49,55,56\">",
"     49,55,56",
"    </a>",
"    ]. Families who are open to working with a therapist experienced in gender care can get the necessary support and resources to best help their child, and keep the family unit together [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early identification also allows the option of medical intervention (for appropriate patients) to avoid the development of unwanted secondary sexual characteristics, the alteration of which may otherwise involve costly future surgeries. Gender is a ubiquitous aspect of the human experience. During routine well-child visits it is important for primary care providers to screen for concerns about gender development and to ask parents and children about the child&rsquo;s play, activities, and how the child feels about his or her gender identity, upcoming puberty, maturing body, and other changes that accompany puberty and adolescence. (See",
"    <a class=\"local\" href=\"#H511652956\">",
"     'Resources'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H231873#H231873\">",
"     \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Suppression of endogenous puberty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, gender nonconformity is apparent to the clinician; in others, the patient or parents may raise the issue of gender nonconformity. In these cases, further exploration of gender nonconformity may be warranted (",
"    <a class=\"graphic graphic_table graphicRef86987 \" href=\"UTD.htm?12/4/12364\">",
"     table 3",
"    </a>",
"    ). Simple reassurance that the child will &ldquo;grow out of it&rdquo; without further exploration may result in delayed referral, evaluation, and professional support [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because some children and adolescents are reluctant to disclose or outwardly express their gender nonconformity, it is also important to ask specific questions about gender and perceived gender identity in children who are visibly gender nonconforming as well as those who have nonspecific mood or behavior concerns.",
"   </p>",
"   <p>",
"    For younger children, the concept may be introduced as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Most kids have a feeling about whether they are a boy or a girl. How do you feel? Do you feel more like a boy, girl, someone in between, or someone different?&hellip; PAUSE&hellip; Tell me more since I talk with a lot of kids whose body and brain may not be exactly on the same page when it comes to being a boy or girl?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For older youth or teens, practitioners might ask [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Many young people have questions about and sometimes struggle with gender. Is this an issue for you?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Some teens explore who they are in terms of their gender, or try to figure out whether they identify more as a male, female, or someone and somewhere in between. How do you identify yourself?",
"     </li>",
"     <li>",
"      &ldquo;Many young people are impacted by gender and sexuality. It is normal for kids to explore these ideas and their identity. I have begun to ask everyone about it. Anything you say about gender and sexuality will be kept private. We are here to help you figure things out in a safe and healthy way.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Out of respect for my patients&rsquo; right to self-identify, I ask all patients what gender pronoun and name they would like me to use for them. What pronoun and name would you like me to use for you?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, it is important to ask patients with gender nonconformity about associated concerns, such as (see",
"    <a class=\"local\" href=\"#H492231856\">",
"     'Associated concerns'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/5,9,61,63\">",
"     5,9,61,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Degree of social isolation, bullying",
"     </li>",
"     <li>",
"      Declining school performance",
"     </li>",
"     <li>",
"      Disrupted family relationships",
"     </li>",
"     <li>",
"      Running",
"      <span class=\"nowrap\">",
"       away/homelessness",
"      </span>",
"     </li>",
"     <li>",
"      Risk taking behaviors (unsafe sex, promiscuity, substance use, self-harm, suicidal ideation)",
"     </li>",
"     <li>",
"      Medically unsupervised use of hormones or &ldquo;herbal&rdquo; hormones (eg, phytoestrogens or androgen-like compounds sold as dietary supplements) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gender dysphoria in children and adolescents is often diagnosed by mental health providers trained in child and adolescent developmental psychopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/4\">",
"     4",
"    </a>",
"    ]. Key aspects include distress or discomfort when gender identity and anatomic sex are not completely congruent. Primary care providers can screen, identify, and refer gender-nonconforming children to supportive mental health providers in order to help children continue to explore their identity and parents&rsquo; ability to support them. (See",
"    <a class=\"local\" href=\"#H462800780\">",
"     'Role of the mental health provider'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194857714\">",
"    <span class=\"h2\">",
"     Confidentiality",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to know and understand national, state, and institutional laws and policies regarding confidentiality. Most states have laws protecting confidentiality regarding testing for HIV and other sexually transmitted infections. However, states may not protect confidentiality regarding gender and sexuality. Privacy and working with youth to allow full honest disclosure requires trust, respect, and some assurances of privacy. Privacy regarding gender, sexual orientation, and sexual behaviors is promoted by major health professional societies (eg, American Academy of Family Physicians, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and the Society for Adolescent Medicine) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=see_link&amp;anchor=H18#H18\">",
"     \"Adolescent sexuality\", section on 'Principles of care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233840\">",
"    <span class=\"h2\">",
"     Education and support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary care",
"    <strong>",
"    </strong>",
"    clinician can be an influential source of information, support, and guidance for the patient and family members [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/23,67\">",
"     23,67",
"    </a>",
"    ]. Given the potential mental and physical health consequences of gender nonconformity in an unaccepting environment, it is important for health care providers to be nonjudgmental and to support their patients in their preferred gender identity (eg, by using the patient&rsquo;s preferred name and pronouns).",
"   </p>",
"   <p>",
"    Specifically, the health care provider can [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/3,22,23,67-69\">",
"     3,22,23,67-69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Help parents and caregivers understand that the trajectory of gender nonconformity in prepubertal children is not predictable and that the most important task is supporting the child and making him or her feel loved. Children who are not accepted and supported by their parents risk isolation and increased anxiety. (See",
"      <a class=\"local\" href=\"#H492231856\">",
"       'Associated concerns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acknowledge the range of emotions that parents may experience when presented with a gender-nonconforming child (rage, confusion, shock, grief at the loss of expectations that they had for their child) and help the parents to support their child while working through their own concerns with a mental health provider. Therapy or parent-to-parent support groups may be helpful in this regard. (See",
"      <a class=\"local\" href=\"#H511652956\">",
"       'Resources'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Suggest that the family follow the child&rsquo;s lead with respect to clothing and hairstyles, making compromises to fit the family&rsquo;s comfort and cultural context.",
"     </li>",
"     <li>",
"      Suggest that the family help the child to develop interests and skills that are less gender specific and shared by all (eg, swimming, cycling, art, etc).",
"     </li>",
"     <li>",
"      Encourage parents and families to embrace a wide range of appropriate behaviors for males and females and to understand and accept behaviors that fall outside the cultural norms for anatomic sex, emphasizing that gender variance is possible without necessarily altering one&rsquo;s gender identity or body; parents can demonstrate their acceptance of gender and sexual minorities by sharing books or watching programs that feature gender or sexual minority characters in a positive light. (See",
"      <a class=\"local\" href=\"#H511652956\">",
"       'Resources'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H25477379#H25477379\">",
"       \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Approach in prepubertal children'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recognize that gender-nonconforming youth will look for information about transitioning, hormones, and surgical interventions on the Internet because such information may not be available through traditional means.",
"     </li>",
"     <li>",
"      Provide reliable information about the various treatment approaches, highlighting the importance of the parents following the child&rsquo;s lead and allowing for the possibility of the child&rsquo;s changing his or her mind; when discussing the possibility of puberty suppression, it is important that the patient and parents know the signs of early puberty (bearing in mind that the gender-nonconforming children may limit opportunities to be seen naked). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H25477604#H25477604\">",
"       \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Types of interventions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Help the child and family create plans for safety, responses to bullying (including cyberbullying), and other social biases (discuss potentially hurtful responses from peers and teachers and suggest and practice helpful responses).",
"     </li>",
"     <li>",
"      Help youth and parents plan for disclosure to extended family, friends, and social contacts, work with the mental health therapist to develop a safety plan around disclosure. (See",
"      <a class=\"local\" href=\"#H9259173\">",
"       'Disclosure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Help the family determine if or when a social",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a physical transition should occur and to prepare for all aspects of the transition (eg, school issues, reactions of extended family members, friends, neighbors, religious community). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H65066665#H65066665\">",
"       \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Social transition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Provide medical documentation for name change, gender change, and other official documents as necessary; the",
"      <a class=\"external\" href=\"file://www.imatyfa.org/permanent_files/safefolder.html\">",
"       TransYouth Family Allies",
"      </a>",
"      Web site, among others, provides information about what to include in the medical documentation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H25477604#H25477604\">",
"       \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Types of interventions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advocate for the child or adolescent in the school system and community (eg, by providing letters of support for the child&rsquo;s expression of his or her gender identity, educating staff and students within the school system).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233847\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care providers can help with referrals for gender-nonconforming youth gender",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their family members.",
"   </p>",
"   <p>",
"    Referral to a multidisciplinary clinic for children with gender nonconformity may be warranted for children and adolescents with consistent, persistent, and insistent gender-nonconforming behaviors and expression. Such a clinic can provide comprehensive evaluation and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link\">",
"     \"Overview of the management of gender nonconformity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral to a mental health provider who has worked with children and adolescents with gender identity concerns may be warranted for youth with evidence of gender dysphoria (eg, aversion to aspects of their body associated with sex; wish to live as opposite sex); coexisting anxiety, depression, or suicidality; or significant interpersonal conflicts with peers (eg, bullying) or parents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/3,62\">",
"     3,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H462800780\">",
"     'Role of the mental health provider'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Referral to a mental health provider or parent support groups also may be warranted for parents of gender-nonconforming children and adolescents who are uncomfortable with their child&rsquo;s behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/3\">",
"     3",
"    </a>",
"    ]. Parents may experience a range of emotions when presented with a gender-nonconforming child. It is common for parents to have rage, confusion, shock, and grief. They may mourn the loss of expectations they had for their child. (See",
"    <a class=\"local\" href=\"#H511652956\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462800780\">",
"    <span class=\"h1\">",
"     ROLE OF THE MENTAL HEALTH PROVIDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental health therapists who have experience working with children with gender identity concerns are an essential part of the health care team for gender-nonconforming youth. Mental health therapists may play several roles, including [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/1,5,67,70-72\">",
"     1,5,67,70-72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessing gender identity in the context of the youth&rsquo;s psychosocial and family milieu and evaluating extent of gender dysphoria",
"     </li>",
"     <li>",
"      Educating about and modeling acceptance of diversity and fluidity in gender and sexuality",
"     </li>",
"     <li>",
"      Addressing the negative impact of gender dysphoria and stigma on mental health; alleviating internalized transphobia (ie, fear of gender nonconformity)",
"     </li>",
"     <li>",
"      Providing support and helping to build the",
"      <span class=\"nowrap\">",
"       resiliency/coping",
"      </span>",
"      skills necessary to navigate difficult social, educational, and professional situations (see",
"      <a class=\"local\" href=\"#H492231856\">",
"       'Associated concerns'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Evaluating and treating coexisting mental health symptoms or conditions that may diminish self-esteem or impede successful transition (eg, depression, anxiety, substance abuse)",
"     </li>",
"     <li>",
"      Providing support to parents and family members who have difficulty adjusting to the child&rsquo;s &ldquo;new&rdquo; identity",
"     </li>",
"     <li>",
"      Providing information about gender nonconformity to parents, family members, teachers, schools, and other communities",
"     </li>",
"     <li>",
"      Assisting in the development of a safety plan around disclosure (see",
"      <a class=\"local\" href=\"#H9259173\">",
"       'Disclosure'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Assisting in transition preparation and planning (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=see_link&amp;anchor=H65066665#H65066665\">",
"       \"Overview of the management of gender nonconformity in children and adolescents\", section on 'Social transition'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H511652956\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources for patients, families, and providers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.childrensnational.org/departmentsandprograms/default.aspx?Id=6178&amp;Type=Program&amp;Name=Gender and Sexuality Psychosocial Programs\">",
"       Children's National Medical Center Gender and Sexuality Psychosocial Programs",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.genderspectrum.org/education\">",
"       Gender Spectrum",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.mchlibrary.info/families/frb_LGBTQ.html\">",
"       Maternal &amp; Child Health Library at Georgetown University",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://imatyfa.org/\">",
"       TransYouth Family Allies",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.transyouthequality.org/\">",
"       Trans Youth Equality Foundation",
"      </a>",
"     </li>",
"     <li>",
"      HYPERLINK",
"      <span class=\"nowrap\">",
"       \"file://transhealth.ucsf.edu/trans?page=lib0002\"",
"      </span>",
"      \o",
"      <span class=\"nowrap\">",
"       \"file://transhealth.ucsf.edu/trans?page=lib0002\"",
"      </span>",
"      University of California, San Francisco Center of Excellence for Transgender Health",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://transhealth.vch.ca/resources/careguidelines.html\">",
"       Vancouver Coastal Health Transgender Health Program",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.wpath.org/\">",
"       World Professional Association for Transgender Health",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Books for children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/5/12378/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It&rsquo;s Perfectly Normal: Changing Bodies, Growing Up, Sex and Sexual Health by Robie H. Harris and Michael Emberley (Candlewick 2009)",
"     </li>",
"     <li>",
"      Changing Bodies, Changing Lives: Expanded Third Edition: A Book for Teens on Sex and Relationships by Ruth Bell (Three Rivers Press 1998)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172535427\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who have a gender identity (innate sense of maleness or femaleness) that does not correspond with their assigned gender (based upon genital anatomy or chromosomes) are referred to as gender-nonconforming or sometimes transgender (",
"      <a class=\"graphic graphic_table graphicRef86993 \" href=\"UTD.htm?10/1/10269\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H182326064\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not clear how young children learn gender, but they are aware of gender differences in infancy. Many children experiment with gender expression and roles at some point during childhood. For unknown and probably multifactorial reasons, in some children, cross-gender behavior and expression is consistent, persistent, and insistent. (See",
"      <a class=\"local\" href=\"#H511653355\">",
"       'Gender development in childhood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gender-nonconforming children present in a variety of ways depending upon their personalities, the flexibility of their environment, and their culture. Prepubertal children with gender nonconformity may prefer clothing, hairstyles, toys, activities, and playmates that usually are reserved for the opposite sex; they may desire genitals that correspond with their gender identity. Pubertal children and adolescents may present with increased distress related to the physical changes of puberty. Children and adolescents who are unable to express their gender concerns may present with emotional or behavioral problems. (See",
"      <a class=\"local\" href=\"#H3426676\">",
"       'Cultural context'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H462800710\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with gender nonconformity are at risk for multiple psychosocial problems including poor relationships, social isolation, verbal and physical victimization, decreased sense of well-being, school problems, symptoms of depression or anxiety, self-harm and suicidality, and homelessness. Disclosure of nonconformity during adolescence is associated with real and concerning dangers. (See",
"      <a class=\"local\" href=\"#H492231856\">",
"       'Associated concerns'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9259173\">",
"       'Disclosure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is impossible to predict with certainty whether gender nonconformity in an individual child will persist into adolescence or adulthood. However, gender dysphoria that intensifies with the onset of puberty rarely subsides. (See",
"      <a class=\"local\" href=\"#H584043130\">",
"       'Trajectory'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary care providers may play an important part in the recognition of gender nonconformity, monitoring for associated concerns, providing education and support, and facilitating appropriate referrals for the patient and family members. (See",
"      <a class=\"local\" href=\"#H462800773\">",
"       'Role of the medical provider'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Referral to a mental health provider who has worked with children with gender identity concerns may be warranted for youth with evidence of gender dysphoria (eg, aversion to aspects of their body associated with sex; wish to live as opposite sex); coexisting anxiety, depression, or suicidality; or significant interpersonal conflicts with peers or parents. (See",
"      <a class=\"local\" href=\"#H462800780\">",
"       'Role of the mental health provider'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Professional Association for Transgender Health (WPATH). WPATH Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7th Version. Available at: www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/2\">",
"      Brown RT. Adolescent sexuality at the dawn of the 21st century. Adolesc Med 2000; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     Perrin EC. Sexual Orientation in Child and Adolescent Health Care, Springer, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/4\">",
"      Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Child and Adolescent Psychiatry. Practice parameter on gay, lesbian or bisexual sexual orientation, gender-nonconformity, and gender discordance in children and adolescents file://www.aacap.org/galleries/PracticeParameters/glbt_practice_parameter_june_2012.pdf (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/6\">",
"      Frankowski BL, American Academy of Pediatrics Committee on Adolescence. Sexual orientation and adolescents. Pediatrics 2004; 113:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/7\">",
"      Edwards-Leeper L, Spack NP. Psychological evaluation and medical treatment of transgender youth in an interdisciplinary \"Gender Management Service\" (GeMS) in a major pediatric center. J Homosex 2012; 59:321.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Gender identity disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th, Washington, DC 2000. p.576.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/9\">",
"      Mallon GP, DeCrescenzo T. Transgender children and youth: a child welfare practice perspective. Child Welfare 2006; 85:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/10\">",
"      Meyer-Bahlburg HF. From mental disorder to iatrogenic hypogonadism: dilemmas in conceptualizing gender identity variants as psychiatric conditions. Arch Sex Behav 2010; 39:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/11\">",
"      Zucker KJ. The DSM diagnostic criteria for gender identity disorder in children. Arch Sex Behav 2010; 39:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/12\">",
"      Shechner T. Gender identity disorder: a literature review from a developmental perspective. Isr J Psychiatry Relat Sci 2010; 47:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/13\">",
"      Martin CL, Ruble D. Children's search for gender cues. CDPS 2004; 13:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/14\">",
"      Zosuls KM, Ruble DN, Tamis-Lemonda CS, et al. The acquisition of gender labels in infancy: implications for gender-typed play. Dev Psychol 2009; 45:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/15\">",
"      Egan SK, Perry DG. Gender identity: a multidimensional analysis with implications for psychosocial adjustment. Dev Psychol 2001; 37:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/16\">",
"      Carver P. Gender identity and adjustment in middle childhood. Sex Roles 2003; 49:95.",
"     </a>",
"    </li>",
"    <li>",
"     Maccoby EE. The Two Sexes: Growing Up Apart, Coming Together, Harvard University Press, Cambridge, MA 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/18\">",
"      Bullough VL. Children and adolescents as sexual beings: a historical overview. Child Adolesc Psychiatr Clin N Am 2004; 13:447.",
"     </a>",
"    </li>",
"    <li>",
"     Kinsey AC, Pomeroy WB, Martin CE. Sexual Behavior in the Human Male, WB Saunders Co, Philadelphia 1948.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/20\">",
"      Piper J, Mannino M. Identity formation for individuals in transition: A narrative family therapy model. Journal of GLBT Family Studies 2008; 4:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/21\">",
"      van Beijsterveldt CE, Hudziak JJ, Boomsma DI. Genetic and environmental influences on cross-gender behavior and relation to behavior problems: a study of Dutch twins at ages 7 and 10 years. Arch Sex Behav 2006; 35:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/22\">",
"      de Vries AL, Cohen-Kettenis PT. Clinical management of gender dysphoria in children and adolescents: the Dutch approach. J Homosex 2012; 59:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/23\">",
"      Olson J, Forbes C, Belzer M. Management of the transgender adolescent. Arch Pediatr Adolesc Med 2011; 165:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/24\">",
"      Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics 2012; 129:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/25\">",
"      Meyer WJ 3rd. Gender identity disorder: an emerging problem for pediatricians. Pediatrics 2012; 129:571.",
"     </a>",
"    </li>",
"    <li>",
"     Zucker KJ. Gender identity. In: Developmental-Behavioral Pediatrics: Evidence and Practice, Wolraich ML, Crotar DD, Dworkin PH, Perrin EC.  (Eds), Mosby Elsevier, Philadelphia 2008. p.825.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/27\">",
"      Steensma TD, van der Ende J, Verhulst FC, Cohen-Kettenis PT. Gender Variance in Childhood and Sexual Orientation in Adulthood: A Prospective Study. J Sex Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     Achenbach TM. Manual for Child Behavior Check List/4-18 and 1991 Profile. University of Vermont Department of Psychiatry, Burlington, VT 1991.",
"    </li>",
"    <li>",
"     Achenbach TM, Edlebrock C. Manual for the Youth Self-Report and Profile. University of Vermont Department of Psychiatry, Burlington, VT 1987",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/30\">",
"      Shields JP, Cohen R, Glassman JR, et al. Estimating population size and demographic characteristics of lesbian, gay, bisexual, and transgender youth in middle school. J Adolesc Health 2013; 52:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/31\">",
"      Zucker KJ. Gender identity development and issues. Child Adolesc Psychiatr Clin N Am 2004; 13:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/32\">",
"      Cohen-Kettenis PT, Owen A, Kaijser VG, et al. Demographic characteristics, social competence, and behavior problems in children with gender identity disorder: a cross-national, cross-clinic comparative analysis. J Abnorm Child Psychol 2003; 31:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/33\">",
"      Fridell SR, Owen-Anderson A, Johnson LL, et al. The playmate and play style preferences structured interview: a comparison of children with gender identity disorder and controls. Arch Sex Behav 2006; 35:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/34\">",
"      Malpas J. Between pink and blue: a multi-dimensional family approach to gender nonconforming children and their families. Fam Process 2011; 50:453.",
"     </a>",
"    </li>",
"    <li>",
"     Teurk CM, Menvielle E, de Jesus J. If you are concerned about your child&rsquo;s gender behaviors. Outreach Program for Children with Gender-Variant Behaviors and their Families, Children's National Medical Center, Washington, DC. Available at: www.childrensnational.org/files/PDF/DepartmentsandPrograms/Neuroscience/Psychiatry/GenderVariantOutreachProgram/GVParentBrochure.pdf (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/36\">",
"      Bussey K, Bandura A. Social cognitive theory of gender development and differentiation. Psychol Rev 1999; 106:676.",
"     </a>",
"    </li>",
"    <li>",
"     Pearson K. Personal communication. Executive Director of Transyouth Family Allies ed2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/38\">",
"      Wallien MS, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. J Am Acad Child Adolesc Psychiatry 2008; 47:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/39\">",
"      Grossman AH, D'Augelli AR. Transgender youth and life-threatening behaviors. Suicide Life Threat Behav 2007; 37:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/40\">",
"      Alanko K, Santtila P, Witting K, et al. Psychiatric symptoms and same-sex sexual attraction and behavior in light of childhood gender atypical behavior and parental relationships. J Sex Res 2009; 46:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/41\">",
"      Landolt MA, Bartholomew K, Saffrey C, et al. Gender nonconformity, childhood rejection, and adult attachment: a study of gay men. Arch Sex Behav 2004; 33:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/42\">",
"      Pl&ouml;derl M, Fartacek R. Childhood gender nonconformity and harassment as predictors of suicidality among gay, lesbian, bisexual, and heterosexual Austrians. Arch Sex Behav 2009; 38:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/43\">",
"      D'Augelli AR, Grossman AH, Starks MT. Childhood gender atypicality, victimization, and PTSD among lesbian, gay, and bisexual youth. J Interpers Violence 2006; 21:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/44\">",
"      Rijn AB, Steensma TD, Kreukels BP, Cohen-Kettenis PT. Self-perception in a clinical sample of gender variant children. Clin Child Psychol Psychiatry 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/45\">",
"      Steensma TD, Biemond R, de Boer F, Cohen-Kettenis PT. Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study. Clin Child Psychol Psychiatry 2011; 16:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/46\">",
"      Houk CP, Lee PA. The diagnosis and care of transsexual children and adolescents: a pediatric endocrinologists' perspective. J Pediatr Endocrinol Metab 2006; 19:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/47\">",
"      de Vries AL, Doreleijers TA, Steensma TD, Cohen-Kettenis PT. Psychiatric comorbidity in gender dysphoric adolescents. J Child Psychol Psychiatry 2011; 52:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/48\">",
"      Yunger JL, Carver PR, Perry DG. Does gender identity influence children's psychological well-being? Dev Psychol 2004; 40:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/49\">",
"      Ryan C, Huebner D, Diaz RM, Sanchez J. Family rejection as a predictor of negative health outcomes in white and Latino lesbian, gay, and bisexual young adults. Pediatrics 2009; 123:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/50\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     Greytak EA, Kosciw JG, Diaz EM. Harsh Realities: The Experiences of Transgender Youth in Our Nation&rsquo;s Schools. Gay, Lesbian and Straight Education Network 2009. Available at: www.glsen.org/binary-data/GLSEN_ATTACHMENTS/file/000/001/1375-1.pdf (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     McCabe S. D.C. police investigating death, attacks on transgender people. The Examiner 2011. Accessed February 23, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/53\">",
"      Roberts AL, Rosario M, Corliss HL, et al. Childhood gender nonconformity: a risk indicator for childhood abuse and posttraumatic stress in youth. Pediatrics 2012; 129:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/54\">",
"      Roberts AL, Rosario M, Corliss HL, et al. Elevated risk of posttraumatic stress in sexual minority youths: mediation by childhood abuse and gender nonconformity. Am J Public Health 2012; 102:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/55\">",
"      Wilson EC, Garofalo R, Harris RD, et al. Transgender female youth and sex work: HIV risk and a comparison of life factors related to engagement in sex work. AIDS Behav 2009; 13:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/56\">",
"      Garofalo R, Deleon J, Osmer E, et al. Overlooked, misunderstood and at-risk: exploring the lives and HIV risk of ethnic minority male-to-female transgender youth. J Adolesc Health 2006; 38:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/57\">",
"      Spack N. Transgenderism. Med Ethics (Burlingt Mass) 2005; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/58\">",
"      Drescher J, Byne W. Gender dysphoric/gender variant (GD/GV) children and adolescents: summarizing what we know and what we have yet to learn. J Homosex 2012; 59:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/59\">",
"      de Vries AL, Steensma TD, Doreleijers TA, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med 2011; 8:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/60\">",
"      M&ouml;ller B, Schreier H, Li A, Romer G. Gender identity disorder in children and adolescents. Curr Probl Pediatr Adolesc Health Care 2009; 39:117.",
"     </a>",
"    </li>",
"    <li>",
"     Feldman J, Goldberg J. Transgender Primary Medical Care: Suggested Guidelines for Clinicians in British Columbia. 2006 transhealth.vch.ca/resources/library/tcpdocs/guidelines-primcare.pdf (Accessed on October 05, 2012).",
"    </li>",
"    <li>",
"     de Vries AL, Cohen-Kettenis PT, Delemarre-Van de Waal, H. Caring for transgender adolescents in BC: Suggested guidelines transhealth.vch.ca/resources/library/tcpdocs/guidelines-adolescent.pdf (Accessed on October 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/63\">",
"      Kreiss JL, Patterson DL. Psychosocial issues in primary care of lesbian, gay, bisexual, and transgender youth. J Pediatr Health Care 1997; 11:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/64\">",
"      American Academy of Family Physicians, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Adolescent Medicine. Protecting adolescents: Ensuring access to care and reporting sexual activity and abuse. J Adolesc Health 2004; 35:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/65\">",
"      Ford C, English A, Sigman G. Confidential Health Care for Adolescents: position paper for the society for adolescent medicine. J Adolesc Health 2004; 35:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/66\">",
"      Association of Women's Health, Obstetric &amp; Neonatal Nursing. Confidentiality in adolescent health care. J Obstet Gynecol Neonatal Nurs 2010; 39:127.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards-Leeper L, Spack NP. Gender identity disorder. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd, Augustyn M, Zuckerman B, Caronna EB.  (Eds), 2011. p.229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/68\">",
"      Olson J. Lesbian, Gay, Bisexual, Transgender and Questioning (LGBTQ) Youth and the Internet: A Virtual Closet or Cornucopia? California Pediatrician 2011; :6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/69\">",
"      Perrin E, Smith N, Davis C, et al. Gender variant and gender dysphoria in two young children. J Dev Behav Pediatr 2010; 31:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/70\">",
"      Bockting W, Knudson G, Goldberg JM. Counseling and mental health care for transgender adults and loved ones. International Journal of Transgenderism 2006; 9:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/71\">",
"      Anton B. Proceedings of the American Psychological Association for the legislative year 2008: Minutes of the annual meeting of the Council of Representatives, February 22-24, 2008, Washington, DC, and August 13 and 17, 2008, Boston, MA, and minutes of the February, June, August, and December 2008 meetings of the Board of Directors. American Psychologist 2008; 64:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/5/12378/abstract/72\">",
"      Menvielle E, Gomez-Lobo V. Management of children and adolescents with gender dysphoria. J Pediatr Adolesc Gynecol 2011; 24:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83665 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12378=[""].join("\n");
var outline_f12_5_12378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H172535427\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172535435\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3426676\">",
"      CULTURAL CONTEXT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H182326064\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H511653355\">",
"      GENDER DEVELOPMENT IN CHILDHOOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H532114114\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462800710\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182326331\">",
"      During childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182326285\">",
"      During adolescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H492231856\">",
"      Associated concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9259173\">",
"      Disclosure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H584043130\">",
"      TRAJECTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9259024\">",
"      Prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9259031\">",
"      After puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462800773\">",
"      ROLE OF THE MEDICAL PROVIDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233832\">",
"      Identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194857714\">",
"      Confidentiality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233840\">",
"      Education and support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233847\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462800780\">",
"      ROLE OF THE MENTAL HEALTH PROVIDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H511652956\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172535427\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/83665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83665|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/25/1424\" title=\"figure 1\">",
"      Paradigm of gender and sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/1/10269\" title=\"table 1\">",
"      Gender nonconformity terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/29/13789\" title=\"table 2\">",
"      Gender nonconformity transition plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/4/12364\" title=\"table 3\">",
"      Clinician response to gender nonconformity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=related_link\">",
"      Adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=related_link\">",
"      Management of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10650?source=related_link\">",
"      Overview of the management of gender nonconformity in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_5_12379="Timing of withdrawal";
var content_f12_5_12379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Timing of alcohol withdrawal syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Syndrome",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Onset after last drink",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Minor withdrawal",
"      </td>",
"      <td>",
"       Tremulousness, mild anxiety, headache, diaphoresis, palpitations, anorexia, GI upset; Normal mental status",
"      </td>",
"      <td>",
"       6 to 36 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seizures",
"      </td>",
"      <td>",
"       Single or brief flurry of generalized, tonic-clonic seizures, short post-ictal period; Status epilepticus rare",
"      </td>",
"      <td>",
"       6 to 48 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholic hallucinosis",
"      </td>",
"      <td>",
"       Visual, auditory, and/or tactile hallucinations with intact orientation and normal vital signs",
"      </td>",
"      <td>",
"       12 to 48 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Delirium tremens",
"      </td>",
"      <td>",
"       Delirium, agitation, tachycardia, hypertension, fever, diaphoresis",
"      </td>",
"      <td>",
"       48 to 96 hours",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12379=[""].join("\n");
var outline_f12_5_12379=null;
var title_f12_5_12380="Signs of lung disease in scleroderma";
var content_f12_5_12380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of lung disease in scleroderma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary fibrosis",
"       </td>",
"       <td>",
"        <p>",
"         Dyspnea",
"        </p>",
"        <p>",
"         Dry cough",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chest expansion",
"        </p>",
"        <p>",
"         Basal crepitations (rales)",
"        </p>",
"        <p>",
"         Clubbing (late, very uncommon)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary hypertension",
"       </td>",
"       <td>",
"        <p>",
"         Dyspnea",
"        </p>",
"        <p>",
"         Ankle edema",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Loud P2",
"        </p>",
"        <p>",
"         Right ventricular heave",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural involvement",
"       </td>",
"       <td>",
"        <p>",
"         Pleuritic chest pain",
"        </p>",
"        <p>",
"         Dyspnea",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pleural rub",
"        </p>",
"        <p>",
"         Pleural effusion (rare)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiectasis",
"       </td>",
"       <td>",
"        <p>",
"         Cough with purulent sputum",
"        </p>",
"        <p>",
"         Dyspnea",
"        </p>",
"       </td>",
"       <td>",
"        Basal crepitations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous pneumothorax",
"       </td>",
"       <td>",
"        <p>",
"         Chest pain",
"        </p>",
"        <p>",
"         Dyspnea",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Resonant percussion",
"        </p>",
"        <p>",
"         Reduced breath sounds",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung cancer (scar type), especially alveolar cell",
"       </td>",
"       <td>",
"        <p>",
"         Cough",
"        </p>",
"        <p>",
"         Hemoptysis",
"        </p>",
"       </td>",
"       <td>",
"        ? Signs of collapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory failure due to respiratory muscle involvement",
"       </td>",
"       <td>",
"        <p>",
"         Dyspnea",
"        </p>",
"        <p>",
"         Reduced chest expansion",
"        </p>",
"       </td>",
"       <td>",
"        Hypoventilation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12380=[""].join("\n");
var outline_f12_5_12380=null;
var title_f12_5_12381="Motor sensory social milestones";
var content_f12_5_12381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Average age of attainment of motor, sensory, and social skills in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 4 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Buttoning and unbuttoning",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 4.5 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dressing self (except tying shoelaces)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Riding a bicycle with training wheels",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cutting across a page with scissors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coloring within the lines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 5 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drawing a square",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Standing on one foot for 15 seconds",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 5.5 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tying shoelaces",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Printing first and last name",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Jumping down several steps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Repetitive finger tapping of thumb and index finger",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tripod pencil grasp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 6 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Riding a bicycle without training wheels",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ability to spread with a dinner knife",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rhythmic skipping",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 7 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drawing a diagonal line",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 8 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            With his or her eyes closed, can tell you which finger you touched (finger gnosia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 8.5 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alternating foot-hop in place",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 9 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sequential finger tapping at rapid speed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drawing two-dimensional cross with same dimensions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 10 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Persistent tandem stance for 10 seconds with eyes closed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Absence of choreiform movements with arms extended",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 11 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Suppressing mirror movements while doing sequential finger tapping",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills attained by 12 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drawing three-dimensional cube with all sides angulated",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Blondis TA. Motor disorders and attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999; 46:899.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12381=[""].join("\n");
var outline_f12_5_12381=null;
var title_f12_5_12382="Gemcitabine plus carboplatin for non-small cell lung cancer";
var content_f12_5_12382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gemcitabine plus carboplatin for non-small cell lung cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 21 days for a maximum of four cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carboplatin",
"        </strong>",
"       </td>",
"       <td>",
"        AUC* = 5 mg/mL x min IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS)",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over 30 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gemcitabine",
"        </strong>",
"       </td>",
"       <td>",
"        1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 100 mL NS (concentration no more than 40 mg/mL) and administer over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE on day 1 and LOW on day 8. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Carboplatin is an irritant. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        The incidence of neutropenic infections was reported to be 9 percent but may be higher in patients 75 years of age or older",
"        <sup>",
"         [1]",
"        </sup>",
"        . Decisions about primary prophylaxis with hematopoietic growth factors should be individualized according to current guidelines. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula*. A lower starting dose of gemcitabine may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count on days 1 and 8 of each cycle during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Electrolytes, renal, and liver function on day 1 of each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity",
"        <sup>",
"         &loz;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        <p>",
"         &bull;",
"         <strong>",
"          Myelotoxicity:",
"         </strong>",
"         Chemotherapy should be delayed for one week if the ANC is &lt;1000 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         and/or the platelet count is less than 75,000/mm",
"         <sup>",
"          3",
"         </sup>",
"         prior to the start of each cycle. Doses for subsequent cycles are reduced by 25 percent if the ANC is 1000 to 1499 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         or platelets are 75,000 to 99,000/mm",
"         <sup>",
"          3",
"         </sup>",
"         on day 22 after the preceding cycle, or if the nadir ANC was &lt;500 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         . A 50 percent dose reduction should be considered if the platelet nadir is &lt;50,000/mm",
"         <sup>",
"          3",
"         </sup>",
"         . Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.",
"        </p>",
"        <p>",
"         Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed and are based upon the same criteria as on day 1. Dose reductions should be maintained for subsequent cycles",
"         <sup>",
"          [1]",
"         </sup>",
"         .",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hemolytic-uremic syndrome (HUS):",
"        </strong>",
"        Consider diagnosis if the patient develops hemolysis and severe thrombocytopenia, with or without renal failure or central nervous system findings. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other nonhematologic toxicity",
"         <sup>",
"          &sect;",
"         </sup>",
"         :",
"        </strong>",
"        Creatinine clearance should be &ge;45 mL/min and grade 3 or 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &le;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25 percent if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, in which a 50 percent dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days. Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed. Dose reductions should be maintained for subsequent cycles",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     ANC: absolute neutrophil count; CBC: complete blood count; IV: intravenous.",
"     <br/>",
"     * AUC (area under the concentration X time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) x (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Dose adjustments in the study may differ slightly from that recommended by the manufacturer. The manufacturer's recommendations can be found in the FDA approved package insert",
"     <sup>",
"      [2,3]",
"     </sup>",
"     .",
"     <br/>",
"     &sect; Toxicity was graded using the Common Terminology Criteria of Adverse Events version 3.0.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Gronberg BH, et al. J Clin Oncol. 2009; 27:3217.",
"      </li>",
"      <li>",
"       Carboplatin injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).",
"      </li>",
"      <li>",
"       Gemzar (gemcitabine hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12382=[""].join("\n");
var outline_f12_5_12382=null;
var title_f12_5_12383="Hip osteoarthritis";
var content_f12_5_12383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hip osteoarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the right hip joint demonstrates marked joint space narrowing, sclerosis about opposing joint space margins, and periarticular osteophyte formation. These features are all characteristic of osteoarthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_5_12383=[""].join("\n");
var outline_f12_5_12383=null;
 